WO2021126884A1 - LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF) - Google Patents

LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF) Download PDF

Info

Publication number
WO2021126884A1
WO2021126884A1 PCT/US2020/065166 US2020065166W WO2021126884A1 WO 2021126884 A1 WO2021126884 A1 WO 2021126884A1 US 2020065166 W US2020065166 W US 2020065166W WO 2021126884 A1 WO2021126884 A1 WO 2021126884A1
Authority
WO
WIPO (PCT)
Prior art keywords
levosimendan
human subject
hfpef
pulmonary
administration
Prior art date
Application number
PCT/US2020/065166
Other languages
French (fr)
Inventor
Douglas Randall
Douglas HAY
Original Assignee
Tenax Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tenax Therapeutics, Inc. filed Critical Tenax Therapeutics, Inc.
Priority to AU2020408323A priority Critical patent/AU2020408323A1/en
Priority to JP2022537748A priority patent/JP2023507626A/en
Priority to CA3161960A priority patent/CA3161960A1/en
Priority to EP20900848.1A priority patent/EP4076398A4/en
Publication of WO2021126884A1 publication Critical patent/WO2021126884A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to the treatment of heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients).
  • Levosimendan is a calcium sensitizer and potassium channel activator drug approved in over 60 countries for intravenous use in hospitalized subjects with acutely decompensated heart failure (ADHF). Levosimendan is currently approved for in-hospital use only, and currently approved only for administration in a hospital setting where adequate monitoring facilities and expertise with the use of inotropic agents are available. (Simdax. Finland: Orion Corporation; 2010.)
  • Levosimendan enhances the calcium sensitivity of contractile proteins by binding to cardiac troponin C in a calcium-dependent manner. Levosimendan increases the contraction force but does not impair ventricular relaxation. In addition, levosimendan opens ATP-sensitive potassium channels in vascular smooth muscle, thus inducing vasodilatation of systemic and coronary arterial resistance vessels and systemic venous capacitance vessels. Levosimendan is also a selective phosphodiesterase III inhibitor in vitro. (Simdax. Finland: Orion Corporation; 2010.)
  • Levosimendan’s activity is mediated through unique mechanisms of action, including: increased cardiac contractility by calcium sensitization of troponin C, vasodilation through opening of potassium channels, and cardioprotective effects via potassium channel opening in mitochondria.
  • Haikala et al. 1995 Pollesello et al. 1994, Sorsa et al. 2004, Yokoshiki et al. 1997, Pataricza et al. 2000, Kaheinen et al. 2001, Erdei et al. 2006, Maytin et al. 2005, Pollesello et al. 2007, du Toit et al. 2008, Louhelainen et al. 2010
  • Levosimendan has been shown to be a potent and selective phosphodiesterase-3 (PDE3) inhibitor in vitro.
  • the drug is PDE3 selective with a PDE3/PDE4 inhibition ratio of 10,000.
  • both isozymes must be inhibited in cardiomyocytes to exert an effect on the cAMP concentration and inotropic effects.
  • the classical PDE inhibitors i.e., milrinone, enoximone, and amrinone
  • inhibit both PDE3 vs. PDE4 is as low as 17-fold), which accounts fully for their inotropic effect.
  • Levosimendan improves endothelial function and enhances diastolic coronary flow by opening the adenosine triphosphate-sensitive potassium channels and increasing nitric oxide production.
  • Levosimendan acts through direct binding to troponin-C at high systolic intracellular calcium concentration as well as detachment from it at low diastolic concentration are facilitated.
  • Levosimendan displayed positive lusitropic effects relative to milrinone and nitroglycerin. The lusitropic effect of levosimendan is independent of the degree of the inotropic effect. (Michaels et al. 2005, Grossini et al. 2005, Hasenfuss et al. 1998, De Luca et al. 2006) Metabolites OR-1896 and OR-1855
  • Levosimendan has an active metabolite that extends its effects well beyond the infusion period. Following intravenous or oral dosing, levosimendan is reduced by intestinal bacteria to form OR-1855 (limited activity) that is acetylated to form OR-1896, an active metabolite. While the patient half-life is approximately 1 hour and cleared a few hours after the end of intravenous infusion, OR-1896 has a prolonged half-life of 70-80 hours in heart failure subjects with roughly equal exposures of OR-1855 and OR-1896 maintained through deacetylation/acetylation pathways.
  • levosimendan is essentially an active prodrug to an active metabolite moiety, OR-1896.
  • OR-1896 is equipotent to levosimendan in its inotropic effects in whole cardiomyocytes and isolated contractile apparatus preparations. However, OR-1896 is profoundly less potent in the inhibition of both PDE3 and PDE4 isozymes. This supports the hypothesis that the main component of the inotropic effect for both levosimendan and OR-1896 is a result of their binding to troponin C and not through PDE inhibition. (Szilagyi et al. 2004)
  • HFpEF and HFrEF are distinct clinical entities. While each type of heart failure accounts for approximately 50% of all heart failure patients, many differences exist between these two forms of heart failure.
  • Pulmonary Hypertension A sustained elevation in left atrial pressure causes pulmonary venous congestion, which often leads to elevation of pulmonary pressures leading to severe right ventricular failure with a low cardiac output, edema, hypoxemia, and severely limited exercise capacity.
  • Pulmonary hypertension (PH) in subjects with heart failure and preserved ejection fraction (PH-HFpEF) is a common form of pulmonary hypertension and has an estimated US prevalence exceeding 1.5 million.
  • PH-HFpEF has been classified within Group II of the World Health Organization (WHO) clinical classification of PH, characterized by PH arising from left heart disease. Regardless of the basis of left heart disease, PH initially develops from a passive backward transmission of filling pressures, mainly driven by left ventricular (LV) diastolic function, resulting in a chronic increase in left atrial pressure and a loss of left atrial compliance.
  • LV left ventricular
  • PH-HFpEF is defined hemodynamically by a pulmonary artery pressure (mPAP) >25 mmHg, a pulmonary capillary wedge pressure (PCWP) >15 mmHg, and a diastolic pressure gradient [diastolic PAP - PCWP] >7mmHg.
  • ESC guidelines in the treatment of PH-HFpEF subjects acknowledge that the accepted treatment target is a reduction of pulmonary wedge pressures using diuretics for congestion.
  • clinical studies have demonstrated neutral results with identified concerns that Pulmonary Hypertension (PH)-targeted therapies could have detrimental effects due to rapid increases in LV filling pressures, resulting in acute pulmonary edema.
  • the ESC guidelines specify that there are currently no established strategies to treat pulmonary vascular disease (PVD) and right ventricular disease (RVD) in HFpEF, with a recommendation (class III) not to use approved PAH treatments in PH-HFpEF subjects. With no demonstrated effective therapy, these subjects have a poor outcome (5 yr. survival ⁇ 50%, frequent hospitalizations). (Shaw et al. 2016, Galie et al. 2009, Goiter et al. 2018, Klapholz et al. 2004)
  • Levosimendan has never previously been studied in the PH-HFpEF population.
  • the complete lack of research regarding levosimendan’ s potential utility in PH-HFpEF likely stems from the fact that inotropes such as levosimendan, are recommended in most heart failure guidelines to be used exclusively in the treatment of HFrEF and not HFpEF patients.
  • the 2013 ACCF/AHA guidelines for management of heart failure specifically limits its recommendation for inotrope use to HFrEF patients, stating “Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.”
  • the SIOVAC trial was a multicenter placebo control trial of sildenafil in patients with PH-left heart disease (LHD) secondary to valvular heart disease.
  • LHD PH-left heart disease
  • This study reinforced the risk associated with use of sildenafil in patients with PH-LHD, and it also supported the recommendations against the use of PDE5i in patients with PH-LHD. Due to these negative results seen to date, the efficacy of PDE5i in PH-HFpEF seems highly unlikely.
  • the multicenter INDIE-HFpEF studied the acute cardiopulmonary hemodynamic effects of inorganic nitrite infusion.
  • the invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF, employing the use of levosimendan, or OR1896, or OR1855. In other embodiments, the treatment of PH-HFpEF through subcutaneous administration is contemplated. In other embodiments, the treatment of PH-HFpEF through oral administration is contemplated. In other embodiments, the treatment of PH-HFPEF through combination therapy of levosimendan, or OR1896, or OR1855 and other cardiovascular drugs is contemplated.
  • PH-HFpEF Pulmonary Hypertension with heart failure with preserved ejection fraction
  • the invention provides levosimendan and medicaments comprising levosimendan for use in any of the methods of the invention.
  • Figures 1A-1B are graphical representations of Example 1 results, showing a decrease in pulmonary capillary wedge pressure (PCWP) after levosimendan administration in 30 patients. These results are based on single 24-hour open label lead- in infusion data.
  • Figure 1A shows the decrease in PCWP after levosimendan infusion during rest with the human subjects’ legs down.
  • Figure IB shows the decrease in PCWP after levosimendan infusion during exercise where the human subject exerts 25 watts.
  • FIGS 2A-2B Right Atrial Pressure (RAP) Pre vs Post Levosimendan Lead-in Infusion
  • RAP right atrial Pressure
  • Figure 2A shows the decrease in RAP after levosimendan infusion during rest with the human subjects’ legs down.
  • Figure 2B shows the decrease in RAP after levosimendan infusion during exercise where the human subject exerts 25 watts.
  • Figures 3A-3B are graphical representations of Example 1 results, showing a decrease in mean pulmonary artery pressure (mPAP) after levosimendan administration in 30 patients. These results are based on single 24-hour open label lead-in infusion data.
  • Panel A shows the decrease in mPAP after levosimendan infusion during rest with the human subjects’ legs down.
  • Panel B shows the decrease in mPAP after levosimendan infusion during exercise where the human subject exerts 25 watts.
  • Figures 4A-4B are graphical representations of Example 1 results, showing an increase in cardiac output (CO) after levosimendan administration in 30 patients. These results are based on single 24-hour open label lead-in infusion data.
  • Panel A shows the increase in CO after levosimendan infusion during rest with the human subjects’ legs down.
  • Panel B shows the increase in CO after levosimendan infusion during exercise where the human subject exerts 25 watts.
  • Figure 5 is a graphical representation of Example 2 results, showing an increase in 6-minute walk distance after levosimendan administration in 8 patients.
  • Figure 7 Exercise Stroke Volume May Predict Response to Levosimendan.
  • Figure 7 is a graphical representation of Example 1 results, showing a predictor of response for PH-HFpEF patients treated with levosimendan in 21 patients. The graph indicates that the greater the change in a patient’s stroke volume between rest and 25 watts of exercise, the greater the reduction in PCWP after administration of levosimendan.
  • Figure 8 PCWP Endpoint - Baseline vs. 6 Weeks. Levosimendan effect on PCWP across positions is significant vs placebo.
  • Figure 8 is a graphical representation of Example 2 results, showing a decrease in pulmonary capillary wedge pressure (PCWP) after levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients).
  • the left panel shows the difference in PCWP after placebo administration during rest with the human subjects’ legs down, legs raised on a supine bicycle, and during exercise where the human subject exerts 25 watts.
  • the right panel shows the decrease in PCWP after levosimendan infusion during rest with the human subjects’ legs down, leg raise on a supine bicycle, and during exercise where the human subject exerts 25 watts.
  • Figures 9A-9C PCWP Change from Baseline at Week 6 - Levosimendan vs Placebo.
  • Figures 9A-9C are a graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a larger decrease in PCWP after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients.
  • Figure 9A shows the decrease in PCWP after levosimendan infusion and placebo infusion during rest with the human subjects’ legs down.
  • Figure 9B shows the decrease in PCWP after levosimendan infusion and placebo infusion with the patients’ legs up in a supine position.
  • Figure 9C shows the decrease in PCWP after levosimendan infusion and placebo infusion during exercise where the human subject exerts 25 watts.
  • Figure 10 PCWP Week 6 - Levosimendan Change from Baseline.
  • Figure 10 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a decrease in PCWP after levosimendan administration in 18 PH-HFpEF patients.
  • Figure 11 RAP Change from Baseline at Week 6 - Levosimendan Treated Patients.
  • Figure 11 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a decrease in right atrial pressure (RAP) after levosimendan administration in 18 PH-HFpEF patients compared to 17 placebo treated patients.
  • RAP right atrial pressure
  • Figures 12A-12C RAP Change at Week 6 - Levosimendan vs Placebo.
  • Figures 12A-12C are graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a larger decrease in RAP after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients.
  • Figure 12A shows the decrease in RAP after levosimendan infusion and placebo infusion during rest with the human subjects’ legs down.
  • Figure 12B shows the decrease in RAP after levosimendan infusion and placebo infusion with the patients’ legs up in a supine position.
  • Figure 12C shows the decrease in RAP after levosimendan infusion and placebo infusion during exercise where the human subject exerts 25 watts.
  • Figure 13 mPAP Week 6 - Levosimendan Change from Baseline.
  • Figure 13 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing a decrease in mean pulmonary artery pressure (mPAP) after levosimendan administration in 18 PH-HFpEF patients compared to 17 placebo treated patients.
  • the figure shows the decrease in mPAP during rest with the human subjects’ legs down, legs raised on a supine bicycle, and during exercise where the human subject exerts 25 watts.
  • Figures 14A-14C mPAP (mmHg) Change at Week 6 - Levosimendan vs Placebo.
  • Figures 14A-14C are graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing a larger decrease in mPAP after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients.
  • Figure 14A shows the decrease in mPAP after levosimendan infusion and placebo infusion during rest with the human subjects’ legs down.
  • Figure 14B shows the decrease in mPAP after levosimendan infusion and placebo infusion with the patients’ legs up in a supine position.
  • Figure 14C shows the decrease in mPAP after levosimendan infusion and placebo infusion during exercise where the human subject exerts 25 watts.
  • Figure 15 Change in Six Minute Walk Distance (meters) from Baseline at Week 6 - Levosimendan vs. Placebo.
  • Figure 15 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing an increase in 6-minute walk distance after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients.
  • Figure 16 Treatment Emergent Adverse Events.
  • Figure 16 shows results of Example 2, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing a comparison of Treatment Emergent Adverse Events (TEAEs) after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 18 additional PH-HFpEF patients.
  • TEAEs Treatment Emergent Adverse Events
  • Figure 17 Treatment Emergent Adverse Events (Incidence of two or more).
  • Figure 17 shows results of Example 2, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing a comparison of specific Treatment Emergent Adverse Events (TEAEs) after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 18 additional PH-HFpEF patients.
  • TEAEs Treatment Emergent Adverse Events
  • Figure 18 Serious Adverse Events.
  • Figure 18 shows results of Example 2, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing Serious Adverse Events, and the Relatedness/Change in Dose of levosimendan.
  • Figure 19 OR1896 Trough Blood Levels at Final RHC Levosimendan Treated Patients.
  • Figure 19 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing OR1896 trough blood levels at final RHC in levosimendan treated patients.
  • Figures 20A-20B are graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing Cardiac Index (Cl) ( Figure 20A) and pulmonary vascular resistance (PVR) ( Figure 20B) after levosimendan administration in 36 PH-HFpEF patients.
  • Cl Cardiac Index
  • PVR pulmonary vascular resistance
  • Figure 20B behaved surprisingly different compared to other variables (i.e. unchanged at week 6). This data suggests that levosimendan is acting differently with respect to chronic (weekly for 5 weeks) vs. acute (24-hour) administration (See, for example, Figures 4A-4B).
  • Figures 21A-21B Baseline vs 24-hour Levosimendan Infusion - Impact on CVP and PCWP.
  • Figure 21A shows impact on CVP.
  • Figure 21B shows impact on PCWP.
  • ‘Baseline’ measurements are shown to the left of “24 Hours’ measurements.
  • Figure 22 Baseline Characteristics among randomized patients.
  • Figure 23 Summary of Overall Hemodynamic Effects of 24-hour Levosimendan Infusion.
  • HR heart rate CVP, central venous pressure
  • PAS pulmonary artery systolic pressure
  • PAD pulmonary artery diastolic pressure
  • PA pulmonary artery
  • PCWP pulmonary capillary wedge pressure
  • AoS arterial systolic pressure
  • Cl cardiac index
  • SVR systemic vascular resistance
  • PVR pulmonary vascular resistance. *p ⁇ .05 compared to baseline.
  • HR heart rate HR heart rate
  • CVP central venous pressure
  • PAS pulmonary artery systolic pressure
  • PAD pulmonary artery diastolic pressure
  • PA pulmonary artery
  • PCWP pulmonary capillary wedge pressure
  • AoS arterial systolic pressure
  • Cl cardiac index
  • SVR systemic vascular resistance
  • PVR pulmonary vascular resistance.
  • Figure 25 Overview of two phase study, with an initial unblinded levosimendan infusion to identify levosimendan “responders” defined as a >4 mmHg reduction of pulmonary capillary wedge pressure (PCWP) during 25 Watt exercise (EX) followed by a subsequent randomized double blind phase.
  • PCWP pulmonary capillary wedge pressure
  • Figure 26 CONSORT diagram showing flow a patients through entire study
  • Figures 27A-27B Comparison of pulmonary capillary wedge pressure (PCWP) and central venous pressure (CVP) between baseline, 24 hours and 6 weeks at rest, with legs up and during 25 Watts exercise. Placebo group shown in Figure 27A and Figure 27B; levosimendan group shown in Figure 27C and Figure 27D. *p ⁇ 0.05 for comparison between respective baseline and 24-hour measurements.
  • PCWP pulmonary capillary wedge pressure
  • CVP central venous pressure
  • Figure 28A Comparison of 6 minute walk distance (6MWD) in treatment and control groups.
  • Figure 28B Rank ordered listing of changes in 6MWD for each patient designated by group assignment. More patients in the treatment group had increased 6MWD, whereas more patients in the control group had decreased 6MWD. *p ⁇ 0.05. DETAILED DESCRIPTION OF THE INVENTION
  • the invention provides a method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of levosimendan, its metabolites OR- 1896 or OR-1855, or a combination thereof, that is effective to treat the PH-HFpEF in the human subject.
  • PH-HFpEF Pulmonary Hypertension Heart Failure with preserved ejection fraction
  • the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure at rest.
  • the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure at rest by 1 to 30 mmHg.
  • the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure at rest at 5 to 35 mmHg.
  • the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure at rest at 10 to 35 mmHg.
  • the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure during exercise by the human subject.
  • the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure during exercise by the human subject by 1 to 40 mmHg.
  • the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure during exercise by the human subject at 10 to 50 mmHg.
  • the treating does not comprise a significant change in pulmonary capillary wedge pressure during exercise by the human subject.
  • the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated.
  • the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated and the reduction is 1 to 30 mmHg.
  • the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated and the stabilization is at 10 to 50 mmHg.
  • the treating comprises a reduction in the human subject’s right atrial pressure at rest. [0071] In some embodiments, the treating comprises a reduction in the human subject’s right atrial pressure at rest by 1 to 30 mmHg.
  • the treating comprises stabilization of the human subject’s right atrial pressure at rest at 1 to 30 mmHg.
  • the treating comprises stabilization of the human subject’s right atrial pressure at rest at 5 to 30 mmHg.
  • the treating comprises a reduction in the human subject’s right atrial pressure during exercise by the human subject.
  • the treating comprises a reduction in the human subject’s right atrial pressure during exercise by the human subject by 1 to 30 mmHg.
  • the treating comprises stabilization of the human subject’s right atrial pressure during exercise by the human subject at 5 to 40 mmHg.
  • the treating comprises a reduction in the human subject’s right atrial pressure when the human subject’s legs are elevated.
  • the treating comprises a reduction in the human subject’s mean pulmonary artery pressure at rest.
  • the treating comprises a reduction in the human subject’s mean pulmonary artery pressure at rest by 1 to 30 mmHg.
  • the treating comprises stabilization of the human subject’s mean pulmonary artery pressure at rest at 15 to 65 mmHg.
  • the treating comprises a reduction in the human subject’s mean pulmonary artery pressure during exercise by the human subject.
  • the treating comprises a reduction in the human subject’s mean pulmonary artery pressure during exercise by the human subject by 1 to 30 mmHg.
  • the treating comprises stabilization of the human subject’s mean pulmonary artery pressure during exercise by the human subject at 25 to 85 mmHg.
  • the treating comprises stabilization of the human subject’s mean pulmonary artery pressure during exercise by the human subject at 25 to 80 mmHg.
  • the treating comprises a reduction in the human subject’s mean pulmonary artery pressure when the human subject’s legs are elevated. [0086] In some embodiments, the treating comprises an increase in the human subject’s cardiac output at rest.
  • the treating comprises an increase in the human subject’s cardiac output at rest by 0.01 to 3 liters/min.
  • the treating comprises stabilization of the human subject’s cardiac output at rest at 2 to 10 liters/min.
  • the treating comprises an increase in the human subject’s cardiac output during exercise by the human subject.
  • the treating comprises an increase in the human subject’s cardiac output during exercise by the human subject by 0.01 to 5 liters/min.
  • the treating comprises an increase in the human subject’s cardiac output during exercise by the human subject by 0.01 to 4 liters/min.
  • the treating comprises stabilization of the human subject’s cardiac output during exercise by the human subject at 3.0 to 15.0 liters/min.
  • the treating does not comprise a significant increase in the human subject’s heart rate.
  • the treating does not comprise an increase in the human subject’s heart rate of more than 10 beats/min.
  • the treating comprises an improvement in the human subject’s quality of life.
  • the improvement in the human subject’s quality of life is measured by a patient reported outcome assessment tool.
  • the improvement in the human subject’s quality of life is measured by a Likert scale that is a five (5) point patient reported outcome assessment tool
  • the treating comprises an improvement in the human subject’s quality of life according to a change in the human subject’s patient reported outcome assessment tool score of at least 1
  • the treating comprises an improvement in the human subject’s quality of life according to a change in the human subject’s patient reported outcome assessment tool score of at least 2 [0100] In some embodiments, the treating comprises an improvement in the human subject’s six (6) minute walk distance.
  • the treating comprises an improvement in the human subject’s six (6) minute walk distance of 5 to 150 meters.
  • the treating comprises an improvement in the physician’s assessment of the human subject’s functional class.
  • the treating comprises a reduction in the incidence of hospitalization for heart failure.
  • the treating comprises a reduction in all-cause mortality.
  • the treating comprises an improvement in right heart failure and/or right ventricular dysfunction.
  • the improvement is evidenced by a reduction in right atrial pressure at rest and during 25 watts of exercise.
  • the human subject is a responder to levosimendan therapy.
  • a responder to levosimendan therapy is a human subject whose pulmonary capillary wedge pressure decreases by at least 4mmHG during bicycle exercise at 25 watts following the initial infusion.
  • a responder to levosimendan therapy is a human subject whose cardiac index decreases by no more than 10% between the baseline measurements and repeated measurements following the initial infusion.
  • the human subject is a responder to levosimendan therapy if the human subject has cardiac reserve.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when determined with a catheter in the human subject’s heart measuring the blood moving out of the left ventricle with every beat.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when estimated with an electrocardiogram and/or echocardiogram.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when determined with a dobutamine stress test.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by at least 0.005 liters.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when determined with a catheter in the human subject’s heart measuring the blood moving out of the left ventricle with every beat.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when estimated with an echocardiogram, right heart catheterization, or other means.
  • the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when determined with a dobutamine stress test.
  • the human subject afflicted with PH-HFpEF has a left ventricular ejection fraction of at least 40%.
  • the human subject afflicted with PH-HFpEF has a baseline pulmonary arterial pressure of at least 35.
  • the human subject afflicted with PH-HFpEF has a baseline pulmonary capillary wedge pressure of at least 20.
  • the human subject afflicted with PH-HFpEF is classified as classification lib by the physician’s assessment of New York Heart Association Classification.
  • the human subject afflicted with PH-HFpEF is classified as classification III by the physician’s assessment of New York Heart Association Classification.
  • the human subject afflicted with PH-HFpEF has the ability to walk at least 50 meters in a six-minute walk test.
  • the human subject afflicted with PH-HFpEF does not have the ability to walk more than 550 meters in a six-minute walk test. [0126] In some embodiments, the human subject afflicted with PH-HFpEF has the ability to walk at least 50 meters, but not more than 550 meters, in a six-minute walk test.
  • the human subject afflicted with PH-HFpEF is not afflicted with heart failure with reduced ejection fraction.
  • the human subject afflicted with PH-HFpEF is not afflicted with heart failure with preserved ejection fraction without pulmonary hypertension.
  • the human subject afflicted with PH-HFpEF has a primary diagnosis of Group 2 PH-HFpEF.
  • the human subject afflicted with PH-HFpEF is not afflicted with coronary artery disease.
  • the human subject afflicted with PH-HFpEF has not had previous percutaneous coronary intervention.
  • the human subject afflicted with PH-HFpEF has not had previous percutaneous coronary intervention, unless the human subject has had a negative stress test within the last year.
  • the human subject afflicted with PH-HFpEF has not had previous cardiac surgery.
  • the human subject afflicted with PH-HFpEF has not had previous cardiac surgery, unless the human subject has had a negative stress test within the last year.
  • the human subject afflicted with PH-HFpEF is not afflicted with congenital heart disease.
  • the human subject afflicted with PH-HFpEF is not afflicted with a clinically significant lung disease.
  • the human subject afflicted with PH-HFpEF does not have a planned heart or lung surgery.
  • the human subject afflicted with PH-HFpEF does not have a cardiac index greater than 4.0 L/min/m2.
  • the human subject afflicted with PH-HFpEF does not concomitantly receive pulmonary vasodilator therapy.
  • the human subject afflicted with PH-HFpEF has not received pulmonary vasodilator therapy within the last 14 days.
  • the human subject afflicted with PH-HFpEF does not receive dialysis treatment.
  • the human subject afflicted with PH-HFpEF does not have a Glomerular Filtration Rate less than 30 mL/min/1.73m2.
  • the human subject afflicted with PH-HFpEF does not have liver dysfunction with Child Pugh Class B or C.
  • the human subject afflicted with PH-HFpEF does not have evidence of systemic infection.
  • the human subject afflicted with PH-HFpEF does not weigh more than 150 kg.
  • the human subject afflicted with PH-HFpEF can manage their symptomatic systolic blood pressure to ensure it is greater than 100 mmHg.
  • the human subject afflicted with PH-HFpEF does not have a heart rate greater than or equal to 100 beats per minute with the drug.
  • the human subject afflicted with PH-HFpEF does not have a heart rate greater than or equal to 100 beats per minute with the drug that is symptomatic and persistent for at least 10 minutes.
  • the human subject afflicted with PH-HFpEF does not have hemoglobin less than 80 g/L.
  • the human subject afflicted with PH-HFpEF does not have serum potassium less than 3.0 mmol/L at baseline.
  • the human subject afflicted with PH-HFpEF does not have serum potassium greater than 5.5 mmol/L at baseline.
  • the human subject afflicted with PH-HFpEF does not have serum potassium less than 3.0 mmol or greater than 5.5 mmol/L at baseline.
  • the human subject afflicted with PH-HFpEF does not have severely compromised immune function.
  • the human subject afflicted with PH-HFpEF is not pregnant.
  • the human subject afflicted with PH-HFpEF is not suspected to be pregnant,
  • the human subject afflicted with PH-HFpEF is not breast-feeding.
  • the human subject afflicted with PH-HFpEF is a patient with Biventricular
  • the administration is self-administered by the human subject.
  • the self-administration takes place in a hospital by the human subject.
  • the self-administration takes place in an outpatient-setting by the human subject.
  • the self-administration takes place outside of a hospital by the human subject.
  • the self-administration takes place at home by the human subject.
  • the administration is not self-administered by the human subject.
  • the administration is administered by a trained professional.
  • the administration takes place in a hospital by the trained professional.
  • the administration takes place in an outpatient-setting by the trained professional.
  • the administration takes place outside of a hospital by the trained professional.
  • the administration takes place at home by the trained professional.
  • the administration is delivered via IV administration.
  • the IV administration accesses the vein through a PICC line.
  • the IV administration accesses the vein through a Port-a-cath.
  • the administration takes place intermittently.
  • the administration takes place weekly.
  • the administration is given via a 24-hour infusion.
  • the administration is given via a weekly 24-hour infusion. [0176] In some embodiments, the administration takes place chronically.
  • the administration is chronic administration given via a less than 24-hour infusion.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 0.9 Normal Saline.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose or 0.9 Normal Saline where the human subject weights less than 85 kg.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 0.9 Normal Saline.
  • the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose or 0.9 Normal Saline where the human subject weights at least 85 kg.
  • the administration lead-in infusion rate is 0.10 mg/kg/min for 24 hours.
  • the administration week 2 infusion rate is 0.075 mg/kg/min for 24 hours.
  • the administration week 3 infusion rate is 0.075 mg/kg/min for 24 hours.
  • the administration week 4 infusion rate is 0.10 mg/kg/min for 24 hours.
  • the administration week 5 infusion rate is 0.10 mg/kg/min for 24 hours.
  • the administration infusion rate is reduced to 0.05 mg/kg/min when the higher dose is not well-tolerated by the human subject.
  • the administration is via oral dosing.
  • the oral dosing comprises an immediate release formulation.
  • the oral dosing comprises an extended-release formulation.
  • the administration is via inhaled delivery.
  • the inhaled delivery comprises an inhaled formulation.
  • the administration is via transdermal delivery.
  • the transdermal delivery comprises a transdermal formulation.
  • the administration is subcutaneous administration.
  • the administration is subcutaneous administration via a subcutaneous drug delivery device.
  • the drug delivery device is a Continuous ambulatory delivery device (CADD) pump.
  • CVD Continuous ambulatory delivery device
  • the subcutaneous administration comprises administration of a subcutaneous formulation.
  • the subcutaneous formulation is the intravenous formulation with additives.
  • the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 150 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.0833 mg/mL in the subcutaneous formulation.
  • the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 250 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.05 mg/mL in the subcutaneous formulation.
  • the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 500 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.025 mg/mL in the subcutaneous formulation.
  • the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 1000 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.0125 mg/mL in the subcutaneous formulation.
  • the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 1500 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.008333 mg/mL in the subcutaneous formulation.
  • the subcutaneous administration of the subcutaneous formulation comprises water in an amount effective to reduce pain caused by the subcutaneous administration.
  • the subcutaneous administration of the subcutaneous formulation comprises buffers to raise the pH higher than 3.5.
  • the subcutaneous administration of the subcutaneous formulation has reduced side effects relative to intravenous administration of levosimendan in the human subject.
  • the subcutaneous administration of the subcutaneous formulation reduces peak plasma concentrations of levosimendan relative to intravenous administration in the human subject.
  • the subcutaneous administration of the subcutaneous formulation reduces peak plasma concentrations of levosimendan relative to intravenous administration in the human subject by at least l% to 25%.
  • the amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof is administered in combination with a cardiovascular drug.
  • an amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof, and an amount of the cardiovascular drug, wherein the amounts when taken together are effective to treat the human subject are periodically adminstered to the human subject.
  • the amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof, and the amount of the cardiovascular drug when administered together is more effective to treat the subject than when each agent at the same amount is administered alone.
  • the amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof, and the amount of the cardiovascular drug when taken together is effective to reduce the symptoms of PH-HFpEF.
  • the cardiovascular drug is a drug used to treat pulmonary arterial hypertension (PAH), World Health Organization (WHO) Groups 1-5 pulmonary hypertension patients, coronary artery disease (CAD), or heart failure with reduced ejection fraction (HFrEF).
  • PAH pulmonary arterial hypertension
  • WHO World Health Organization
  • CAD coronary artery disease
  • HFrEF heart failure with reduced ejection fraction
  • the cardiovascular drug is a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta- blocker (BB), an angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), a natriuretic peptide, a K-
  • the cardiovascular drug is a pulmonary vasodilator drug.
  • the pulmonary vasodilator is a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), or a prostacyclin.
  • PDE5 phosphodiesterase-5
  • ERA endothelin receptor antagonist
  • the amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, administered in combination with the pulmonary vasodilator drug is administered to a human subject afflicted with pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc-PH-HFpEF).
  • no arrythmias, atrial or ventricular are observed when comparing baseline electrocardiographic monitoring with 72-hour monitoring after 5 weeks of treatment.
  • weekly 24-hour dosing of levosimendan is safe and well tolerated.
  • treating presents no more statistically significant adverse events than the matching placebo.
  • the weekly 24-hour dosing of levosimendan results in steady state blood levels of OR1896 in the range of 0.20 ng/mL to 25.00 ng/mL.
  • the invention also provides an article of manufacture comprising: a. a 5mL vial dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol; b. 250 mL of 5% Dextrose or 0.9 Normal Saline; and c. a buffer for increasing pH.
  • the invention also provides use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
  • PH-HFpEF Pulmonary Hypertension Heart Failure with preserved ejection fraction
  • the invention also provides use of an amount of levosimendan, its metabolites OR- 1896 or OR-1855, or a combination thereof, for preparing medicament for administering to a human subject afflicted with Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF to effectively treat PH-HFpEF in the human subject.
  • PH-HFpEF Pulmonary Hypertension Heart Failure with preserved ejection fraction
  • the invention also provides a medicament comprising an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for use in effectively treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
  • PH-HFpEF Pulmonary Hypertension Heart Failure with preserved ejection fraction
  • the invention also provides use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, in combination with a cardiovascular drug to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
  • PH-HFpEF Pulmonary Hypertension Heart Failure with preserved ejection fraction
  • the invention also provides use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for preparing a medicament in combination with a cardiovascular drug for administering to a human subject afflicted with Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) to effectively treat PH-HFpEF in the human subject.
  • PH-HFpEF Pulmonary Hypertension Heart Failure with preserved ejection fraction
  • the invention also provides a medicament comprising an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for use in combination with a cardiovascular drug to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
  • PH-HFpEF Pulmonary Hypertension Heart Failure with preserved ejection fraction
  • the invention also provides a subcutaneous formulation of levosimendan for use in treating PH-HFpEF in a human subject afflicted with PH-HFpEF, wherein the subcutaneous formulation is obtained from a dried powder, wherein the dried powder is obtained from a pharmaceutical composition comprising: (a) levosimendan; (b) sulfo-butyl -ether beta-cyclodextrin; (c) sodium hydroxide or acetic acid; and water for injection.
  • the amount of levosimendan is 2.5mg / ml water for injection.
  • the amount of sulfo-butyl -ether beta-cyclodextrin is 0.175mg / ml water for injection.
  • the sodium hydroxide or acetic acid is in a suitable amount to adjust the pH to a range of 7.2 to 7.8.
  • the pharmaceutical composition is fdter sterilized.
  • the pharmaceutical composition is lyophilized.
  • subcutaneous formulation of levosimendan is obtained from the dried powder by reconstitution of the dried powder in an amount of aqueous solution suitable for subcutaneous administration.
  • the reconstituted subcutaneous formulation is pH adjusted to 7.2 to 7.8 with sodium hydroxide or acetic acid.
  • the invention provides a method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of a cardiovascular drug that is effective to treat the PH-HFpEF in the human subject, wherein the cardiovascular drug is selected from the group consisting of a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta-blocker (BB), an angiotensin converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor
  • a PDE inhibitor a
  • the invention provides a method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of a pulmonary vasodilator drug that is effective to treat the PH-HFpEF in the human subject, wherein the pulmonary vasodilator drug is selected from the group consisting of a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), and a prostacyclin.
  • PDE5 phosphodiesterase-5
  • ERA endothelin receptor antagonist
  • the amount of the pulmonary vasodilator drug is administered to a human subject afflicted with pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc -PH-HFpEF).
  • the invention provides a cardiovascular drug for use in treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a subject, wherein the cardiovascular drug is selected from the group consisting of a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta-blocker (BB), an angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxi
  • the cardiovascular drug is selected from the
  • the invention provides a pulmonary vasodilator drug for use in treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a subject, wherein the pulmonary vasodilator drug is selected from the group consisting of a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), and a prostacyclin.
  • PDE5 phosphodiesterase-5
  • ERA endothelin receptor antagonist
  • the Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) is pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc -PH-HFpEF).
  • the subject is orally administered a capsule comprising up to O.lmg, 0.25mg, 0.5mg, 0.75mg, lmg, 2mg, 3mg, or 4mg, more preferably l-3mg, of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof.
  • the subject is administered a capsule once a day for a time period of 1-60 days, preferably 14 days.
  • the subject increases the number of capsules taken per day after every time period if the treatment is tolerated by the subject.
  • the subject is orally administered between 0.1-10mg of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, per day, preferably between l-4mg of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof per day.
  • the subject received a final intravenous injection of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof at least one day, more preferably at least one week, before beginning oral administration of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof.
  • the compound to be administered is in the form of a composition (referred to as the composition of the invention) comprising a therapeutically effective amount of at least one of said compound.
  • the term "effective amount” means an amount of compound that is capable of reducing and/or attenuating a disorder or symptom as described herein.
  • the specific dose of a compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the physiological state of the subject, and the severity of the condition being treated.
  • Any suitable route may be used to administer the medicament or levosimendan of the invention to a subject.
  • suitable administration routes may be systemic routes.
  • administering is administering systemically.
  • the composition is formulated for systemic administration.
  • administration systemically is through an enteral route.
  • administration through an enteral route is oral administration.
  • the composition is formulated for oral administration.
  • administration intermittently takes place via 24-hour, weekly administration.
  • the administration takes place chronically for less than 24 hours.
  • the dose is levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose, 0.9 Normal Saline, or other diluent where the human subject weights less than 85 kg.
  • the dose is levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose, 0.9 Normal Saline, or other diluent where the human subject weights at least 85 kg.
  • the infusion rate is between 0.075 and 0.10 pg/kg/min for 24 hours.
  • the administration is delivered via oral dosing.
  • the dosing can be an immediate release or extended release formulation.
  • the administration is delivered via inhalation of an inhaled formulation.
  • the administration is delivered via transdermal delivery of a transdermal formulation.
  • the invention is an article of manufacture including the 5mL vial dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol; 250 mL of 5% Dextrose or 0.9 Normal Saline; and a buffer for increasing pH.
  • the amount of levosimendan is effective to treat PH-HFpEF in a human subject.
  • the amount of levosimendan for preparing medicament for administration is effective to treat PH-HFpEF in a human subject.
  • the medicament has an amount of levosimendan that is effective to treat PH- HFpEF in a human subject.
  • the amount of levosimendan in combination with a cardiovascular drug is effective to treat PH-HFpEF in a human subject.
  • the amount of levosimendan in combination with a cardiovascular drug for preparing medicament for administration is effective to treat PH-HFpEF in a human subject.
  • the medicament has an amount of levosimendan in combination with a cardiovascular drug that is effective to treat PH-HFpEF in a human subject.
  • the weekly 24-hour dosing of levosimendan results in steady state blood levels of OR1896 in the range of 0.20 ng/mL to 25.00 ng/mL.
  • levosimendan means levosimendan base or a pharmaceutically acceptable salt thereof.
  • the active compounds for use according to the invention may be provided in any form suitable forthe intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the compound of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the L-tartrate, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like.
  • Such salts may be formed by procedures well known and described in the art.
  • PH is the abbreviation for Pulmonary Hypertension. PH encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance. (Oldroyd et al. 2019)
  • HFpEF is the abbreviation for heart failure with preserved ejection fraction. HFpEF is when a patient is afflicted with heart failure while their ejection fraction remains > 40%. (Kelly et al. 2015)
  • PH-HFpEF is the abbreviation for Pulmonary Hypertension with heart failure with preserved ejection fraction.
  • PH-HFpEF is defined by a high pulmonary artery pressure, high left ventricular end- diastolic pressure and a normal ejection fraction. (Lai et al. 2019)
  • PCWP is the abbreviation for pulmonary capillary wedge pressure.
  • PCWP is the pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch.
  • PCWP estimates left atrial pressure.
  • RAP is the abbreviation for right atrial pressure.
  • RAP is the blood pressure in the right atrium of the heart.
  • RAP reflects the amount of blood returning to the heart and the ability of the heart to pump the blood into the arterial system.
  • mPAP is the abbreviation for mean pulmonary artery pressure. mPAP is generated by the right ventricle ejecting blood into the pulmonary circulation, which acts as a resistance to the output from the right ventricle.
  • PVR is the abbreviation for pulmonary vascular resistance. PVR refers to the resistance in the arteries that supply blood to the lungs. (Schnur 2017)
  • CO is the abbreviation for cardiac output. CO is the volume of blood being pumped by the heart per unit time. (Vincent 2008)
  • Cl is the abbreviation for cardiac index.
  • Cl is a hemodynamic parameter that relates the cardiac output from the left ventricle in one minute to the body surface area. This measurement relates heart performance to the size of the individual. (Shea 2019)
  • HR is the abbreviation for heart rate. HR is the speed of the heartbeat measured by the number of contractions of the heart per minute. ( Heart.org 2015)
  • PR is the abbreviation for pulse rate. PR is the measurement of the heart rate. ( Heart.org 2015)
  • BP is the abbreviation for blood pressure.
  • BP is the pressure of circulating blood within the major arterial system of the body. (Brezinski 1990)
  • 6MWT is the abbreviation for six-minute walk test. 6MWT is a performance-based test used to measure functional exercise capacity. The 6MWT measures the distance an individual is able to walk over a total of 6 minutes at a constant and normal pace. (Vandoni et al. 2018)
  • Likert scale is a psychometric scale commonly involved in research that employs questionnaires. In the below-mentioned clinical trial, a six-question, five-point Likert Scale is provided to patients to assess their quality of life. (HELP clinical trial protocol)
  • ECG is the abbreviation for echocardiogram.
  • An ECG is a record of a person’ s heartbeat produced by echocardiography.
  • An ECG is a test that uses high frequency sound waves (ultrasound) to make pictures of your heart. ( heart.org 2015)
  • Dobutamine stress test is a form of ECG where stress is induced on the heart by administering dobutamine into a vein to assess the heart’s function and structures. This test mimics the effects of exercise on the heart.
  • New York Heart Association Functional Classification provides a simple way of classifying the extent of heart failure.
  • a patient in Class I has no limitation of physical activity.
  • a patient in Class II has slight limitation of physical activity.
  • a patient in Class III has marked limitation of physical activity.
  • a patient in Class IV is unable to carry on any physical activity without discomfort.
  • every patient is assigned a class letter based on an objective assessment.
  • a patient in Class A has no objective evidence of cardiovascular disease.
  • a patient in Class B has objective evidence of minimal cardiovascular disease.
  • a patient in Class C has objective evidence of moderately severe cardiovascular disease.
  • a patient in Class D has objective evidence of severe cardiovascular disease. (Y ancy et al. 2013)
  • Self-administration is administration of the formulation administered by the human subject afflicted with the disease. (HELP clinical trial protocol)
  • Outpatient setting is a setting where the patients do not require admittance for overnight care. (W orld Health Organization 2009)
  • Trained professional indicates a doctor, nurse, home healthcare nurse, or other person with training and/or experience and/or a license in the medical profession.
  • TEAEs is the abbreviation for Treatment Emergent Adverse Events.
  • the TEAEs of special interest are hypotension, atrial fibrillation, other significant arrhythmia, resuscitated death stroke.
  • Other TEAEs include, but are not limited to, headache, increased heart rate, fatigue, cardiac failure acute, dyspnea, vascular access site pain, muscle spasm, and hypokalaemia.
  • SAEs is the abbreviation for Serious Adverse Events.
  • SAEs include, but are not limited to, infections and infestations, device related infection; infections and infestations, bacteremia; cardiac disorders, cardiac failure acute; and cardiac disorders, cardiac failure acute.
  • acute administration means administration of a drug, e.g. levosimendan, in a brief period of time, for example, delivery of a single dose of a drug, delivery of doses of a drug in rapid succession, or delivery of a drug on short time scale, preferably less than 48 hours.
  • Acute administration of a drug is generally intended for the drug to have a beneficial effect on a condition in the short-term.
  • acute administration of levosimendan may be performed such that the amount of levosimendan administered is intended for the levosimendan drug to directly improve a condition, e.g. PH- HFpEF, prior to any significant activity of a levosimendan metabolite.
  • Acute administration is generally performed by a trained professional, for example, by intravenous administration in a clinical setting.
  • chronic administration means an extended and repeated administration of a drug, e.g. levosimendan. For example, delivery of multiple or repeated doses of a drug over the course of a long-time scale, preferably at least a week.
  • Chronic administration of a drug is generally intended for the drug or its metabolites to have a continued beneficial effect on a condition or to prevent or slow deterioration of a disease-state over time.
  • Chronic administration is often delivered to a subject by the subject themselves (i.e. self-administration), for example, by oral or subcutaneous administration.
  • the present invention also relates to subcutaneous administration of levosimendan in a subcutaneous formulation to achieve the effects disclosed herein. Due to the potentially irritating, vesicant, and extravasation effects of administering inotropes and vasoactive substances, such as levosimendan, subcutaneous administration of the existing levosimendan formulation has not previously been investigated. Nevertheless, subcutaneous administration may be used where a less invasive route of delivery would be a novel method of administration.
  • the subcutaneous route of levosimendan administration may be better tolerated than intravenous delivery.
  • Subcutaneous administration may reduce and delay absorption of levosimendan, resulting in lower peak plasma concentrations of levosimendan as compared to intravenous administration. This may avoid the occurrence of typical side effects of levosimendan administration, particularly hypotension caused by the maximum concentration of levosimendan (Cmax) because higher plasma concentrations and a higher Cmax of levosimendan typically leads to more frequent side effects, such as hypotension.
  • Cmax maximum concentration of levosimendan
  • Subcutaneous administration of levosimendan offers a clear advantage in terms of eliminating the potential for central line infections that are common with IV chronic administration via PICC and port-a- cath devices that are often necessary for convenient repeated IV access.
  • One delivery device suitable for subcutaneous administration is an ambulatory infusion pump, such as a CADD pump, which stands for continuous ambulatory delivery device pump. Additionally, subcutaneous administration could be delivered through a simple prefilled syringe, syringe pump, injection pen, autoinjector, micropump, or patch device. (Bittner et al. 2018) [0308] Although in the present instance the subcutaneous formulation would be substantially similar to the intravenous formulation, certain additives could be introduced to make the treatment more tolerable for the patient. Buffers, such as water, sodium bicarbonate, or other similar buffering agents that are known to increase pH, could be added to increase the pH of the subcutaneous formulation.
  • Buffers such as water, sodium bicarbonate, or other similar buffering agents that are known to increase pH, could be added to increase the pH of the subcutaneous formulation.
  • the subcutaneous administration of levosimendan can be administered intermittently as well as chronically.
  • the intermittent administration can take place weekly for a 24-hour period.
  • subcutaneous administration makes it much simpler for the patient to self-administer the levosimendan formulation.
  • Subcutaneous administration of levosimendan can support an expanded range of dilutions and corresponding concentration while still being viable.
  • subcutaneous administrations are known in the art, and any such method may be used for subcutaneous administration of levosimendan.
  • Examples of subcutaneous administration methods include, but are not limited to, manual needle injection and various subcutaneous drug delivery devices such as subcutaneous administration systems that deliver a drug via a pump apparatus such as performed with certain insulin pump systems, e.g. the Omnipod ⁇ system.
  • the subcutaneous formulation comprises water in an amount effective to reduce pain caused by the administration.
  • the subcutaneous formulation comprises buffers to raise the pH higher than 3.0.
  • the subcutaneous administration reduces side effects relative to intravenous administration.
  • the subcutaneous administration reduces peak plasma concentrations of levosimendan relative to intravenous administration by at least 1% to 25%.
  • a pharmaceutical composition of levosimendan for treatment in subjects in need thereof, for example, for treatment of heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients), by subcutaneous administration is in a formulation comprising: (a) an effective amount of levosimendan, its metabolites OR- 1896 or OR-1855, or a combination thereof; (b) a cyclodextrin or a cyclodextrin derivative; and (c) one or more additional pharmaceutically acceptable additives.
  • the cyclodextrin derivative comprises an alpha-cyclodextrin derivative, a beta- cyclodextrin derivative, or a gamma-cyclodextrin derivative.
  • the cyclodextrin derivative comprises sodium sulfonate salt.
  • the cyclodextrin derivative comprises a butyl ether spacer group, an alkyl ether space group, or a combination thereof.
  • the cyclodextrin derivative comprises sulfobutylether.
  • the cyclodextrin derivative comprises sulfobutylether beta-cyclodextrin.
  • the cyclodextrin or cyclodextrin derivative is in an amount of about 50 mg/ml to about 400 mg/ml, preferably in an amount of about 100 mg/ml to about 300 mg/ml.
  • the formulation comprises a pH of about 5 to about 9, preferably a pH of about 6 to about 8.
  • the one or more pharmaceutically acceptable additives comprise one or more non-citrate buffering agents.
  • the one or more pharmaceutically acceptable additives comprise a phosphate buffer.
  • the one or more pharmaceutically acceptable additives comprise one or more pH-modifying agents.
  • the one or more pharmaceutically acceptable additives comprise one or more preservatives, one or more antioxidants, one or more carriers, or a combination thereof.
  • the one or more carriers comprise a liquid media selected from a group consisting of solutions, suspensions, hydrogels, liposomes, emulsions, and a combination thereof.
  • the one or more carriers alter the absorption characteristics in a way that extend the effectiveness and or minimize side effects.
  • the levosimendan is in an amount of about 0.1 mg/ml to about 100 mg/ml, preferably in an amount of about 0.1 mg/ml to about 30 mg/ml.
  • the formulation is substantially free of alcohol.
  • the formulation is alcohol-free.
  • the formulation is preservative-free.
  • the formulation is in the form of particles.
  • the formulation is lyophilized.
  • the formulation is spray-dried.
  • a pharmaceutical composition for subcutaneous administration of levosimendan is in a formulation comprising: (a) levosimendan in an amount of about 0.1 mg/ml to about 10 mg/ml; (b) a cyclodextrin or a cyclodextrin derivative in an amount of about 50 mg/ml to about 500 mg/ml; and (c) phosphate buffer of about 1 mM to about 20 mM.
  • the formulation has a pH of about 6 to about 8.
  • the formulation is substantially free of alcohol.
  • the formulation is lyophilized.
  • levosimendan formulations that have been described for intravenous administration may be adopted for subcutaneous administration.
  • levosimendan formulations suitable for subcutaneous administration include, but are not limited to, a pharmaceutical composition, comprising levosimendan as active ingredient, and a solubilizer selected from the group consisting of cyclodextrins, consisting of sulfo-butyl- ether beta-cyclodextrin, alpha-cyclodextrin and methyl-beta-cyclodextrin and mixtures thereof, fatty acid esters of glycerol, polyethylene derivatives of alpha-tocopherol, bile acids, with the proviso that the use of co-solvents such as ethanol, propyleneglycol, polyethyleneglycol, poloxamers or polyvinylpyrroli
  • the solubilizer is D-alpha tocopheryl polyethylene glycol 1000 succinate or a bile salt, which is preferably selected from the group consisting of sodium glycocholate, taurocholic acid sodium salt, taurodeoxycholic acid sodium salt and sodium cholate, or mixtures thereof.
  • the micelles are polymeric micelles, preferably polyethylene oxide)- poly(propylene oxide) block copolymer micelles, or mixed micelles composed of soy phosphatidylcholine/sodium glycocholate or hybrid micelles.
  • the pharmaceutical composition comprises levosimendan as active ingredient, and sulfo-butyl-ether beta-cyclodextrin as a solubilizer, with the proviso that the use of co-solvents comprised of ethanol, propyleneglycol, polyethyleneglycol, poloxamers or polyvinylpyrrolidon is excluded.
  • sulfo-butyl-ether beta-cyclodextrin is preferably present in a mmolar ratio compared to levosimendan within a range of 1-15 mmol cyclodextrine(s): 1 mmol levosimendan.
  • the excess of cyclodextrine(s) is 4-12 mmol cyclodextrine(s): 1 mmol levosimendan, still more preferably 6-10 mmol cyclodextrine(s): 1 mmol levosimendan.
  • levosimendan is present in solubilized form.
  • levosimendan is solubilized by micellarization or by complexation.
  • the pharmaceutical composition is in the form of a solution, more preferably in the form of an aqueous solution.
  • the amount of the solubilizer is 2 to 45 percent by weight of the pharmaceutical composition.
  • the pH of the solution is in the range of 7.0 to 8.0., more preferably in the range of 7.2 to 7.8.
  • the levosimendan in an amount of 1 to 15 mg/ml solution.
  • a dried powder is obtained from the pharmaceutical composition for use as a medicament in treating heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients).
  • the dried powder is obtainable by drying a solution comprising the solubilized levosimendan, and is reconstituted to a solution suitable for subcutaneous administration.
  • the dried powder for use is a subcutaneous infusion concentrate comprising the levosimendan in an amount of 1 to 15 mg/ml solution.
  • the concentrate is to be adjusted to a pH in the range of 7.2 to 8.0.
  • the solvent for reconstitution of the dried powder for use is water, or an isotonic buffer system.
  • the water has a pH in the range of 7.2 to 7.8, or the isotonic buffer system has a pH in the range of 7.2 to 7.4
  • the dried powder is obtainable by drying a solution comprising the solubilized levosimendan and a suitable pharmaceutical vehicle used for freeze-drying.
  • the present discolusre provides a subcutaneous formulation of levosimendan for use in treating PH-HFpEF in a human subject afflicted with PH-HFpEF, wherein the subcutaneous formulation is obtained from a dried powder, wherein the dried powder is obtained from a pharmaceutical composition comprising: (a) levosimendan; (b) sulfo-butyl-ether beta-cyclodextrin; (c) sodium hydroxide or acetic acid; and water for injection.
  • the amount of levosimendan is 2.5mg / ml water for injection.
  • the amount of sulfo-butyl-ether beta-cyclodextrin is 0.175mg / ml water for injection.
  • the sodium hydroxide or acetic acid is in a suitable amount to adjust the pH to a range of 7.2 to 7.8.
  • the pharmaceutical composition is fdter sterilized.
  • the pharmaceutical composition is lyophilized.
  • the subcutaneous formulation of levosimendan is obtained from the dried powder by reconstituting the dried powder in an amount of aqueous solution suitable for subcutaneous administration.
  • the reconstituted subcutaneous formulation is pH adjusted to 7.2 to 7.8 with sodium hydroxide or acetic acid.
  • the present invention also relates to oral administration of levosimendan in an oral formulation to achieve the effects disclosed herein.
  • oral administration such as: being easily administered and titrated, facilitating patient control, and reducing nursing burden.
  • oral administration is in the form of hard or soft gelatin capsules, pills, capsules, tablets, including coated tablets, dragees, elixirs, suspensions, liquids, gels, slurries or syrups and controlled release forms thereof.
  • the invention provides a method of administering levosimendan in the form of a tablet, a capsule, or in a liquid.
  • Suitable carriers for oral administration are well known in the art.
  • Compositions for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries as desired, to obtain tablets or dragee cores.
  • suitable excipients include fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, and sodium carbomethylcellulose, and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • disintegrating agents such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate, may be added.
  • Capsules and cartridges of, for example, gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base, such as lactose or starch.
  • Solid dosage forms for oral administration include without limitation capsules, tablets, pills, powders, and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms can also comprise, as it normal practice, additional substances other than inert diluents, e.g., lubricating, agents.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • enteric coating refers to a coating which controls the location of composition absorption within the digestive system.
  • Non-limiting examples for materials used for enteric coating are fatty acids, waxes, plant fibers or plastics.
  • Liquid dosage forms for oral administration may further contain adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
  • the administration is delivered via oral dosing, and the oral dosing can be an immediate release or extended release formulation.
  • a pharmaceutical composition of levosimendan for treatment in subjects in need thereof, for example, for treatment of heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients), by oral administration is in a formulation comprising an effective amount of levosimendan, its metabolites OR- 1896 or OR- 1855, or a combination thereof and one or more additional pharmaceutically acceptable additives.
  • the oral formulation comprises levosimendan, its metabolites OR- 1896 or OR- 1855, or a combination thereof in the amount of O.lmg, 0.25mg, 0.5mg, 0.75mg, lmg, 2mg, 3mg, or 4mg.
  • the oral formulation comprises microcrystalline cellulose.
  • the oral formulation comprises alginic acid.
  • the oral formulation comprises steric acid.
  • the oral formulation is in a capsule form.
  • the oral formulation is the capsule form is a HPMC capsule.
  • the oral formulation comprise in a capsule form and the oral formulation comprises lmg levosimendan, 96.4mg microcrystalline cellulose, 30.0mg alginic acid, and 5.3mg stearic acid.
  • the oral dosage form comprises levosimendan in the amount of O.lmg, 0.25mg, 0.5mg, 0.75mg, lmg, 2mg, 3mg, or 4mg, more preferably in the amount of l-3mg.
  • a subject is orally administered a capsule comprising levosimendan in the amount of lmg once per day.
  • the oral dosing may be titrated according to, for example, the effectiveness of the treatment, tolerability, changes in heart rate, and body weight of the subject.
  • the titration of levosimendan may be in lmg increments and range from 1-lOmg per day, more preferably between l-4mg per day.
  • the titration of levosimendan administration may occur over the course of days, weeks, or months.
  • the effect of duration at a particular dosage amount on tolerability should also be considered when titrating, e.g. the tolerability of a subject to the levosimendan oral treatment may increase with an increase in duration at a particular dosage amount.
  • a subject may begin an oral levosimendan treatment course at lmg/day (i.e. ingesting one capsule comprising lmg levosimendan per day).
  • the subject may maintain a levosimendan dosage of lmg/day for two weeks.
  • the levosimendan dosage is well-tolerated and heart rate is increased ⁇ 15 BPM, the subject can titrate up to a dosage of 2mg/day (i.e. ingesting two capsules, each comprising lmg levosimendan, per day).
  • the subject may continue to titrate up in increments of lmg levosimendan in this manner until an optimal oral dosage is achieved, for example, up to lOmg of levosimendan per day.
  • a subject receiving levosimendan by other administration routes may be transitioned to an oral dosing scheme.
  • a subject receiving levosimendan by intravenous injection may begin an oral dosing after receiving a final 24-hour infusion of levosimendan.
  • the oral dosing of levosimendan may begin within days or weeks, for example, one week, of the final 24- hour infusion.
  • the oral dosage may begin at lmg/day, followed by titration as indicated above.
  • “combination” means an assemblage of reagents for use in therapy either by simultaneous, contemporaneous, or fixed-dose combination delivery.
  • Simultaneous delivery refers to delivery of an admixture (whether a true mixture, a suspension, an emulsion or other physical combination) of the drugs.
  • the combination may be the admixture or separate containers of the levosimendan and a second agent that are combined just prior to delivery.
  • Contemporaneous delivery refers to the separate delivery of the levosimendan and second agent at the same time, or at times sufficiently close together that an additive or preferably synergistic activity relative to the activity of either the levosimendan or the cardiovascular drug alone is observed.
  • Fixed-dose combination delivery refers to the delivery of two or more drugs contained in a single dosage form for oral administration, such as a capsule or tablet.
  • second agent for use in combination therapy includes any one of the following: Phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA) (e.g., Bosentan, Ambrisentan), a Prostanoid (e.g., Trepostinil, Selexipag, Ralinepag), a Soluble Guanylate Cyclase stimulator (e.g., Riociguat), a nitrate or nitrite, a calcium channel blocker (CCB), fatty acid oxidation inhibitors (e.g., Ranolazine, Trimetazidine), a beta-blocker (BB), an Angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor (e.g., Sacubitril, Sampatrilat, Gemopatrilat, Fasidotril, Omapatrilat, Candoxatril), a neprilysin and angiotens
  • PDE5 Phosphodieste
  • the recommended dose and schedule for Entresto is 24/26 mg twice daily (24 mg of sacubitril and 26 mg of valsartan). The dose is doubled every two to four weeks, as tolerated by the patient.
  • the composition recited hereinabove is described in U.S. Patent Nos. 7,468,390; 8,101,659; 8,404,744; 8,796,331; 8,877,938; and 9,388,134, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Sacubitril is 24 mg twice daily. The dose is doubled every two to four weeks, as tolerated by the patient.
  • the recommended dose and schedule for Ranolazine is 500 mg twice daily.
  • the dose is increased to 1000 mg twice daily, as needed, based on clinical symptoms.
  • the composition recited hereinabove is described in U.S. Patent Nos. 6,303,607; 6,369,062; 6,479,496; 6,503,911; 6,525,057; 6,562,826; 6,617,328; 6,620,814; 6,852,724; and 6,864,258, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Bosentan is 62.5 mg twice daily for patients > 12 years of age. After 4 weeks, the dose is increased to 125 mg twice daily if the patient weighs greater than 40 kg, and the dose is not changed if the patient weights less than 40kg.
  • the composition recited hereinabove is described in U.S. Patent Nos. 7,959,945 and 8,309,126, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Ambrisentan is 5 mg orally once a day.
  • the dose is increased to 10 mg orally once a day, if 5 mg is tolerated by the patient.
  • the composition recited hereinabove is described in U.S. Patent Nos. 8,377,933; 9,474,752; and 9,549,926, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Trepostinil is 0.25 mg orally every 12 hours or 0.125 mg every 8 hours for oral extended-release tablets; 3 breaths (18 meg) per treatment session 4 times per day or if not tolerated then reduce to 1 or 2 breaths and subsequently increase to 3 breaths as tolerated for inhalation; or 1.25 ng/kg/min via continuous subcutaneous or IV infusion or 0.625 ng/kg/min if the larger dose cannot be tolerated for patients new to prostacyclin infusion therapy.
  • the composition recited hereinabove is described in U.S. Patent Nos. 10,076,505; 7,999,007; 8,653,137; 8,658,694; 9,199,908; 9,593,066; 9,604,901; and 9,713,599, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Selexipag is 200 meg orally twice a day.
  • the dose is incrementally increased by 200 meg orally twice a day at weekly intervals to the highest tolerated dose, not to exceed 1600 meg orally twice a day.
  • the composition recited hereinabove is described in U.S. Patent Nos. 7,205,302;8,791,122; 9,173,881; and 9,284,280, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Ralinepag is 10 pg twice daily to 300 pg twice daily.
  • the composition recited hereinabove is described in Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial (Torres et al. 2019), the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Riociguat is 1 mg orally 3 times a day. This dose is increased as tolerated, but is not to exceed 2.5 mg orally 3 times a day.
  • the composition recited hereinabove is described in U.S. Patent Nos. 6,743,798 and 7,173,037, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Trimetazidine is 60 mg/day to 140 mg/day.
  • the composition recited hereinabove is described in Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease (Chrusciel et al. 2014), the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Sampatrilat is 50 mg to 100 mg daily.
  • composition recited hereinabove is described in Sustained Antihypertensive Actions of a Dual Angiotensin-Converting Enzyme Neutral Endopeptidase Inhibitor, Sampatrilat, in Black Hypertensive Subjects (Norton et al. 1999), the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Fasidotril is 100 mg twice daily.
  • the composition recited hereinabove is described in Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans (Laurent et al. 2000), the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Omapatrilat is 10 mg to 80 mg daily.
  • the composition recited hereinabove is described in Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial (Kostis et al. 2004), the entire contents of which are incorporated by reference.
  • OCTAVE Omapatrilat Cardiovascular Treatment vs. Enalapril
  • the recommended dose and schedule for Candoxatril is 200 mg twice a day to 400 mg twice a day.
  • the composition recited hereinabove is described in Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure (Northridge et al. 1999), the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Digoxin is 8 to 12 mcg/kg through intravenous administration for the total loading dose and increased to 0.1 to 0.4 mg/day for the maintenance regiment.
  • the dose and schedule is 10 to 15 mcg/kg for the total loading dose and increased to 3.4 to 5.1 mcg/kg/day.
  • Another dosing option is 0.125 to 0.25 mg per day for oral or intravenous administration, with higher doses of 0.375 to 0.5 mg/day rarely needed.
  • the composition recited hereinabove is described in Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction (Virgadamo et al. 2015), the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Ivabradine is 5 mg orally twice a day with meals. This dose is increased as tolerated, but is not to exceed 7.5 mg orally twice a day.
  • the composition recited hereinabove is described in U.S. Patent Nos. 7,361,649; 7,361,650; 7,867,996; and 7,879,842, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Hydralazine is 10 mg orally 4 times a day for the first 2 to 4 days, increased to 25 mg orally 4 times a day for the balance of the first week. This dose is increased to 50 mg orally 4 times a day for week 2 and subsequent weeks.
  • the composition recited hereinabove is described in U.S. Patent Nos. 6,465,463 and 6,784,177, the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Seralaxin is three 48-hour intravenous infusions of 30 pg/kg/day.
  • the composition recited hereinabove is described in RELAX-REPEAT: A Multicenter, Prospective, Randomized, Double-Blind Study Evaluating the Safety and Tolerability of Repeat Doses of Serelaxin in Patients with Chronic Heart Failure (Teerlink et al. 2016), the entire contents of which are incorporated by reference.
  • the recommended dose and schedule for Nesiritide is 2 mcg/kg IV bolus, followed by 0.01 mcg/kg/min via continuous IV infusion; not to be titrated more frequently than every 3 hours to a maximum of 0.03 mcg/kg/min.
  • the composition recited hereinabove is described in U.S. Patent No. 5,114,923, the entire contents of which are incorporated by reference.
  • K-ATP channel activators e.g. pinacidil, diazoxide, bimakalim, levocromakalim, cromakalim, rimakalim, and nicorandil, etc.
  • nitrates e.g. nitroglycerin-NTG, isosorbide dinitrate, etc.
  • nitrites e.g. sodium nitrite, amyl nitrite, etc.
  • NO donors- Sodium nitroprusside, Nitric Oxide, Molsidomine, linsidomine
  • PDE inhibitors e.g.
  • natriuretic peptides such as BNP (e.g. nesiritide), ANP (e.g. carparetide and ularitide), CDNP (e.g. cenderitide), and others (e.g. CNP, DNP, MANP, etc.); NEP inhibitors (e.g. sacubitril, sampatrilat/sympatril, fasidotril, omapatrilat/omapatril, candoxatril, etc.); and ARNIs (Entresto).
  • a combination therapy with levosimendan may include any of the above second agents, a diuretic, or both.
  • Cpc-PH-HFpEF combined pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction
  • a combination therapy of Levosimendan with a pulmonary vasodilator including but not limited to, phosphodiesterase-5 inhibitors (PDE-5 inhibitors, e.g. sildenafil, tadalafil, etc.); endothelin receptor antagonists (ERAs, e.g. bosentan, ambrisentan, etc.); and prostacyclins (e.g. epoprostenol, iloprost, Treprostinil, etc.) may provide therapeutic benefits to Cpc-PH-HFpEF patients.
  • PDE-5 inhibitors e.g. sildenafil, tadalafil, etc.
  • ERAs endothelin receptor antagonists
  • prostacyclins e.g. epoprostenol, iloprost, Treprostinil, etc.
  • Each drug can be administered in the dose and regiment that has been disclosed in the drug’s aforementioned literature.
  • the embodiments referred to above refer to several drugs being substantially effective in the body at a same time.
  • Several drugs can be administered substantially at the same time, or can be administered at different times but have effect on the body at the same time. For example, this includes administering levosimendan before or subsequently, while functioning of levosimendan in the body is substantially extant.
  • a multicenter, Phase II, double-blind, randomized, placebo-controlled study is conducted of levosimendan in pulmonary hypertension patients with heart failure and preserved left ventricular ejection fraction (PH-HFpEF) designed to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects.
  • PH-HFpEF left ventricular ejection fraction
  • Subjects are administered Levosimendan as follows: A sterile Levosimendan 2.5 mg/mL concentrated solution that is diluted in 250-500mL of 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/mL solution for infusion.
  • Subjects are administered Matching Placebo as follows: A sterile Placebo 2.5mg/mL concentrate solution that is diluted in 250-500mL of 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/mL solution for infusion.
  • Dialysis at randomization either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafiltration.
  • SBP Symptomatic low systolic blood pressure
  • Enrolled PH-HFpEF subjects receive a lead-in 24-hour levosimendan infusion to determine their hemodynamic response and eligibility for the double-blind phase of the study.
  • a total of 36 “responders” are randomized in the double-blind, placebo-controlled phase.
  • “Responders” are identified as those subjects with a > 4mmHg reduction in PCWP during bicycle exercise (25 watts) and no more than a 10% decrease in cardiac index between the baseline measurements and repeated measurements following the initial infusion.
  • Study drug is administered via i.v. infusion over 24 hours weekly through Week 5 via a PICC line. Infusions (Week 2-5) are done in the subject’s home by a study nurse. Patients return to the study site for a visit between the Week 3 and Week 4 infusions for assessment of subject safety/response and need for dose adjustment. Each subject is to return on Week 6 for assessment of efficacy and safety on study drug. A right heart catheter will be inserted to obtain hemodynamic measurements at rest and exercise at baseline, the following day after the lead-in 24-hour infusion, and during Week 6.
  • levosimendan supplied as a concentrated solution (2.5 mg/mL), is mixed with diluent and administered intravenously at 0.10 pg/kg/min for 24 hours +/- 30 min.
  • study drug concentrated solution (2.5 mg/mL), levosimendan or placebo, is mixed with diluent and administered via a PICC line as weekly infusions at 0.075 pg/kg/min for 24 hours.
  • Patients undergo a dose escalation at Week 4 and 5 (0.10 pg/kg/min for 24 hours) unless there has been a meaningful change in blood pressure or heart rate.
  • Infusion rates may be reduced to 0.05 pg/kg/min if the higher dose is not we 11 -tolerated at any time during the initial 5 weeks.
  • the study is divided into a Screening phase, a Lead-In phase, and a Double-Blind treatment phase.
  • the Screening, Lead-In, Interim Office (between Weeks 3 and 4) and Week 6 visits occurs at the investigator’s office.
  • Infusions at Weeks 2, 3, 4 and 5 occur at the subject’s home under the care of a home healthcare nurse.
  • Subjects are instructed to contact the investigator at any time during the 24 hour at home infusions to report adverse events, or at any time they would like to speak with the investigator regarding the study or to report adverse events during the entirety of the trial.
  • Visits during the Lead-In phase of the trial require a subject to be hospitalized for the entire infusion period, which at a minimum will last 24 hours. Once the infusion is complete, hemodynamic measurements are collected to ensure subject eligibility. Visits for Week 2 through Week 6 are calculated based on the date of the Lead-in infusion.
  • Obtain signed main study ICF (must be obtained prior to performance of any study-specific tests or evaluations that are not considered standard of care), confirm inclusion/exclusion criteria, history of qualifying hemodynamics, conduct a medical history, body weight, record prior/concomitant medications including all prescription and non-prescription drugs, vitamins, and dietary or herbal supplements, record demographic information, perform complete physical examination, including height and body weight, urine pregnancy test (women of child-bearing potential only), hematology and clinical chemistry blood samples, measure vital signs (BP, PR, respiratory rate, temperature), Child-Pugh Class, NYHA Functional Class, Conduct 12-lead ECG, Echocardiogram (within 3 months of Day 0) that must be repeated prior to Baseline, and perform 6-minute walk test.
  • the sheath is then used for access for the right heart catheterization study following the 24-hour levosimendan infusion, and then removed), right heart catheterization measurements: baseline (prior to levosimendan infusion) and post 24-hour infusion to establish qualifying baseline hemodynamics at rest and exercise and to establish qualifying response to levosimendan during exercise, assess adverse events, assess concomitant medications and/or procedures, pharmacokinetic sampling (to be taken at the end of infusion: 24 +/- 2 hours), genotyping sampling (to be taken at the end of infusion: 24 +/- 2 hours). Subjects who do not respond to levosimendan based on hemodynamic measurements are withdrawn from screening. A PICC line is placed in patients that meet eligibility criteria and who are randomized into the Double-Blind phase of the study.
  • Visits at Weeks 2, 3, 4, and 5 are performed within +/- 48 hours of the scheduled visit. Visits for Weeks 2-5 are calculated based on the date of the Lead-in infusion. These visits are performed at the subject’s home with the aid of the home health care nurse. The home health care nurse remains with the patient for the first 2-3 hours of the infusion to ensure patient safety. The home health care nurse visits the patient again at 24 hours to stop the infusion and assess the patient’s status. During this visit, the following procedures are performed: Record any changes in procedures, prescription and non-prescription drugs, vitamins, and dietary or herbal supplements; measure vital signs prior to starting the infusion, after the first 2 hours (+/- 30 min), and after 24 hours (+/- 30 min); assess adverse events and study drug administration.
  • the Interim Office Visit is performed 48 hours prior to the Week 4 infusion visit. This visit is performed at the investigator’s office. Infusions do occur at the office during these visits. During this visit, the following procedures are performed: 6-minute walk test, quality of life (QOL) assessment, NYHA Functional Class determination, body weight, dispense cardiac monitoring patch, and all procedures listed in the Weekly infusion visits with the exception of infusion. [0475] Visits at Week 6 should be performed 3-6 days following completion of the Week 5 infusion.
  • the 6-minute walk test (6MWT) is performed at approximately the same time of day at each study visit after the Baseline Visit and ideally, one of the first assessments to be performed.
  • the ECHO and subject questionnaire are performed after the 6MWT has been completed.
  • the 6MWT is performed using the methods described in the American Thoracic Society (ATS) Statement: Guidelines for the Six-Minute Walk Test. The test is performed at approximately the same time of day when assessed and by the same evaluator whenever possible.
  • ATS American Thoracic Society
  • the 2-dimensional (2D) echocardiogram complete with contrast is performed by trained personnel.
  • These assessments are standard transthoracic 2D echocardiograms (with contrast to optimize accuracy and precision of intracardiac measurements. These may include, but are not limited to: left ventricular systolic and diastolic function, size, mass, and geometry; right ventricular size and function; pulmonary artery size; left atrial dimensions, volumes, and pressures; valvular (aortic, mitral, tricuspid and pulmonary) stenosis and regurgitation (severity); and pulmonary artery systolic pressure (PASP) and inferior vena cava (IVC) caliber.
  • PASP pulmonary artery systolic pressure
  • IVC inferior vena cava
  • Vital signs and body weight include: body temperature, heart rate, respiratory rate, and blood pressure (systolic and diastolic blood pressure). Blood pressure is determined by cuff (using the same method, same arm, and in the same position throughout the study).
  • the Hematology and Coagulation Panel includes the following tests: hematocrit, hemoglobin, white blood cell (WBC) count with differential, platelet count, prothrombin time, and partial thromboplastin time.
  • the Serum Chemistry Panel includes the following test: sodium, potassium, bicarbonate, blood urea nitrogen (BUN), and creatinine.
  • PCWP decrease Hemodynamic response to treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF can be predicted by a patient’s change in stroke volume seen between rest and exercise.
  • Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a significantly greater reduction in right atrial pressure compared to subjects afflicted with PH-HFpEF treated with a placebo.
  • Treatment with weekly 24-hour infusions of 0.075 - 0.1 mg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a significantly greater reduction in mean pulmonary arterial pressure compared to subjects afflicted with PH-HFpEF treated with a placebo.
  • Dialysis developed since enrollment in parent study (either hemodialysis, peritoneal dialysis, continuous veno venous hemofdtration, or ultrafdtration).
  • SBP stolic blood pressure
  • Subjects are visited by the home healthcare nurse until they can satisfactorily demonstrate their ability to self-administer the study drug with a target for self-administration at Weeks 4-6, but not lasting past 8 weeks. After 8 weeks, home healthcare support ceases. Home healthcare visits can be scheduled later in the study if the investigator identifies a clinically urgent need. The subject is instructed on the preparation, administration, and disposal/retum of levosimendan (including ancillary supplies) by the home healthcare nurse. The process for distribution of study drug to the subject’s home is the same throughout the study
  • Study drug concentrated solution (2.5 mg/mL), levosimendan, is mixed with diluent and administered as weekly infusions at 0.075 pg/kg/min for 24 hrs. Patients may have a dose escalation at Weeks 3 at a rate of 0.10 pg/kg/min for 24 hours, unless there has been a meaningful change in blood pressure or heart rate or other prohibitive rationale.
  • the home health care nurse visits the subject to assist with the infusions to ensure the patient is self-sufficient in use of the port-a-cath.
  • a subject that chooses to continue with a PICC line after Week 3 is transitioned to a port-a-cath once the PICC line fails or will be discontinued from the study.
  • the Investigator obtains written informed consent from each patient, after which confirmation of eligibility criteria is performed.
  • confirmation of eligibility criteria is performed.
  • the following procedures are performed: Obtain signed main study ICF (must be obtained prior to performance of any study-specific tests or evaluations that are not considered standard of care); confirm inclusion/exclusion criteria, concomitant medications including all prescription and non-prescription drugs, vitamins, and dietary or herbal supplements; perform complete physical examination, including height and body weight; and information documented in the parent study for the following procedures is transferred to the eCRF of the current study.
  • Subjects are visited by the home healthcare nurse until they can satisfactorily demonstrate their ability to self-administer the study drug, with a target for self-administration 4-6 weeks after beginning the study. After 8 weeks, home healthcare support ceases. Home health care visits can be scheduled later in the study if the investigator identifies a clinically urgent need. Once a subject adequately demonstrates their ability to self-administer the study drug, the procedures listed below will become not-applicable, other than reporting any adverse events to the investigational site. These visits may be performed at the subject’s home. Subjects are instructed to inform the investigator of any infusion related events or AEs that occur during this visit. During these visits, the following procedures are performed (as applicable): Record any changes in procedures, prescription and non-prescription drugs, vitamins, and dietary or herbal supplements; measure vital signs; assess adverse events; and study drug administration and accountability.
  • Example 1 A study is conducted analogous to Example 1. However, certain parameters are modified to allow for a different form of administration. [0531] A subcutaneous levosimendan formulation administered via subcutaneous administration. The subcutaneous formulation will be substantially similar to the intravenous formulation in Example 1.
  • Results are substantially similar to the result of Example 1, with a decrease in injection site and/or central line infections when compared to intravenous infusion administration. Additionally, an increase in quality of life assessment and/or convenience of administration occurs due to the easier route of delivery.
  • a levosimendan formulation is administered substantially as in Example 1, but administered in combination with Entresto.
  • Results are substantially similar to Example 1, with an improvement in cardiovascular hemodynamics, exercise performance, and quality of life.
  • a levosimendan formulation is administered substantially as in Example 1, but administered in combination with Sacubitril and/or other neprilsyn inhibitors.
  • Results are substantially similar to Example 1, with an improvement in cardiovascular hemodynamics, exercise performance, and quality of life.
  • a levosimendan formulation is administered substantially as in Example 1, but administered in combination with Ranolazine.
  • Results are substantially similar to Example 1, with an improvement in cardiovascular hemodynamics, exercise performance, and quality of life.
  • a pharmacokinetic study was conducted in male Sprague Dawley rats to compare subcutaneous administration of a composition of the present invention with IV administration of a formulation of levosimendan. The study evaluated levosimendan blood levels and pain at the injection site.
  • This study involved comparing the results of administering two subcutaneous compositions according to embodiments of the present invention to a previous pharmacokinetic study in which male rats were dosed by tail vein levosimendan as an IV bolus injection at 0.5 mg/kg using a 0.25 mg/ml solution.
  • this study comprised three study arms: a. IV administration of a composition comprising levosimendan (0.25 mg/ml) and phosphate buffer (10 mmolar), prepared in sterile water for injection and adjusted to a pH of 7.0 to 7.9 using 1 N NaOH or 10 N NaOH; this composition was administered at a dose of 0.5 mg/kg.
  • Subcutaneous administration of a composition comprising levosimendan (1.0 mg/ml), Captisol® (100 mg/ml), and phosphate buffer (10 mmolar), prepared in sterile water for injection and adjusted to a pH of 7.0 to 7.9 using 1 N NaOH or 10 N NaOH; this composition was administered at a dose of 0.5 mg/kg.
  • a composition comprising levosimendan (1.0 mg/ml), Captisol® (300 mg/ml), and phosphate buffer (10 mmolar), prepared in sterile water for injection and adjusted to a pH of 7.0 to 7.9 using 1 N NaOH or 10 N NaOH; this composition was administered at a dose of 0.5 mg/kg.
  • compositions were sterile fdtered using a sterile 0.22 micron Millex-GV PVDF filter syringe filter prior to administration.
  • naive male Sprague Dawley rats were used that were between 10 to 12 months old. Blood samples were collected from the rats pre-dose and at the following time points after the dose: 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr, and 18 hr. Five 0.5-ml to 1.0-ml blood samples were collected from each rat. Four of these samples were collected from the tail vein and the fifth sample was collected by cardiac puncture following deep anesthesia with isoflurane inhalation and exsanguination. In each study arm, rats were divided into two groups, group A and group B, that contained three rats each.
  • Sample collection points were alternated between three rats in group A and three rats in group B. Thus, samples were collected from group A rats at pre-dose, 15 min, 1 hr, 4 hr and 12 hr. Samples were collected from group B rats at 5 min, 30 min, 2 hr, 8 hr and 18 hr. A thoracotomy was preformed to insure death. Each arm of the study used six rats for a total of 18 rats. [0546] During the study following the subcutaneous and IV injections, the rats were observed for any clinical signs of adverse reactions. Behavior including licking, biting or scratching of the injection area, any loss of mobility, restlessness, unresponsiveness, and abnormal postures was monitored. No abnormal observations occurred, as the rats continued to act normally throughout the study.
  • Plasma samples were stored in tubes containing EDTA as an anticoagulant and kept in an ice bath until centrifuged to separate the plasma. The plasma samples were stored at -20°C until assayed. Plasma obtained from each of the samples was used for liquid chromatographic/mass spectroscopic analysis of the compound.
  • Plasma samples were analyzed for levosimendan and OR- 1896 (the primary metabolite) by HPLC/MS/MS.
  • a protein precipitation method was employed for sample preparation by the addition of an acetonitrile spiking solution or acetonitrile, and internal standard to a plasma sample or blank plasma.
  • the internal standard for levosimendan was 13C6-labeled levosimendan
  • for OR-1896 was 13C6-labeled ORM-25632 (racemic form of OR-1896).
  • the mixture was vortexed and centrifuged. Approximately 75-80 m ⁇ was transferred to an autosampler vial with a plastic insert.
  • HPLC/MS/MS method consisted of a Restek Raptor Biphenyl column, 2.7 pm, 100 x 3 mm.
  • Mobile phase A consisted of 5 mM Ammonium Formate/0.1% Formic acid and mobile phase B was methanol.
  • the flow rate was set to 0.6 ml/min and injection volume was 10 pi.
  • Detection was performed with a Sciex 3200 Qtrap mass spectrometer in MRM mode.
  • OR-1896 plasma concentrations after IV and subcutaneous dosing. OR-1896, the major active metabolite of levosimendan, demonstrated very similar plasma concentrations regardless of route of administration or formulation.
  • Example 8 [0557] A study is conducted analogous to Example 7. However, certain parameters are modified to allow for the subcutaneous administration of levosimendan.
  • Results are substantially similar to Example 7, with a decrease in injection site and/or central line infections when compared to intravenous infusion administration. Additionally, an increase in quality of life assessment and/or convenience of administration occurs due to the easier route of delivery.
  • Examples of major HFrEF clinical trials that have excluded HFpEF patients include: LIDO, REVIVE, SURVIVE, RUSSLAN, and LEVO-CTS. All of these trials have excluded patients with an ejection fraction > 36%.
  • all clinical trials that have evaluated chronic intermittent dosing of levosimendan have excluded HFpEF patients.
  • Examples of clinical trials that have evaluated chronic intermittent dosing of levosimendan that have excluded HFpEF patients include: LIONHEART, LEVOREP, LAICA, and numerous other single-center trials. Kleber et al.
  • Levosimendan dosing in previous acute heart failure trials employed single 24-hour infusions of 0.5 to 0.2 mcg/kg/min to treat acutely decompensated heart failure patients in a hospital setting.
  • Other trials have evaluated repeated or intermittent dosing of levosimendan in chronic heart failure patients, and these studies have employed a range of dosing alternatives that utilize IV infusions of less than 24 hours and administered with a repeated dosing frequency of every 2 to 4 weeks in a hospital setting.
  • No studies to date have employed weekly 24-hour infusions administered outside of a hospital setting.
  • levosimendan is surprisingly found to provide effective treatment for a human subject afflicted with pulmonary hypertension and heart failure with preserved ejection fraction (PH- HFpEF).
  • Levosimendan can improve cardiovascular hemodynamics, exercise capacity, and quality of life.
  • the study showed evidence that the levosimendan infusion was able to reduce pulmonary capillary wedge pressure, right atrial pressure, and mean pulmonary arterial pressure. Additionally, levosimendan infusion was able to increase cardiac output, quality of life and 6-minute walk distance.
  • levosimendan is also surprisingly found to be safe when administered in a non hospital or non-clinical setting and when self-administered.
  • Levosimendan treatment was provided in an outpatient setting, as well as in the human subject’s home. Based on the results from the study, there is confirmation for the first time that home administration of levosimendan can be done safely in PH-HFpEF patients.
  • levosimendan is also surprisingly found to be safe when given to PH-HFpEF patients in weekly 24-hour infusions. While other studies have evaluated intermittent dosing of levosimendan to treat HFrEF patients, none of these studies have evaluated weekly 24-hour infusions of levosimendan. Most of these other studies evaluated infusions every 2, 3, 4 weeks with infusion durations of only 6-12 hours.
  • Results presented herein also show that we have discovered a means of identifying PH-HFpEF patients who have a high likelihood of responding to levosimendan, i.e. a means of identifying PH-HFpEF responders to levosimendan.
  • Hasenfuss, G., et al. (1998). influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 98(20), 2141-2147.
  • Kivikko, M., et al. (2002). Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. The Journal of Clinical Pharmacology, 42(1), 43-51.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

Description

LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART
FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)
[0001] This application claims the benefit of U.S. Provisional Application Nos. 63/064,671 filed August 12, 2020, 63/033,773 filed June 2, 2020, 62/988,720 filed March 12, 2020, 62/967,920 filed January 30, 2020, and 62/948,735 filed December 16, 2019, the contents of each of which are hereby incorporated by reference.
[0002] Throughout this application, various publications are referenced, including referenced in parenthesis. The disclosures of all publications mentioned in this application in their entireties are hereby incorporated by reference into this application in order to provide additional description of the art to which this invention pertains and of the features in the art which can be employed with this invention.
FIELD OF THE INVENTION
[0003] The invention relates to the treatment of heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients).
BACKGROUND OF THE INVENTION Levosimendan
[0004] Levosimendan is a calcium sensitizer and potassium channel activator drug approved in over 60 countries for intravenous use in hospitalized subjects with acutely decompensated heart failure (ADHF). Levosimendan is currently approved for in-hospital use only, and currently approved only for administration in a hospital setting where adequate monitoring facilities and expertise with the use of inotropic agents are available. (Simdax. Finland: Orion Corporation; 2010.)
[0005] Levosimendan enhances the calcium sensitivity of contractile proteins by binding to cardiac troponin C in a calcium-dependent manner. Levosimendan increases the contraction force but does not impair ventricular relaxation. In addition, levosimendan opens ATP-sensitive potassium channels in vascular smooth muscle, thus inducing vasodilatation of systemic and coronary arterial resistance vessels and systemic venous capacitance vessels. Levosimendan is also a selective phosphodiesterase III inhibitor in vitro. (Simdax. Finland: Orion Corporation; 2010.)
[0006] Levosimendan has been studied exclusively in heart failure patients with reduced ejection fraction (HFrEF). In fact, with the single exception of the Hemodynamic Evaluation of Levosimendan in HP-HFpEF (HELP) Study (Borlaug 2020, Burkhoff 2020) that this invention is based upon, all of the many prior multi center randomized placebo-controlled trials of levosimendan in heart failure patients have specifically excluded heart failure patients with preserved ejection fraction (HFpEF). The complete lack of clinical research evaluating levosimendan in HFpEF and PH-HFpEF patients is consistent with the historical treatment paradigm that levosimendan should be used to treat HFrEF patients. The HELP Study represents a major departure from this traditional mindset and as a result the findings from this novel clinical trial represent significant and surprising discoveries regarding the benefits of levosimendan in PH-HFpEF patients.
[0007] In HFrEF patients, the positive inotropic and vasodilatory actions of levosimendan result in an increased contractile force, and a reduction in both preload and afterload, without adversely affecting diastolic function. Hemodynamic studies in healthy volunteers and in patients with stable and unstable heart failure have shown a dose-dependent effect of levosimendan given intravenously as loading dose (3 micrograms/kg to 24 micrograms/kg) and continuous infusion (0.05 to 0.2 micrograms/kg per minute). Compared with placebo, in HFrEF patients levosimendan increased cardiac output, stroke volume, ejection fraction, and heart rate and reduced systolic blood pressure, diastolic blood pressure, pulmonary capillary wedge pressure, right atrial pressure, and peripheral vascular resistance. (Simdax. Finland: Orion Corporation; 2010.)
[0008] Levosimendan’s activity is mediated through unique mechanisms of action, including: increased cardiac contractility by calcium sensitization of troponin C, vasodilation through opening of potassium channels, and cardioprotective effects via potassium channel opening in mitochondria. (Haikala et al. 1995, Haikala et al. 1995, Pollesello et al. 1994, Sorsa et al. 2004, Yokoshiki et al. 1997, Pataricza et al. 2000, Kaheinen et al. 2001, Erdei et al. 2006, Maytin et al. 2005, Pollesello et al. 2007, du Toit et al. 2008, Louhelainen et al. 2010)
[0009] Levosimendan has been shown to be a potent and selective phosphodiesterase-3 (PDE3) inhibitor in vitro. The drug is PDE3 selective with a PDE3/PDE4 inhibition ratio of 10,000. However, both isozymes must be inhibited in cardiomyocytes to exert an effect on the cAMP concentration and inotropic effects. The classical PDE inhibitors (i.e., milrinone, enoximone, and amrinone) inhibit both PDE3 vs. PDE4 is as low as 17-fold), which accounts fully for their inotropic effect. (Y okoshiki et al. 1997, Szilagyi et al. 2004)
[0010] Levosimendan improves endothelial function and enhances diastolic coronary flow by opening the adenosine triphosphate-sensitive potassium channels and increasing nitric oxide production. Levosimendan acts through direct binding to troponin-C at high systolic intracellular calcium concentration as well as detachment from it at low diastolic concentration are facilitated. Levosimendan displayed positive lusitropic effects relative to milrinone and nitroglycerin. The lusitropic effect of levosimendan is independent of the degree of the inotropic effect. (Michaels et al. 2005, Grossini et al. 2005, Hasenfuss et al. 1998, De Luca et al. 2006) Metabolites OR-1896 and OR-1855
[0011] Levosimendan has an active metabolite that extends its effects well beyond the infusion period. Following intravenous or oral dosing, levosimendan is reduced by intestinal bacteria to form OR-1855 (limited activity) that is acetylated to form OR-1896, an active metabolite. While the patient half-life is approximately 1 hour and cleared a few hours after the end of intravenous infusion, OR-1896 has a prolonged half-life of 70-80 hours in heart failure subjects with roughly equal exposures of OR-1855 and OR-1896 maintained through deacetylation/acetylation pathways. The OR-1896 metabolite has been shown to retain similar hemodynamic and pharmacologic properties of levosimendan and maintain roughly equivalents to levosimendan in preclinical models. This activity occurs despite considerably lower plasma concentrations relative to levosimendan, an apparent result of a large percentage of unbound OR-1896 in circulation. Thus, in extended repeated dosing, levosimendan is essentially an active prodrug to an active metabolite moiety, OR-1896. (Louhelainen et al. 2010, Erdei et al. 2006, Szilagyi et al. 2004, Banfor et al. 2008, Louhelainen et al. 2009, Segreti et al. 2008)
[0012] OR-1896 is equipotent to levosimendan in its inotropic effects in whole cardiomyocytes and isolated contractile apparatus preparations. However, OR-1896 is profoundly less potent in the inhibition of both PDE3 and PDE4 isozymes. This supports the hypothesis that the main component of the inotropic effect for both levosimendan and OR-1896 is a result of their binding to troponin C and not through PDE inhibition. (Szilagyi et al. 2004)
[0013] Clinical observations demonstrate that short-term levosimendan administration is followed by long-term hemodynamic changes that parallel the levels of OR-1896. Patients have been observed with detectable concentrations of both metabolites, OR-1896 and OR-1855, in follow-ups two weeks after treatment. Despite OR-1855’s observed inactivity, OR-1896 greatly extends the parent levosimendan’s activity and provides the primary active moiety in subjects receiving intermittent intravenous levosimendan therapy. (Banfor et al. 2007, Kivikko et al. 2003, Kivikko et al. 2002)
[0014] Based on knowledge of OR-1896 and OR-1855, administration of the metabolites could be used analogously to levosimendan, with adjustments made for the metabolites’ own parameters. Both metabolites could be delivered through various routes of administration, including but not limited to, oral, intravenous, and subcutaneous administration. The dose chosen depends on the specific route of administration. In all cases, the target dosing would be intended to achieve a steady-state concentration of OR-1896 of 0.5 to 10.0 ng/ml. The relationship between levosimendan and OR-1896 and OR-1855, along with the interaction between the metabolites, is discussed in Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure (Kivikko et al. 2002), the entire contents of which are incorporated by reference. Types of Heart Failure - HFrEF vs. HFpEF
[0015] HFpEF and HFrEF are distinct clinical entities. While each type of heart failure accounts for approximately 50% of all heart failure patients, many differences exist between these two forms of heart failure.
[0016] A recent review by Shaw et al. described some of the distinct features of HFpEF and HFrEF, summarized in the chart below. The review noted that over the past three decades, HFrEF evolved into its own distinct therapeutic entity due to the efficacy of neurohormonal inhibition seen in large outcome clinical trials. However, HFpEF has not undergone a similar evolution due to the consistent failure of large trials testing neurohormonal inhibition either individually or on meta-analysis. (Shaw et al. 2016) limrpal Structural* Fi«timmls ami Ultra sirnainr i LV (Uw etansfics in HF F ami HEr!F
Figure imgf000006_0001
Pulmonary Hypertension - Heart failure with preserved ejection fraction (PH-HFpEF)
[0017] Many HFpEF patients have coexisting Pulmonary Hypertension. A sustained elevation in left atrial pressure causes pulmonary venous congestion, which often leads to elevation of pulmonary pressures leading to severe right ventricular failure with a low cardiac output, edema, hypoxemia, and severely limited exercise capacity. Pulmonary hypertension (PH) in subjects with heart failure and preserved ejection fraction (PH-HFpEF) is a common form of pulmonary hypertension and has an estimated US prevalence exceeding 1.5 million. (Oktay et al. 2013, Oudiz et al. 2007, Hoeper et al. 2016)
[0018] PH-HFpEF has been classified within Group II of the World Health Organization (WHO) clinical classification of PH, characterized by PH arising from left heart disease. Regardless of the basis of left heart disease, PH initially develops from a passive backward transmission of filling pressures, mainly driven by left ventricular (LV) diastolic function, resulting in a chronic increase in left atrial pressure and a loss of left atrial compliance. These mechanical components of pulmonary venous congestion may trigger pulmonary vasoconstriction, decreased nitric oxide (NO) availability, increased endothelin expression, desensitization to natriuretic peptide -induced vasodilation, and vascular remodeling. Finally, these changes often lead to advanced pulmonary vascular disease, increased right ventricle (RV) afterload, and RV failure. PH-HFpEF is defined hemodynamically by a pulmonary artery pressure (mPAP) >25 mmHg, a pulmonary capillary wedge pressure (PCWP) >15 mmHg, and a diastolic pressure gradient [diastolic PAP - PCWP] >7mmHg. (Galie et al. 2009, McLaughlin et al. 2009, Simonneau et al. 2009, Dixon et al. 2015)
[0019] ESC guidelines in the treatment of PH-HFpEF subjects acknowledge that the accepted treatment target is a reduction of pulmonary wedge pressures using diuretics for congestion. However, clinical studies have demonstrated neutral results with identified concerns that Pulmonary Hypertension (PH)-targeted therapies could have detrimental effects due to rapid increases in LV filling pressures, resulting in acute pulmonary edema. Thus, the ESC guidelines specify that there are currently no established strategies to treat pulmonary vascular disease (PVD) and right ventricular disease (RVD) in HFpEF, with a recommendation (class III) not to use approved PAH treatments in PH-HFpEF subjects. With no demonstrated effective therapy, these subjects have a poor outcome (5 yr. survival <50%, frequent hospitalizations). (Shaw et al. 2016, Galie et al. 2009, Goiter et al. 2018, Klapholz et al. 2004)
[0020] Levosimendan has never previously been studied in the PH-HFpEF population. The complete lack of research regarding levosimendan’ s potential utility in PH-HFpEF likely stems from the fact that inotropes such as levosimendan, are recommended in most heart failure guidelines to be used exclusively in the treatment of HFrEF and not HFpEF patients. As an example, the 2013 ACCF/AHA guidelines for management of heart failure specifically limits its recommendation for inotrope use to HFrEF patients, stating “Use of parenteral inotropic agents in hospitalized patients without documented severe systolic dysfunction, low blood pressure, or impaired perfusion and evidence of significantly depressed cardiac output, with or without congestion, is potentially harmful.”
Failed Treatment Attempts [0021] Additionally, none of the currently approved drugs used to treat other forms of pulmonary hypertension have shown to be effective in PH-HFpEF. In fact, all prior trials that have tested other drugs in PH-HFpEF have repeatedly reported neutral to negative results. (ElGuindy et al. 2012).
[0022] Numerous review articles have been published attempting to consolidate the repeated failures in attempted treatments of PH-HFpEF. One, in particular, Pulmonary Vascular Disease in the Setting of Heart Failure with Preserved Ejection Fraction, written by Andrea R. Levine et al., consolidated all the background information behind the disease while also applying this background information to previously failed attempts. The comments on failed attempts of various therapeutics is referenced below to help explain the vast difficulty in treating PH-HFpEF.
[0023] One targeted pathway in previous clinical trials was the Nitrate-NO-sGC-cGMP pathway. While several small, single-center trials have reported positive results treating PH-HFpEF with PDE5i, a large multicenter study was negative, making it unlikely that PDE5i will ever be an approved therapy for PH- HFpEF. In 2015, Hoendermis et al. found no change in mPAP after 12 weeks of sildenafil administration in 52 patients. The RELAX trial sought to establish whether chronic sildenafil administration changed peak oxygen consumption at 24 weeks in patients with HFpEF. However, long term sildenafil treatment failed to improve six-minute walk time, clinical status, or quality of life in this multicenter trial of 216 patients. The SIOVAC trial was a multicenter placebo control trial of sildenafil in patients with PH-left heart disease (LHD) secondary to valvular heart disease. This study reinforced the risk associated with use of sildenafil in patients with PH-LHD, and it also supported the recommendations against the use of PDE5i in patients with PH-LHD. Due to these negative results seen to date, the efficacy of PDE5i in PH-HFpEF seems highly unlikely. The multicenter INDIE-HFpEF studied the acute cardiopulmonary hemodynamic effects of inorganic nitrite infusion. However, this study was also unsuccessful, as it was unable to demonstrate any improvement in the primary endpoint of peak oxygen consumption during cardiopulmonary exercise or secondary endpoints including activity level, quality of life score, or NT-proBNP in patients treated with inhaled sodium nitrite 3 times a day for 4 weeks. Another study, conducted by Simon et al., further evaluated inhaled nitrites in PH-HFpEF patients with some promising data related to cardiopulmonary hemodynamics; however, improvements in clinical endpoints have not been demonstrated to date. The DILATE trial and SOCRATES-PRESERVED trial both assessed the acute hemodynamic effects of sGC stimulators, riociguat and vericiguat respectively. Although the DILATE trial showed some promising results, the primary outcome was not achieved in mean pulmonary arterial pressure, along with no change in TPG or pulmonary vascular resistance. The SOCRATES-PRESERVED trial ended with similar results, where the primary endpoints also saw no significant changes. (Levine et al. 2019) [0024] Endothelin receptors are another previously targeted molecular target for treatment of PH- HFpEF. MELODY- 1 was a small pilot study evaluating macitentan in patients with left heart disease. However, primary outcomes were fluid retention and worsening of the New York Heart Association (NYHA) functional class. Additionally, no change was seen in hemodynamic parameters such as pulmonary vascular resistance, mean pulmonary arterial pressure, or pulmonary artery wedge pressure. The BADDHY trial also attempted using an endothelin receptor antagonist, bosentan, in patients with PH-HFpEF, but no improvements were seen in the six minute walk test or echocardiographic evaluation of pulmonary hypertension. Patients who received bosentan actually had worse clinical outcomes than those who only received the placebo. Neither of these two studies indicated any success with endothelin receptor antagonists in treating PH-HFpEF. (Levine et al. 2019)
[0025] The largest clinical trial in HFpEF to date was the PARAGON-HF trial conducted by Novartis. This trial was designed to evaluate the effect of sacubitril/valsartan on HFpEF patients. PARAGON-HF was yet another example of a large clinical trial where the reduction in the primary endpoint was not statistically significant. (Novartis 2019)
[0026] According to 2009 ACCF/AHA and 2015 ESC/ERS Guidelines, there is no current clinically approved treatment for PH-HFpEF. Given the numerous amount of failures and adverse effects known in the field as summarized above, no drug can be expected to treat PH-HFPEF, but there is a strong need in the field to find a treatment for this currently untreatable disease. (Levine et al. 2019).
SUMMARY OF THE INVENTION
[0027] The invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF, employing the use of levosimendan, or OR1896, or OR1855. In other embodiments, the treatment of PH-HFpEF through subcutaneous administration is contemplated. In other embodiments, the treatment of PH-HFpEF through oral administration is contemplated. In other embodiments, the treatment of PH-HFPEF through combination therapy of levosimendan, or OR1896, or OR1855 and other cardiovascular drugs is contemplated.
[0028] The invention provides levosimendan and medicaments comprising levosimendan for use in any of the methods of the invention.
[0029] Other objects, features and advantages of the present invention will become clear from the following description and drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figures 1A-1B: Pulmonary Capillary Wedge Pressure (PCWP) Pre vs Post Levosimendan Lead-in Infusion Open-Label Levosimendan Responders (n=30). Figures 1A-1B are graphical representations of Example 1 results, showing a decrease in pulmonary capillary wedge pressure (PCWP) after levosimendan administration in 30 patients. These results are based on single 24-hour open label lead- in infusion data. Figure 1A shows the decrease in PCWP after levosimendan infusion during rest with the human subjects’ legs down. Figure IB shows the decrease in PCWP after levosimendan infusion during exercise where the human subject exerts 25 watts.
[0031] Figures 2A-2B: Right Atrial Pressure (RAP) Pre vs Post Levosimendan Lead-in Infusion Open-Label Levosimendan Responders (n=30) is a graphical representation of results of Example 1, showing a decrease in right atrial pressure (RAP) after levosimendan administration in 30 patients.
These results are based on single 24-hour open label lead-in infusion data. Figure 2A shows the decrease in RAP after levosimendan infusion during rest with the human subjects’ legs down. Figure 2B shows the decrease in RAP after levosimendan infusion during exercise where the human subject exerts 25 watts.
[0032] Figures 3A-3B: Mean Pulmonary Arterial Pressure (mPAP) Pre vs Post Levosimendan Leand-in Infusion Open-Label Levosimendan Responders (n=30). Figures 3A-3B are graphical representations of Example 1 results, showing a decrease in mean pulmonary artery pressure (mPAP) after levosimendan administration in 30 patients. These results are based on single 24-hour open label lead-in infusion data. Panel A shows the decrease in mPAP after levosimendan infusion during rest with the human subjects’ legs down. Panel B shows the decrease in mPAP after levosimendan infusion during exercise where the human subject exerts 25 watts.
[0033] Figures 4A-4B: Cardiac Output Pre vs Post Levosimendan Lead-in Infusion Open-label Levosimendan Responders (n=30). Figures 4A-4B are graphical representations of Example 1 results, showing an increase in cardiac output (CO) after levosimendan administration in 30 patients. These results are based on single 24-hour open label lead-in infusion data. Panel A shows the increase in CO after levosimendan infusion during rest with the human subjects’ legs down. Panel B shows the increase in CO after levosimendan infusion during exercise where the human subject exerts 25 watts.
[0034] Figure 5: Six Minute Walk Distance Open-Label Extension Study (n=8). Figure 5 is a graphical representation of Example 2 results, showing an increase in 6-minute walk distance after levosimendan administration in 8 patients.
[0035] Figure 6: Evidence of Improved Quality of Life - Patient Self-Assessment - Extension Study, 5 Point Likert Scale. Figure 6 is a graphical representation of Example 2 results, showing an increase in quality of life assessment after levosimendan administration according to the 5 Point Likert Scale in 8 patients.
[0036] Figure 7: Exercise Stroke Volume May Predict Response to Levosimendan. Figure 7 is a graphical representation of Example 1 results, showing a predictor of response for PH-HFpEF patients treated with levosimendan in 21 patients. The graph indicates that the greater the change in a patient’s stroke volume between rest and 25 watts of exercise, the greater the reduction in PCWP after administration of levosimendan.
[0037] Figure 8: PCWP Endpoint - Baseline vs. 6 Weeks. Levosimendan effect on PCWP across positions is significant vs placebo. Figure 8 is a graphical representation of Example 2 results, showing a decrease in pulmonary capillary wedge pressure (PCWP) after levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients). The left panel shows the difference in PCWP after placebo administration during rest with the human subjects’ legs down, legs raised on a supine bicycle, and during exercise where the human subject exerts 25 watts. The right panel shows the decrease in PCWP after levosimendan infusion during rest with the human subjects’ legs down, leg raise on a supine bicycle, and during exercise where the human subject exerts 25 watts. † Tested in a mixed effect model using treatments as factors and position as a random effect.
[0038] Figures 9A-9C: PCWP Change from Baseline at Week 6 - Levosimendan vs Placebo. Figures 9A-9C are a graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a larger decrease in PCWP after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients. Figure 9A shows the decrease in PCWP after levosimendan infusion and placebo infusion during rest with the human subjects’ legs down. Figure 9B shows the decrease in PCWP after levosimendan infusion and placebo infusion with the patients’ legs up in a supine position. Figure 9C shows the decrease in PCWP after levosimendan infusion and placebo infusion during exercise where the human subject exerts 25 watts.
[0039] Figure 10: PCWP Week 6 - Levosimendan Change from Baseline. Figure 10 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a decrease in PCWP after levosimendan administration in 18 PH-HFpEF patients. [0040] Figure 11: RAP Change from Baseline at Week 6 - Levosimendan Treated Patients. Figure 11 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a decrease in right atrial pressure (RAP) after levosimendan administration in 18 PH-HFpEF patients compared to 17 placebo treated patients. The figure shows the decrease in RAP during rest with the human subjects’ legs down, legs raised on a supine bicycle, and during exercise where the human subject exerts 25 watts.
[0041] Figures 12A-12C: RAP Change at Week 6 - Levosimendan vs Placebo. Figures 12A-12C are graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients (18 levosimendan treated and 17 placebo treated patients), showing a larger decrease in RAP after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients. Figure 12A shows the decrease in RAP after levosimendan infusion and placebo infusion during rest with the human subjects’ legs down. Figure 12B shows the decrease in RAP after levosimendan infusion and placebo infusion with the patients’ legs up in a supine position. Figure 12C shows the decrease in RAP after levosimendan infusion and placebo infusion during exercise where the human subject exerts 25 watts.
[0042] Figure 13: mPAP Week 6 - Levosimendan Change from Baseline. Figure 13 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing a decrease in mean pulmonary artery pressure (mPAP) after levosimendan administration in 18 PH-HFpEF patients compared to 17 placebo treated patients. The figure shows the decrease in mPAP during rest with the human subjects’ legs down, legs raised on a supine bicycle, and during exercise where the human subject exerts 25 watts.
[0043] Figures 14A-14C: mPAP (mmHg) Change at Week 6 - Levosimendan vs Placebo. Figures 14A-14C are graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing a larger decrease in mPAP after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients. Figure 14A shows the decrease in mPAP after levosimendan infusion and placebo infusion during rest with the human subjects’ legs down. Figure 14B shows the decrease in mPAP after levosimendan infusion and placebo infusion with the patients’ legs up in a supine position. Figure 14C shows the decrease in mPAP after levosimendan infusion and placebo infusion during exercise where the human subject exerts 25 watts.
[0044] Figure 15: Change in Six Minute Walk Distance (meters) from Baseline at Week 6 - Levosimendan vs. Placebo. Figure 15 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing an increase in 6-minute walk distance after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 17 additional PH-HFpEF patients.
[0045] Figure 16: Treatment Emergent Adverse Events. Figure 16 shows results of Example 2, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing a comparison of Treatment Emergent Adverse Events (TEAEs) after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 18 additional PH-HFpEF patients.
[0046] Figure 17: Treatment Emergent Adverse Events (Incidence of two or more). Figure 17 shows results of Example 2, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing a comparison of specific Treatment Emergent Adverse Events (TEAEs) after levosimendan administration in 18 PH-HFpEF patients compared to placebo administration in 18 additional PH-HFpEF patients.
[0047] Figure 18: Serious Adverse Events. Figure 18 shows results of Example 2, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing Serious Adverse Events, and the Relatedness/Change in Dose of levosimendan.
[0048] Figure 19: OR1896 Trough Blood Levels at Final RHC Levosimendan Treated Patients.
Figure 19 is a graphical representation of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 36 PH-HFpEF patients, showing OR1896 trough blood levels at final RHC in levosimendan treated patients.
[0049] Figures 20A-20B are graphical representations of Example 2 results, where levosimendan or placebo was administered via weekly 24-hour IV infusions for a period of 5 weeks to 35 PH-HFpEF patients, showing Cardiac Index (Cl) (Figure 20A) and pulmonary vascular resistance (PVR) (Figure 20B) after levosimendan administration in 36 PH-HFpEF patients. PVR and Cl behaved surprisingly different compared to other variables (i.e. unchanged at week 6). This data suggests that levosimendan is acting differently with respect to chronic (weekly for 5 weeks) vs. acute (24-hour) administration (See, for example, Figures 4A-4B).
[0050] Figures 21A-21B: Baseline vs 24-hour Levosimendan Infusion - Impact on CVP and PCWP.
All values differ between baseline and 24-hours LEVO infusion by paired t-test. Figure 21A shows impact on CVP. Figure 21B shows impact on PCWP. In both Figures 21-21B, ‘Baseline’ measurements are shown to the left of “24 Hours’ measurements.
[0051] Figure 22: Baseline Characteristics among randomized patients. [0052] Figure 23: Summary of Overall Hemodynamic Effects of 24-hour Levosimendan Infusion.
Figure 23 shows the acute (24 hours) effects of open-label levosimendan (n=44). 85% of patients exhibited a >4 mmHg decrease of PCWP. Abbreviations: HR heart rate; CVP, central venous pressure; PAS, pulmonary artery systolic pressure; PAD, pulmonary artery diastolic pressure; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; AoS, arterial systolic pressure; Cl, cardiac index; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance. *p<.05 compared to baseline.
[0053] Figure 24: Baseline and 6 weeks hemodynamic parameters values for all randomized patients (n= 18 placebo and 17 levosimendan treatment patients). Least squares (LS) means and confidence intervals (Cl) are from analysis of variance (ANOVA) model for change from baseline with treatment group as a factor. †Between group differences p=0.04 by mixed effects mixed effect repeated measures model. Abbreviations: HR heart rate; CVP, central venous pressure; PAS, pulmonary artery systolic pressure; PAD, pulmonary artery diastolic pressure; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; AoS, arterial systolic pressure; Cl, cardiac index; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance.
[0054] Figure 25: Overview of two phase study, with an initial unblinded levosimendan infusion to identify levosimendan “responders” defined as a >4 mmHg reduction of pulmonary capillary wedge pressure (PCWP) during 25 Watt exercise (EX) followed by a subsequent randomized double blind phase.
[0055] Figure 26: CONSORT diagram showing flow a patients through entire study
[0056] Figures 27A-27B: Comparison of pulmonary capillary wedge pressure (PCWP) and central venous pressure (CVP) between baseline, 24 hours and 6 weeks at rest, with legs up and during 25 Watts exercise. Placebo group shown in Figure 27A and Figure 27B; levosimendan group shown in Figure 27C and Figure 27D. *p<0.05 for comparison between respective baseline and 24-hour measurements.
[0057] Figure 28A: Comparison of 6 minute walk distance (6MWD) in treatment and control groups. Figure 28B: Rank ordered listing of changes in 6MWD for each patient designated by group assignment. More patients in the treatment group had increased 6MWD, whereas more patients in the control group had decreased 6MWD. *p<0.05. DETAILED DESCRIPTION OF THE INVENTION
[0058] According to some embodiments, the invention provides a method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of levosimendan, its metabolites OR- 1896 or OR-1855, or a combination thereof, that is effective to treat the PH-HFpEF in the human subject.
[0059] In some embodiments, the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure at rest.
[0060] In some embodiments, the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure at rest by 1 to 30 mmHg.
[0061] In some embodiments, the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure at rest at 5 to 35 mmHg.
[0062] In some embodiments, the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure at rest at 10 to 35 mmHg.
[0063] In some embodiments, the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure during exercise by the human subject.
[0064] In some embodiments, the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure during exercise by the human subject by 1 to 40 mmHg.
[0065] In some embodiments, the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure during exercise by the human subject at 10 to 50 mmHg.
[0066] In some embodiments, the treating does not comprise a significant change in pulmonary capillary wedge pressure during exercise by the human subject.
[0067] In some embodiments, the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated.
[0068] In some embodiments, the treating comprises a reduction in the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated and the reduction is 1 to 30 mmHg.
[0069] In some embodiments, the treating comprises stabilization of the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated and the stabilization is at 10 to 50 mmHg.
[0070] In some embodiments, the treating comprises a reduction in the human subject’s right atrial pressure at rest. [0071] In some embodiments, the treating comprises a reduction in the human subject’s right atrial pressure at rest by 1 to 30 mmHg.
[0072] In some embodiments, the treating comprises stabilization of the human subject’s right atrial pressure at rest at 1 to 30 mmHg.
[0073] In some embodiments, the treating comprises stabilization of the human subject’s right atrial pressure at rest at 5 to 30 mmHg.
[0074] In some embodiments, the treating comprises a reduction in the human subject’s right atrial pressure during exercise by the human subject.
[0075] In some embodiments, the treating comprises a reduction in the human subject’s right atrial pressure during exercise by the human subject by 1 to 30 mmHg.
[0076] In some embodiments, the treating comprises stabilization of the human subject’s right atrial pressure during exercise by the human subject at 5 to 40 mmHg.
[0077] In some embodiments, the treating comprises a reduction in the human subject’s right atrial pressure when the human subject’s legs are elevated.
[0078] In some embodiments, the treating comprises a reduction in the human subject’s mean pulmonary artery pressure at rest.
[0079] In some embodiments, the treating comprises a reduction in the human subject’s mean pulmonary artery pressure at rest by 1 to 30 mmHg.
[0080] In some embodiments, the treating comprises stabilization of the human subject’s mean pulmonary artery pressure at rest at 15 to 65 mmHg.
[0081] In some embodiments, the treating comprises a reduction in the human subject’s mean pulmonary artery pressure during exercise by the human subject.
[0082] In some embodiments, the treating comprises a reduction in the human subject’s mean pulmonary artery pressure during exercise by the human subject by 1 to 30 mmHg.
[0083] In some embodiments, the treating comprises stabilization of the human subject’s mean pulmonary artery pressure during exercise by the human subject at 25 to 85 mmHg.
[0084] In some embodiments, the treating comprises stabilization of the human subject’s mean pulmonary artery pressure during exercise by the human subject at 25 to 80 mmHg.
[0085] In some embodiments, the treating comprises a reduction in the human subject’s mean pulmonary artery pressure when the human subject’s legs are elevated. [0086] In some embodiments, the treating comprises an increase in the human subject’s cardiac output at rest.
[0087] In some embodiments, the treating comprises an increase in the human subject’s cardiac output at rest by 0.01 to 3 liters/min.
[0088] In some embodiments, the treating comprises stabilization of the human subject’s cardiac output at rest at 2 to 10 liters/min.
[0089] In some embodiments, the treating comprises an increase in the human subject’s cardiac output during exercise by the human subject.
[0090] In some embodiments, the treating comprises an increase in the human subject’s cardiac output during exercise by the human subject by 0.01 to 5 liters/min.
[0091] In some embodiments, the treating comprises an increase in the human subject’s cardiac output during exercise by the human subject by 0.01 to 4 liters/min.
[0092] In some embodiments, the treating comprises stabilization of the human subject’s cardiac output during exercise by the human subject at 3.0 to 15.0 liters/min.
[0093] In some embodiments, the treating does not comprise a significant increase in the human subject’s heart rate.
[0094] In some embodiments, the treating does not comprise an increase in the human subject’s heart rate of more than 10 beats/min.
[0095] In some embodiments, the treating comprises an improvement in the human subject’s quality of life.
[0096] In some embodiments, the improvement in the human subject’s quality of life is measured by a patient reported outcome assessment tool.
[0097] In some embodiments, the improvement in the human subject’s quality of life is measured by a Likert scale that is a five (5) point patient reported outcome assessment tool
[0098] In some embodiments, the treating comprises an improvement in the human subject’s quality of life according to a change in the human subject’s patient reported outcome assessment tool score of at least 1
[0099] In some embodiments, the treating comprises an improvement in the human subject’s quality of life according to a change in the human subject’s patient reported outcome assessment tool score of at least 2 [0100] In some embodiments, the treating comprises an improvement in the human subject’s six (6) minute walk distance.
[0101] In some embodiments, the treating comprises an improvement in the human subject’s six (6) minute walk distance of 5 to 150 meters.
[0102] In some embodiments, the treating comprises an improvement in the physician’s assessment of the human subject’s functional class.
[0103] In some embodiments, the treating comprises a reduction in the incidence of hospitalization for heart failure.
[0104] In some embodiments, the treating comprises a reduction in all-cause mortality.
[0105] In some embodiments, the treating comprises an improvement in right heart failure and/or right ventricular dysfunction.
[0106] In some embodiments, the improvement is evidenced by a reduction in right atrial pressure at rest and during 25 watts of exercise.
[0107] In some embodiments, the human subject is a responder to levosimendan therapy.
[0108] In some embodiments, a responder to levosimendan therapy is a human subject whose pulmonary capillary wedge pressure decreases by at least 4mmHG during bicycle exercise at 25 watts following the initial infusion.
[0109] In some embodiments, a responder to levosimendan therapy is a human subject whose cardiac index decreases by no more than 10% between the baseline measurements and repeated measurements following the initial infusion.
[0110] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject has cardiac reserve.
[0111] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject.
[0112] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when determined with a catheter in the human subject’s heart measuring the blood moving out of the left ventricle with every beat.
[0113] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when estimated with an electrocardiogram and/or echocardiogram. [0114] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when determined with a dobutamine stress test.
[0115] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by at least 0.005 liters.
[0116] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when determined with a catheter in the human subject’s heart measuring the blood moving out of the left ventricle with every beat.
[0117] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when estimated with an echocardiogram, right heart catheterization, or other means.
[0118] In some embodiments, the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when determined with a dobutamine stress test.
[0119] In some embodiments, the human subject afflicted with PH-HFpEF has a left ventricular ejection fraction of at least 40%.
[0120] In some embodiments, the human subject afflicted with PH-HFpEF has a baseline pulmonary arterial pressure of at least 35.
[0121] In some embodiments, the human subject afflicted with PH-HFpEF has a baseline pulmonary capillary wedge pressure of at least 20.
[0122] In some embodiments, the human subject afflicted with PH-HFpEF is classified as classification lib by the physician’s assessment of New York Heart Association Classification.
[0123] In some embodiments, the human subject afflicted with PH-HFpEF is classified as classification III by the physician’s assessment of New York Heart Association Classification.
[0124] In some embodiments, the human subject afflicted with PH-HFpEF has the ability to walk at least 50 meters in a six-minute walk test.
[0125] In some embodiments, the human subject afflicted with PH-HFpEF does not have the ability to walk more than 550 meters in a six-minute walk test. [0126] In some embodiments, the human subject afflicted with PH-HFpEF has the ability to walk at least 50 meters, but not more than 550 meters, in a six-minute walk test.
[0127] In some embodiments, the human subject afflicted with PH-HFpEF is not afflicted with heart failure with reduced ejection fraction.
[0128] In some embodiments, the human subject afflicted with PH-HFpEF is not afflicted with heart failure with preserved ejection fraction without pulmonary hypertension.
[0129] In some embodiments, the human subject afflicted with PH-HFpEF has a primary diagnosis of Group 2 PH-HFpEF.
[0130] In some embodiments, the human subject afflicted with PH-HFpEF is not afflicted with coronary artery disease.
[0131] In some embodiments, the human subject afflicted with PH-HFpEF has not had previous percutaneous coronary intervention.
[0132] In some embodiments, the human subject afflicted with PH-HFpEF has not had previous percutaneous coronary intervention, unless the human subject has had a negative stress test within the last year.
[0133] In some embodiments, the human subject afflicted with PH-HFpEF has not had previous cardiac surgery.
[0134] In some embodiments, the human subject afflicted with PH-HFpEF has not had previous cardiac surgery, unless the human subject has had a negative stress test within the last year.
[0135] In some embodiments, the human subject afflicted with PH-HFpEF is not afflicted with congenital heart disease.
[0136] In some embodiments, the human subject afflicted with PH-HFpEF is not afflicted with a clinically significant lung disease.
[0137] In some embodiments, the human subject afflicted with PH-HFpEF does not have a planned heart or lung surgery.
[0138] In some embodiments, the human subject afflicted with PH-HFpEF does not have a cardiac index greater than 4.0 L/min/m2.
[0139] In some embodiments, the human subject afflicted with PH-HFpEF does not concomitantly receive pulmonary vasodilator therapy. [0140] In some embodiments, the human subject afflicted with PH-HFpEF has not received pulmonary vasodilator therapy within the last 14 days.
[0141] In some embodiments, the human subject afflicted with PH-HFpEF does not receive dialysis treatment.
[0142] In some embodiments, the human subject afflicted with PH-HFpEF does not have a Glomerular Filtration Rate less than 30 mL/min/1.73m2.
[0143] In some embodiments, the human subject afflicted with PH-HFpEF does not have liver dysfunction with Child Pugh Class B or C.
[0144] In some embodiments, the human subject afflicted with PH-HFpEF does not have evidence of systemic infection.
[0145] In some embodiments, the human subject afflicted with PH-HFpEF does not weigh more than 150 kg.
[0146] In some embodiments, the human subject afflicted with PH-HFpEF can manage their symptomatic systolic blood pressure to ensure it is greater than 100 mmHg.
[0147] In some embodiments, the human subject afflicted with PH-HFpEF does not have a heart rate greater than or equal to 100 beats per minute with the drug.
[0148] In some embodiments, the human subject afflicted with PH-HFpEF does not have a heart rate greater than or equal to 100 beats per minute with the drug that is symptomatic and persistent for at least 10 minutes.
[0149] In some embodiments, the human subject afflicted with PH-HFpEF does not have hemoglobin less than 80 g/L.
[0150] In some embodiments, the human subject afflicted with PH-HFpEF does not have serum potassium less than 3.0 mmol/L at baseline.
[0151] In some embodiments, the human subject afflicted with PH-HFpEF does not have serum potassium greater than 5.5 mmol/L at baseline.
[0152] In some embodiments, the human subject afflicted with PH-HFpEF does not have serum potassium less than 3.0 mmol or greater than 5.5 mmol/L at baseline.
[0153] In some embodiments, the human subject afflicted with PH-HFpEF does not have severely compromised immune function.
[0154] In some embodiments, the human subject afflicted with PH-HFpEF is not pregnant. [0155] In some embodiments, the human subject afflicted with PH-HFpEF is not suspected to be pregnant,
[0156] In some embodiments, the human subject afflicted with PH-HFpEF is not breast-feeding.
[0157] In some embodiments, the human subject afflicted with PH-HFpEF is a patient with Biventricular
Failure.
[0158] In some embodiments, the administration is self-administered by the human subject.
[0159] In some embodiments, the self-administration takes place in a hospital by the human subject.
[0160] In some embodiments, the self-administration takes place in an outpatient-setting by the human subject.
[0161] In some embodiments, the self-administration takes place outside of a hospital by the human subject.
[0162] In some embodiments, the self-administration takes place at home by the human subject.
[0163] In some embodiments, the administration is not self-administered by the human subject.
[0164] In some embodiments, the administration is administered by a trained professional.
[0165] In some embodiments, the administration takes place in a hospital by the trained professional.
[0166] In some embodiments, the administration takes place in an outpatient-setting by the trained professional.
[0167] In some embodiments, the administration takes place outside of a hospital by the trained professional.
[0168] In some embodiments, the administration takes place at home by the trained professional.
[0169] In some embodiments, the administration is delivered via IV administration.
[0170] In some embodiments, the IV administration accesses the vein through a PICC line.
[0171] In some embodiments, the IV administration accesses the vein through a Port-a-cath.
[0172] In some embodiments, the administration takes place intermittently.
[0173] In some embodiments, the administration takes place weekly.
[0174] In some embodiments, the administration is given via a 24-hour infusion.
[0175] In some embodiments, the administration is given via a weekly 24-hour infusion. [0176] In some embodiments, the administration takes place chronically.
[0177] In some embodiments, the administration is chronic administration given via a less than 24-hour infusion.
[0178] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol.
[0179] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume.
[0180] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose.
[0181] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 0.9 Normal Saline.
[0182] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose or 0.9 Normal Saline where the human subject weights less than 85 kg.
[0183] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume.
[0184] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose.
[0185] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 0.9 Normal Saline.
[0186] In some embodiments, the administration is a dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose or 0.9 Normal Saline where the human subject weights at least 85 kg. [0187] In some embodiments, the administration lead-in infusion rate is 0.10 mg/kg/min for 24 hours.
[0188] In some embodiments, the administration week 2 infusion rate is 0.075 mg/kg/min for 24 hours.
[0189] In some embodiments, the administration week 3 infusion rate is 0.075 mg/kg/min for 24 hours.
[0190] In some embodiments, the administration week 4 infusion rate is 0.10 mg/kg/min for 24 hours.
[0191] In some embodiments, the administration week 5 infusion rate is 0.10 mg/kg/min for 24 hours.
[0192] In some embodiments, the administration infusion rate is reduced to 0.05 mg/kg/min when the higher dose is not well-tolerated by the human subject.
[0193] In some embodiments, the administration is via oral dosing.
[0194] In some embodiments, the oral dosing comprises an immediate release formulation.
[0195] In some embodiments, the oral dosing comprises an extended-release formulation.
[0196] In some embodiments, the administration is via inhaled delivery.
[0197] In some embodiments, the inhaled delivery comprises an inhaled formulation.
[0198] In some embodiments, the administration is via transdermal delivery.
[0199] In some embodiments, the transdermal delivery comprises a transdermal formulation.
[0200] In some embodiments, the administration is subcutaneous administration.
[0201] In some embodiments, the administration is subcutaneous administration via a subcutaneous drug delivery device.
[0202] In some embodiments, the drug delivery device is a Continuous ambulatory delivery device (CADD) pump.
[0203] In some embodiments, the subcutaneous administration comprises administration of a subcutaneous formulation.
[0204] In some embodiments, the subcutaneous formulation is the intravenous formulation with additives.
[0205] In some embodiments, the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 150 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.0833 mg/mL in the subcutaneous formulation. [0206] In some embodiments, the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 250 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.05 mg/mL in the subcutaneous formulation.
[0207] In some embodiments, the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 500 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.025 mg/mL in the subcutaneous formulation.
[0208] In some embodiments, the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 1000 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.0125 mg/mL in the subcutaneous formulation.
[0209] In some embodiments, the subcutaneous formulation comprises 12.5 mg of levosimendan in a non-aqueous formulation that is added to 1500 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.008333 mg/mL in the subcutaneous formulation.
[0210] In some embodiments, the subcutaneous administration of the subcutaneous formulation comprises water in an amount effective to reduce pain caused by the subcutaneous administration.
[0211] In some embodiments, the subcutaneous administration of the subcutaneous formulation comprises buffers to raise the pH higher than 3.5.
[0212] In some embodiments, the subcutaneous administration of the subcutaneous formulation has reduced side effects relative to intravenous administration of levosimendan in the human subject.
[0213] In some embodiments, the subcutaneous administration of the subcutaneous formulation reduces peak plasma concentrations of levosimendan relative to intravenous administration in the human subject.
[0214] In some embodiments, the subcutaneous administration of the subcutaneous formulation reduces peak plasma concentrations of levosimendan relative to intravenous administration in the human subject by at least l% to 25%.
[0215] In some embodiments, the amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof, is administered in combination with a cardiovascular drug. [0216] In some embodiments, an amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof, and an amount of the cardiovascular drug, wherein the amounts when taken together are effective to treat the human subject, are periodically adminstered to the human subject.
[0217] In some embodiments, the amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof, and the amount of the cardiovascular drug when administered together is more effective to treat the subject than when each agent at the same amount is administered alone.
[0218] In some embodiments, the amount of levosimendan its metabolites OR-1896 or OR-1855, or a combination thereof, and the amount of the cardiovascular drug when taken together is effective to reduce the symptoms of PH-HFpEF.
[0219] In some embodiments, the cardiovascular drug is a drug used to treat pulmonary arterial hypertension (PAH), World Health Organization (WHO) Groups 1-5 pulmonary hypertension patients, coronary artery disease (CAD), or heart failure with reduced ejection fraction (HFrEF).
[0220] In some embodiments, the cardiovascular drug is a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta- blocker (BB), an angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), a natriuretic peptide, a K-ATP channel activator, a NEP inhibitor, or a prostacyclin.
[0221] In some embodiments, the cardiovascular drug is a pulmonary vasodilator drug.
[0222] In some embodiments, the pulmonary vasodilator is a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), or a prostacyclin.
[0223] In some embodiments, the amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, administered in combination with the pulmonary vasodilator drug is administered to a human subject afflicted with pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc-PH-HFpEF).
[0224] In some embodiments, no arrythmias, atrial or ventricular, are observed when comparing baseline electrocardiographic monitoring with 72-hour monitoring after 5 weeks of treatment.
[0225] In some embodiments, weekly 24-hour dosing of levosimendan is safe and well tolerated.
[0226] In some embodiments, treating presents no more statistically significant adverse events than the matching placebo. [0227] In some embodiments, the weekly 24-hour dosing of levosimendan results in steady state blood levels of OR1896 in the range of 0.20 ng/mL to 25.00 ng/mL.
[0228] According to some embodiments, the invention also provides an article of manufacture comprising: a. a 5mL vial dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol; b. 250 mL of 5% Dextrose or 0.9 Normal Saline; and c. a buffer for increasing pH.
[0229] According to some embodiments, the invention also provides use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
[0230] According to some embodiments, the invention also provides use of an amount of levosimendan, its metabolites OR- 1896 or OR-1855, or a combination thereof, for preparing medicament for administering to a human subject afflicted with Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF to effectively treat PH-HFpEF in the human subject.
[0231] According to some embodiments, the invention also provides a medicament comprising an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for use in effectively treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
[0232] According to some embodiments, the invention also provides use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, in combination with a cardiovascular drug to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
[0233] According to some embodiments, the invention also provides use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for preparing a medicament in combination with a cardiovascular drug for administering to a human subject afflicted with Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) to effectively treat PH-HFpEF in the human subject.
[0234] According to some embodiments, the invention also provides a medicament comprising an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for use in combination with a cardiovascular drug to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
[0235] According to some embodiments, the invention also provides a subcutaneous formulation of levosimendan for use in treating PH-HFpEF in a human subject afflicted with PH-HFpEF, wherein the subcutaneous formulation is obtained from a dried powder, wherein the dried powder is obtained from a pharmaceutical composition comprising: (a) levosimendan; (b) sulfo-butyl -ether beta-cyclodextrin; (c) sodium hydroxide or acetic acid; and water for injection.
[0236] In some embodiments, the amount of levosimendan is 2.5mg / ml water for injection.
[0237] In some embodiments, the amount of sulfo-butyl -ether beta-cyclodextrin is 0.175mg / ml water for injection.
[0238] In some embodiments, the sodium hydroxide or acetic acid is in a suitable amount to adjust the pH to a range of 7.2 to 7.8.
[0239] In some embodiments, the pharmaceutical composition is fdter sterilized.
[0240] In some embodiments, the pharmaceutical composition is lyophilized.
[0241] In some embodiments, subcutaneous formulation of levosimendan is obtained from the dried powder by reconstitution of the dried powder in an amount of aqueous solution suitable for subcutaneous administration.
[0242] In some embodiments, the reconstituted subcutaneous formulation is pH adjusted to 7.2 to 7.8 with sodium hydroxide or acetic acid.
[0243] According to some embodiments, the invention provides a method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of a cardiovascular drug that is effective to treat the PH-HFpEF in the human subject, wherein the cardiovascular drug is selected from the group consisting of a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta-blocker (BB), an angiotensin converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), a natriuretic peptide, a K-ATP channel activator, aNEP inhibitor, and a prostacyclin. [0244] According to some embodiments, the invention provides a method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of a pulmonary vasodilator drug that is effective to treat the PH-HFpEF in the human subject, wherein the pulmonary vasodilator drug is selected from the group consisting of a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), and a prostacyclin.
[0245] In some embodiments, the amount of the pulmonary vasodilator drug is administered to a human subject afflicted with pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc -PH-HFpEF).
[0246] According to some embodiments, the invention provides a cardiovascular drug for use in treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a subject, wherein the cardiovascular drug is selected from the group consisting of a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta-blocker (BB), an angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), a natriuretic peptide, a K-ATP channel activator, a NEP inhibitor, and a prostacyclin.
[0247] According to some embodiments, the invention provides a pulmonary vasodilator drug for use in treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a subject, wherein the pulmonary vasodilator drug is selected from the group consisting of a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), and a prostacyclin.
[0248] In some embodiments, the Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) is pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc -PH-HFpEF).
[0249] In some embodiments, the subject is orally administered a capsule comprising up to O.lmg, 0.25mg, 0.5mg, 0.75mg, lmg, 2mg, 3mg, or 4mg, more preferably l-3mg, of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof.
[0250] In some embodiments, the subject is administered a capsule once a day for a time period of 1-60 days, preferably 14 days. [0251] In some embodiments, the subject increases the number of capsules taken per day after every time period if the treatment is tolerated by the subject.
[0252] In some embodiments, the subject is orally administered between 0.1-10mg of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, per day, preferably between l-4mg of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof per day.
[0253] In some embodiments, the subject received a final intravenous injection of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof at least one day, more preferably at least one week, before beginning oral administration of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof.
[0254] Throughout this application, where a parameter range is provided, all integers within that range, and tenths and hundredths thereof as appropriate, shall be considered to also be provided and disclosed in this application as being contemplated by the invention. For example, 02-5 mg/kg/day” is to be considered as a disclosure of 0.2 mg/kg/day, 0.3 mg/kg/day, 0.4 mg/kg/day, 0.5 mg/kg/day, 0.6 mg/kg/day etc. up to 5.0 mg/kg/day.
[0255] According to some embodiments, the compound to be administered (e.g. levosimendan) is in the form of a composition (referred to as the composition of the invention) comprising a therapeutically effective amount of at least one of said compound. As used herein, the term "effective amount" means an amount of compound that is capable of reducing and/or attenuating a disorder or symptom as described herein. The specific dose of a compound administered according to this invention will, of course, be determined by the particular circumstances surrounding the case including, for example, the compound administered, the route of administration, the physiological state of the subject, and the severity of the condition being treated.
[0256] Any suitable route may be used to administer the medicament or levosimendan of the invention to a subject.
[0257] According to some embodiments, suitable administration routes may be systemic routes. According to some embodiments, administering is administering systemically. According to some embodiments, the composition is formulated for systemic administration.
[0258] According to another embodiment, administration systemically is through an enteral route. According to another embodiment, administration through an enteral route is oral administration. According to some embodiments, the composition is formulated for oral administration. [0259] In an embodiment the administration intermittently takes place via 24-hour, weekly administration.
[0260] In an embodiment the administration takes place chronically for less than 24 hours.
[0261] In an embodiment the dose is levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose, 0.9 Normal Saline, or other diluent where the human subject weights less than 85 kg.
[0262] In an embodiment the dose is levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose, 0.9 Normal Saline, or other diluent where the human subject weights at least 85 kg.
[0263] In an embodiment the infusion rate is between 0.075 and 0.10 pg/kg/min for 24 hours.
[0264] In an embodiment the administration is delivered via oral dosing. The dosing can be an immediate release or extended release formulation.
[0265] In an embodiment the administration is delivered via inhalation of an inhaled formulation.
[0266] In an embodiment the administration is delivered via transdermal delivery of a transdermal formulation.
[0267] In an embodiment the invention is an article of manufacture including the 5mL vial dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol; 250 mL of 5% Dextrose or 0.9 Normal Saline; and a buffer for increasing pH.
[0268] In an embodiment the amount of levosimendan is effective to treat PH-HFpEF in a human subject.
[0269] In an embodiment the amount of levosimendan for preparing medicament for administration is effective to treat PH-HFpEF in a human subject.
[0270] In an embodiment the medicament has an amount of levosimendan that is effective to treat PH- HFpEF in a human subject.
[0271] In an embodiment the amount of levosimendan in combination with a cardiovascular drug is effective to treat PH-HFpEF in a human subject.
[0272] In an embodiment the amount of levosimendan in combination with a cardiovascular drug for preparing medicament for administration is effective to treat PH-HFpEF in a human subject. [0273] In an embodiment the medicament has an amount of levosimendan in combination with a cardiovascular drug that is effective to treat PH-HFpEF in a human subject.
[0274] In an embodiment no arrythmias, atrial or ventricular, are observed when comparing baseline electrocardiographic monitoring with 72-hour monitoring after 5 weeks of treatment.
[0275] In an embodiment the weekly 24-hour dosing of levosimendan results in steady state blood levels of OR1896 in the range of 0.20 ng/mL to 25.00 ng/mL.
Definitions/ Abbreviations
[0276] As used herein, the term “levosimendan” means levosimendan base or a pharmaceutically acceptable salt thereof. The active compounds for use according to the invention may be provided in any form suitable forthe intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the compound of the invention.
[0277] Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the L-tartrate, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like. Such salts may be formed by procedures well known and described in the art.
[0278] PH is the abbreviation for Pulmonary Hypertension. PH encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance. (Oldroyd et al. 2019)
[0279] HFpEF is the abbreviation for heart failure with preserved ejection fraction. HFpEF is when a patient is afflicted with heart failure while their ejection fraction remains > 40%. (Kelly et al. 2015)
[0280] PH-HFpEF is the abbreviation for Pulmonary Hypertension with heart failure with preserved ejection fraction. PH-HFpEF is defined by a high pulmonary artery pressure, high left ventricular end- diastolic pressure and a normal ejection fraction. (Lai et al. 2019)
[0281] PCWP is the abbreviation for pulmonary capillary wedge pressure. PCWP is the pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch. PCWP estimates left atrial pressure. (Peacock et al. 2004) [0282] RAP is the abbreviation for right atrial pressure. RAP is the blood pressure in the right atrium of the heart. RAP reflects the amount of blood returning to the heart and the ability of the heart to pump the blood into the arterial system.
[0283] mPAP is the abbreviation for mean pulmonary artery pressure. mPAP is generated by the right ventricle ejecting blood into the pulmonary circulation, which acts as a resistance to the output from the right ventricle.
[0284] PVR is the abbreviation for pulmonary vascular resistance. PVR refers to the resistance in the arteries that supply blood to the lungs. (Schnur 2017)
[0285] CO is the abbreviation for cardiac output. CO is the volume of blood being pumped by the heart per unit time. (Vincent 2008)
[0286] Cl is the abbreviation for cardiac index. Cl is a hemodynamic parameter that relates the cardiac output from the left ventricle in one minute to the body surface area. This measurement relates heart performance to the size of the individual. (Shea 2019)
[0287] HR is the abbreviation for heart rate. HR is the speed of the heartbeat measured by the number of contractions of the heart per minute. ( Heart.org 2015)
[0288] PR is the abbreviation for pulse rate. PR is the measurement of the heart rate. ( Heart.org 2015)
[0289] BP is the abbreviation for blood pressure. BP is the pressure of circulating blood within the major arterial system of the body. (Brezinski 1990)
[0290] 6MWT is the abbreviation for six-minute walk test. 6MWT is a performance-based test used to measure functional exercise capacity. The 6MWT measures the distance an individual is able to walk over a total of 6 minutes at a constant and normal pace. (Vandoni et al. 2018)
[0291] Likert scale is a psychometric scale commonly involved in research that employs questionnaires. In the below-mentioned clinical trial, a six-question, five-point Likert Scale is provided to patients to assess their quality of life. (HELP clinical trial protocol)
[0292] ECG is the abbreviation for echocardiogram. An ECG is a record of a person’ s heartbeat produced by echocardiography. An ECG is a test that uses high frequency sound waves (ultrasound) to make pictures of your heart. ( heart.org 2015)
[0293] Dobutamine stress test is a form of ECG where stress is induced on the heart by administering dobutamine into a vein to assess the heart’s function and structures. This test mimics the effects of exercise on the heart. (Hawthorne et al. 2012) [0294] New York Heart Association Functional Classification provides a simple way of classifying the extent of heart failure. A patient in Class I has no limitation of physical activity. A patient in Class II has slight limitation of physical activity. A patient in Class III has marked limitation of physical activity. A patient in Class IV is unable to carry on any physical activity without discomfort. In addition to these class numbers based of patient symptoms, every patient is assigned a class letter based on an objective assessment. A patient in Class A has no objective evidence of cardiovascular disease. A patient in Class B has objective evidence of minimal cardiovascular disease. A patient in Class C has objective evidence of moderately severe cardiovascular disease. A patient in Class D has objective evidence of severe cardiovascular disease. (Y ancy et al. 2013)
[0295] Self-administration is administration of the formulation administered by the human subject afflicted with the disease. (HELP clinical trial protocol)
[0296] Outpatient setting is a setting where the patients do not require admittance for overnight care. (W orld Health Organization 2009)
[0297] Trained professional indicates a doctor, nurse, home healthcare nurse, or other person with training and/or experience and/or a license in the medical profession.
[0298] TEAEs is the abbreviation for Treatment Emergent Adverse Events. The TEAEs of special interest are hypotension, atrial fibrillation, other significant arrhythmia, resuscitated death stroke. Other TEAEs include, but are not limited to, headache, increased heart rate, fatigue, cardiac failure acute, dyspnea, vascular access site pain, muscle spasm, and hypokalaemia.
[0299] SAEs is the abbreviation for Serious Adverse Events. SAEs include, but are not limited to, infections and infestations, device related infection; infections and infestations, bacteremia; cardiac disorders, cardiac failure acute; and cardiac disorders, cardiac failure acute.
[0300] As used herein, the term “acute administration” means administration of a drug, e.g. levosimendan, in a brief period of time, for example, delivery of a single dose of a drug, delivery of doses of a drug in rapid succession, or delivery of a drug on short time scale, preferably less than 48 hours. Acute administration of a drug is generally intended for the drug to have a beneficial effect on a condition in the short-term. For example, acute administration of levosimendan may be performed such that the amount of levosimendan administered is intended for the levosimendan drug to directly improve a condition, e.g. PH- HFpEF, prior to any significant activity of a levosimendan metabolite. Acute administration is generally performed by a trained professional, for example, by intravenous administration in a clinical setting.
[0301] As used herein, the term “chronic administration” means an extended and repeated administration of a drug, e.g. levosimendan. For example, delivery of multiple or repeated doses of a drug over the course of a long-time scale, preferably at least a week. Chronic administration of a drug is generally intended for the drug or its metabolites to have a continued beneficial effect on a condition or to prevent or slow deterioration of a disease-state over time. Chronic administration is often delivered to a subject by the subject themselves (i.e. self-administration), for example, by oral or subcutaneous administration.
Subcutaneous Administration
[0302] The present invention also relates to subcutaneous administration of levosimendan in a subcutaneous formulation to achieve the effects disclosed herein. Due to the potentially irritating, vesicant, and extravasation effects of administering inotropes and vasoactive substances, such as levosimendan, subcutaneous administration of the existing levosimendan formulation has not previously been investigated. Nevertheless, subcutaneous administration may be used where a less invasive route of delivery would be a novel method of administration.
[0303] Notwithstanding the potential extravasation concerns with subcutaneous administration, the subcutaneous route of levosimendan administration may be better tolerated than intravenous delivery. Subcutaneous administration may reduce and delay absorption of levosimendan, resulting in lower peak plasma concentrations of levosimendan as compared to intravenous administration. This may avoid the occurrence of typical side effects of levosimendan administration, particularly hypotension caused by the maximum concentration of levosimendan (Cmax) because higher plasma concentrations and a higher Cmax of levosimendan typically leads to more frequent side effects, such as hypotension.
[0304] Subcutaneous administration of levosimendan offers a clear advantage in terms of eliminating the potential for central line infections that are common with IV chronic administration via PICC and port-a- cath devices that are often necessary for convenient repeated IV access.
[0305] Despite exhibiting a delay in levosimendan absorption along with lower plasma concentrations, subcutaneous administration of levosimendan unexpectedly results in a similar plasma concentration profile of the levosimendan metabolite OR- 1896. This results in a better safety profile, due to the comparable levels of OR- 1896 in the blood without the high peak plasma concentration of levosimendan.
[0306] There are numerous practical advantages with subcutaneous administration such as: being easily titrated, facilitating patient control, reliable records of dosing, reducing nursing burden, and reducing the risk of drug diversion.
[0307] One delivery device suitable for subcutaneous administration is an ambulatory infusion pump, such as a CADD pump, which stands for continuous ambulatory delivery device pump. Additionally, subcutaneous administration could be delivered through a simple prefilled syringe, syringe pump, injection pen, autoinjector, micropump, or patch device. (Bittner et al. 2018) [0308] Although in the present instance the subcutaneous formulation would be substantially similar to the intravenous formulation, certain additives could be introduced to make the treatment more tolerable for the patient. Buffers, such as water, sodium bicarbonate, or other similar buffering agents that are known to increase pH, could be added to increase the pH of the subcutaneous formulation.
[0309] Like the administration of the intravenous formulation, the subcutaneous administration of levosimendan can be administered intermittently as well as chronically. The intermittent administration can take place weekly for a 24-hour period. In addition to being administered by a trained professional, subcutaneous administration makes it much simpler for the patient to self-administer the levosimendan formulation.
[0310] Subcutaneous administration of levosimendan can support an expanded range of dilutions and corresponding concentration while still being viable.
Figure imgf000036_0001
[0311] Overall, data supports that subcutaneous administration is simpler than intravenous infusions, can reduce drug delivery-related healthcare costs and resources, and is largely preferred by both patients and health care providers (Bittner et al. 2018).
[0312] Several methods of subcutaneous administrations are known in the art, and any such method may be used for subcutaneous administration of levosimendan. Examples of subcutaneous administration methods include, but are not limited to, manual needle injection and various subcutaneous drug delivery devices such as subcutaneous administration systems that deliver a drug via a pump apparatus such as performed with certain insulin pump systems, e.g. the Omnipod© system. [0313] In an embodiment the subcutaneous formulation comprises water in an amount effective to reduce pain caused by the administration.
[0314] In an embodiment the subcutaneous formulation comprises buffers to raise the pH higher than 3.0.
[0315] In an embodiment the subcutaneous administration reduces side effects relative to intravenous administration.
[0316] In an embodiment the subcutaneous administration reduces peak plasma concentrations of levosimendan relative to intravenous administration by at least 1% to 25%.
[0317] Levosimendan formulations that have been described for subcutaneous administration are described in, for example, PCT International Publication No. WO 2020/041180 A1 (Application No. PCT/US2019/047032), the entire contents of which are incorporated by reference.
[0318] In some embodiments, a pharmaceutical composition of levosimendan for treatment in subjects in need thereof, for example, for treatment of heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients), by subcutaneous administration is in a formulation comprising: (a) an effective amount of levosimendan, its metabolites OR- 1896 or OR-1855, or a combination thereof; (b) a cyclodextrin or a cyclodextrin derivative; and (c) one or more additional pharmaceutically acceptable additives.
[0319] In an embodiment, the cyclodextrin derivative comprises an alpha-cyclodextrin derivative, a beta- cyclodextrin derivative, or a gamma-cyclodextrin derivative.
[0320] In an embodiment, the cyclodextrin derivative comprises sodium sulfonate salt.
[0321] In an embodiment, the cyclodextrin derivative comprises a butyl ether spacer group, an alkyl ether space group, or a combination thereof.
[0322] In an embodiment, the cyclodextrin derivative comprises sulfobutylether.
[0323] In an embodiment, the cyclodextrin derivative comprises sulfobutylether beta-cyclodextrin.
[0324] In an embodiment, the cyclodextrin or cyclodextrin derivative is in an amount of about 50 mg/ml to about 400 mg/ml, preferably in an amount of about 100 mg/ml to about 300 mg/ml.
[0325] In an embodiment, the formulation comprises a pH of about 5 to about 9, preferably a pH of about 6 to about 8.
[0326] In an embodiment, the one or more pharmaceutically acceptable additives comprise one or more non-citrate buffering agents. [0327] In an embodiment, the one or more pharmaceutically acceptable additives comprise a phosphate buffer.
[0328] In an embodiment, the one or more pharmaceutically acceptable additives comprise one or more pH-modifying agents.
[0329] In an embodiment, wherein the one or more pharmaceutically acceptable additives comprise one or more preservatives, one or more antioxidants, one or more carriers, or a combination thereof.
[0330] In an embodiment, the one or more carriers comprise a liquid media selected from a group consisting of solutions, suspensions, hydrogels, liposomes, emulsions, and a combination thereof.
[0331] In an embodiment, the one or more carriers alter the absorption characteristics in a way that extend the effectiveness and or minimize side effects.
[0332] In an embodiment, the levosimendan is in an amount of about 0.1 mg/ml to about 100 mg/ml, preferably in an amount of about 0.1 mg/ml to about 30 mg/ml.
[0333] In an embodiment, the formulation is substantially free of alcohol.
[0334] In an embodiment, the formulation is alcohol-free.
[0335] In an embodiment, the formulation is preservative-free.
[0336] In an embodiment, the formulation is in the form of particles.
[0337] In an embodiment, the formulation is lyophilized.
[0338] In an embodiment, the formulation is spray-dried.
[0339] In an embodiment, a pharmaceutical composition for subcutaneous administration of levosimendan is in a formulation comprising: (a) levosimendan in an amount of about 0.1 mg/ml to about 10 mg/ml; (b) a cyclodextrin or a cyclodextrin derivative in an amount of about 50 mg/ml to about 500 mg/ml; and (c) phosphate buffer of about 1 mM to about 20 mM.
[0340] In an embodiment, the formulation has a pH of about 6 to about 8.
[0341] In an embodiment, the formulation is substantially free of alcohol.
[0342] In an embodiment, the formulation is lyophilized.
[0343] Furthermore, levosimendan formulations that have been described for intravenous administration may be adopted for subcutaneous administration. For example, see U.S. Patent No. 10,507,179, the entire contents of which are incorporated by reference. [0344] In some embodiments, levosimendan formulations suitable for subcutaneous administration include, but are not limited to, a pharmaceutical composition, comprising levosimendan as active ingredient, and a solubilizer selected from the group consisting of cyclodextrins, consisting of sulfo-butyl- ether beta-cyclodextrin, alpha-cyclodextrin and methyl-beta-cyclodextrin and mixtures thereof, fatty acid esters of glycerol, polyethylene derivatives of alpha-tocopherol, bile acids, with the proviso that the use of co-solvents such as ethanol, propyleneglycol, polyethyleneglycol, poloxamers or polyvinylpyrrolidon is excluded.
[0345] In an embodiment, the solubilizer is D-alpha tocopheryl polyethylene glycol 1000 succinate or a bile salt, which is preferably selected from the group consisting of sodium glycocholate, taurocholic acid sodium salt, taurodeoxycholic acid sodium salt and sodium cholate, or mixtures thereof.
[0346] In an embodiment, the micelles are polymeric micelles, preferably polyethylene oxide)- poly(propylene oxide) block copolymer micelles, or mixed micelles composed of soy phosphatidylcholine/sodium glycocholate or hybrid micelles.
[0347] In an embodiment, the pharmaceutical composition comprises levosimendan as active ingredient, and sulfo-butyl-ether beta-cyclodextrin as a solubilizer, with the proviso that the use of co-solvents comprised of ethanol, propyleneglycol, polyethyleneglycol, poloxamers or polyvinylpyrrolidon is excluded.
[0348] In an embodiment, sulfo-butyl-ether beta-cyclodextrin is preferably present in a mmolar ratio compared to levosimendan within a range of 1-15 mmol cyclodextrine(s): 1 mmol levosimendan. Preferably the excess of cyclodextrine(s) is 4-12 mmol cyclodextrine(s): 1 mmol levosimendan, still more preferably 6-10 mmol cyclodextrine(s): 1 mmol levosimendan.
[0349] In an embodiment, levosimendan is present in solubilized form.
[0350] In an embodiment, levosimendan is solubilized by micellarization or by complexation.
[0351] In an embodiment, the pharmaceutical composition is in the form of a solution, more preferably in the form of an aqueous solution.
[0352] In an embodiment, the amount of the solubilizer is 2 to 45 percent by weight of the pharmaceutical composition.
[0353] In an embodiment, the pH of the solution is in the range of 7.0 to 8.0., more preferably in the range of 7.2 to 7.8.
[0354] In an embodiment, the levosimendan in an amount of 1 to 15 mg/ml solution. [0355] In an embodiment, a dried powder is obtained from the pharmaceutical composition for use as a medicament in treating heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients). The dried powder is obtainable by drying a solution comprising the solubilized levosimendan, and is reconstituted to a solution suitable for subcutaneous administration.
[0356] In an embodiment, the dried powder for use is a subcutaneous infusion concentrate comprising the levosimendan in an amount of 1 to 15 mg/ml solution.
[0357] In an embodiment, the concentrate is to be adjusted to a pH in the range of 7.2 to 8.0.
[0358] In an embodiment, the solvent for reconstitution of the dried powder for use is water, or an isotonic buffer system.
[0359] In an embodiment, the water has a pH in the range of 7.2 to 7.8, or the isotonic buffer system has a pH in the range of 7.2 to 7.4
[0360] In an embodiment, the dried powder is obtainable by drying a solution comprising the solubilized levosimendan and a suitable pharmaceutical vehicle used for freeze-drying.
[0361] The present discolusre provides a subcutaneous formulation of levosimendan for use in treating PH-HFpEF in a human subject afflicted with PH-HFpEF, wherein the subcutaneous formulation is obtained from a dried powder, wherein the dried powder is obtained from a pharmaceutical composition comprising: (a) levosimendan; (b) sulfo-butyl-ether beta-cyclodextrin; (c) sodium hydroxide or acetic acid; and water for injection.
[0362] In an embodiment, the amount of levosimendan is 2.5mg / ml water for injection.
[0363] In an embodiment, the amount of sulfo-butyl-ether beta-cyclodextrin is 0.175mg / ml water for injection.
[0364] In an embodiment, the sodium hydroxide or acetic acid is in a suitable amount to adjust the pH to a range of 7.2 to 7.8.
[0365] In an embodiment, the pharmaceutical composition is fdter sterilized.
[0366] In an embodiment, the pharmaceutical composition is lyophilized.
[0367] In an embodiment, the subcutaneous formulation of levosimendan is obtained from the dried powder by reconstituting the dried powder in an amount of aqueous solution suitable for subcutaneous administration. [0368] In an embodiment, the reconstituted subcutaneous formulation is pH adjusted to 7.2 to 7.8 with sodium hydroxide or acetic acid.
Oral Administration
[0369] The present invention also relates to oral administration of levosimendan in an oral formulation to achieve the effects disclosed herein. There are numerous practical advantages with oral administration such as: being easily administered and titrated, facilitating patient control, and reducing nursing burden.
[0370] According to some embodiments, oral administration is in the form of hard or soft gelatin capsules, pills, capsules, tablets, including coated tablets, dragees, elixirs, suspensions, liquids, gels, slurries or syrups and controlled release forms thereof. Thus, the invention provides a method of administering levosimendan in the form of a tablet, a capsule, or in a liquid.
[0371] Suitable carriers for oral administration are well known in the art. Compositions for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries as desired, to obtain tablets or dragee cores. Non-limiting examples of suitable excipients include fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, and sodium carbomethylcellulose, and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
[0372] If desired, disintegrating agents, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate, may be added. Capsules and cartridges of, for example, gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base, such as lactose or starch.
[0373] Solid dosage forms for oral administration include without limitation capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as it normal practice, additional substances other than inert diluents, e.g., lubricating, agents. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. The term “enteric coating”, as used herein, refers to a coating which controls the location of composition absorption within the digestive system. Non-limiting examples for materials used for enteric coating are fatty acids, waxes, plant fibers or plastics. Liquid dosage forms for oral administration may further contain adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents. [0374] In an embodiment, the administration is delivered via oral dosing, and the oral dosing can be an immediate release or extended release formulation.
[0375] In some embodiments, a pharmaceutical composition of levosimendan for treatment in subjects in need thereof, for example, for treatment of heart failure with preserved ejection fraction, specifically in human subjects who also have pulmonary hypertension (PH-HFpEF patients), by oral administration is in a formulation comprising an effective amount of levosimendan, its metabolites OR- 1896 or OR- 1855, or a combination thereof and one or more additional pharmaceutically acceptable additives.
[0376] In an embodiment, the oral formulation comprises levosimendan, its metabolites OR- 1896 or OR- 1855, or a combination thereof in the amount of O.lmg, 0.25mg, 0.5mg, 0.75mg, lmg, 2mg, 3mg, or 4mg.
[0377] In an embodiment, the oral formulation comprises microcrystalline cellulose.
[0378] In an embodiment, the oral formulation comprises alginic acid.
[0379] In an embodiment, the oral formulation comprises steric acid.
[0380] In an embodiment, the oral formulation is in a capsule form.
[0381] In an embodiment, the oral formulation is the capsule form is a HPMC capsule.
[0382] In an embodiment the oral formulation comprise in a capsule form and the oral formulation comprises lmg levosimendan, 96.4mg microcrystalline cellulose, 30.0mg alginic acid, and 5.3mg stearic acid.
[0383] In an embodiment, the oral dosage form comprises levosimendan in the amount of O.lmg, 0.25mg, 0.5mg, 0.75mg, lmg, 2mg, 3mg, or 4mg, more preferably in the amount of l-3mg.
[0384] In an embodiment, a subject is orally administered a capsule comprising levosimendan in the amount of lmg once per day. The oral dosing may be titrated according to, for example, the effectiveness of the treatment, tolerability, changes in heart rate, and body weight of the subject. The titration of levosimendan may be in lmg increments and range from 1-lOmg per day, more preferably between l-4mg per day.
[0385] The titration of levosimendan administration may occur over the course of days, weeks, or months. The effect of duration at a particular dosage amount on tolerability should also be considered when titrating, e.g. the tolerability of a subject to the levosimendan oral treatment may increase with an increase in duration at a particular dosage amount.
[0386] For example, a subject may begin an oral levosimendan treatment course at lmg/day (i.e. ingesting one capsule comprising lmg levosimendan per day). The subject may maintain a levosimendan dosage of lmg/day for two weeks. After two weeks, if the levosimendan dosage is well-tolerated and heart rate is increased <15 BPM, the subject can titrate up to a dosage of 2mg/day (i.e. ingesting two capsules, each comprising lmg levosimendan, per day). The subject may continue to titrate up in increments of lmg levosimendan in this manner until an optimal oral dosage is achieved, for example, up to lOmg of levosimendan per day.
[0387] A subject receiving levosimendan by other administration routes, for example, intravenous injection, may be transitioned to an oral dosing scheme. For example, a subject receiving levosimendan by intravenous injection may begin an oral dosing after receiving a final 24-hour infusion of levosimendan. The oral dosing of levosimendan may begin within days or weeks, for example, one week, of the final 24- hour infusion. The oral dosage may begin at lmg/day, followed by titration as indicated above.
Combination Therapy
[0388] The administration of two drugs to treat a given condition, such as PH-HFpEF, raises a number of potential problems. In vivo interactions between two drugs are complex. The effects of any single drug are related to its absorption, distribution, and elimination. When two drugs are introduced into the body, each drug can affect the absorption, distribution, and elimination of the other and hence, alter the effects of the other. For instance, one drug may inhibit, activate or induce the production of enzymes involved in a metabolic route of elimination of the other drug (Guidance for Industry, 2006). In one example, combined administration of GA and interferon (IFN) has been experimentally shown to abrogate the clinical effectiveness of either therapy. (Brod 2000) In another experiment, it was reported that the addition of prednisone in combination therapy with IFN-b antagonized its up-regulator effect. Thus, when two drugs are administered to treat the same condition, it is unpredictable whether each will complement, have no effect on, or interfere with, the therapeutic activity of the other in a human subject.
[0389] Not only may the interaction between two drugs affect the intended therapeutic activity of each drug, but the interaction may increase the levels of toxic metabolites (Guidance for Industry, 2006). The interaction may also heighten or lessen the side effects of each drug. Hence, upon administration of two drugs to treat a disease, it is unpredictable what change will occur in the negative side profile of each drug. In one example, the combination of natalizumab and interferon b-la was observed to increase the risk of unanticipated side effects. (Vollmer, 2008; Rudick 2006; Kleinschmidt-DeMasters, 2005; Langer-Gould 2005)
[0390] Additionally, it is difficult to accurately predict when the effects of the interaction between the two drugs will become manifest. For example, metabolic interactions between drugs may become apparent upon the initial administration of the second drug, after the two have reached a steady-state concentration or upon discontinuation of one of the drugs. (Guidance for Industry, 2006)
[0391] As used herein, “combination” means an assemblage of reagents for use in therapy either by simultaneous, contemporaneous, or fixed-dose combination delivery. Simultaneous delivery refers to delivery of an admixture (whether a true mixture, a suspension, an emulsion or other physical combination) of the drugs. In this case, the combination may be the admixture or separate containers of the levosimendan and a second agent that are combined just prior to delivery. Contemporaneous delivery refers to the separate delivery of the levosimendan and second agent at the same time, or at times sufficiently close together that an additive or preferably synergistic activity relative to the activity of either the levosimendan or the cardiovascular drug alone is observed. Fixed-dose combination delivery refers to the delivery of two or more drugs contained in a single dosage form for oral administration, such as a capsule or tablet.
[0392] As used herein, “second agent” for use in combination therapy includes any one of the following: Phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA) (e.g., Bosentan, Ambrisentan), a Prostanoid (e.g., Trepostinil, Selexipag, Ralinepag), a Soluble Guanylate Cyclase stimulator (e.g., Riociguat), a nitrate or nitrite, a calcium channel blocker (CCB), fatty acid oxidation inhibitors (e.g., Ranolazine, Trimetazidine), a beta-blocker (BB), an Angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor (e.g., Sacubitril, Sampatrilat, Gemopatrilat, Fasidotril, Omapatrilat, Candoxatril), a neprilysin and angiotensin receptor blocker (ANRI) (e.g., Entresto), an Angiotensin II receptor blocker (ARB), a diuretic, an Aldosterone antagonist, Digoxin, Ivabradine, Hydralazine, Seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), or Nesiritide.
[0393] The recommended dose and schedule for Entresto is 24/26 mg twice daily (24 mg of sacubitril and 26 mg of valsartan). The dose is doubled every two to four weeks, as tolerated by the patient. The composition recited hereinabove is described in U.S. Patent Nos. 7,468,390; 8,101,659; 8,404,744; 8,796,331; 8,877,938; and 9,388,134, the entire contents of which are incorporated by reference.
[0394] The recommended dose and schedule for Sacubitril is 24 mg twice daily. The dose is doubled every two to four weeks, as tolerated by the patient.
[0395] The recommended dose and schedule for Ranolazine is 500 mg twice daily. The dose is increased to 1000 mg twice daily, as needed, based on clinical symptoms. The composition recited hereinabove is described in U.S. Patent Nos. 6,303,607; 6,369,062; 6,479,496; 6,503,911; 6,525,057; 6,562,826; 6,617,328; 6,620,814; 6,852,724; and 6,864,258, the entire contents of which are incorporated by reference.
[0396] The recommended dose and schedule for Bosentan is 62.5 mg twice daily for patients > 12 years of age. After 4 weeks, the dose is increased to 125 mg twice daily if the patient weighs greater than 40 kg, and the dose is not changed if the patient weights less than 40kg. The composition recited hereinabove is described in U.S. Patent Nos. 7,959,945 and 8,309,126, the entire contents of which are incorporated by reference.
[0397] The recommended dose and schedule for Ambrisentan is 5 mg orally once a day. The dose is increased to 10 mg orally once a day, if 5 mg is tolerated by the patient. The composition recited hereinabove is described in U.S. Patent Nos. 8,377,933; 9,474,752; and 9,549,926, the entire contents of which are incorporated by reference.
[0398] The recommended dose and schedule for Trepostinil is 0.25 mg orally every 12 hours or 0.125 mg every 8 hours for oral extended-release tablets; 3 breaths (18 meg) per treatment session 4 times per day or if not tolerated then reduce to 1 or 2 breaths and subsequently increase to 3 breaths as tolerated for inhalation; or 1.25 ng/kg/min via continuous subcutaneous or IV infusion or 0.625 ng/kg/min if the larger dose cannot be tolerated for patients new to prostacyclin infusion therapy. The composition recited hereinabove is described in U.S. Patent Nos. 10,076,505; 7,999,007; 8,653,137; 8,658,694; 9,199,908; 9,593,066; 9,604,901; and 9,713,599, the entire contents of which are incorporated by reference.
[0399] The recommended dose and schedule for Selexipag is 200 meg orally twice a day. The dose is incrementally increased by 200 meg orally twice a day at weekly intervals to the highest tolerated dose, not to exceed 1600 meg orally twice a day. The composition recited hereinabove is described in U.S. Patent Nos. 7,205,302;8,791,122; 9,173,881; and 9,284,280, the entire contents of which are incorporated by reference.
[0400] The recommended dose and schedule for Ralinepag is 10 pg twice daily to 300 pg twice daily. The composition recited hereinabove is described in Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial (Torres et al. 2019), the entire contents of which are incorporated by reference.
[0401] The recommended dose and schedule for Riociguat is 1 mg orally 3 times a day. This dose is increased as tolerated, but is not to exceed 2.5 mg orally 3 times a day. The composition recited hereinabove is described in U.S. Patent Nos. 6,743,798 and 7,173,037, the entire contents of which are incorporated by reference.
[0402] The recommended dose and schedule for Trimetazidine is 60 mg/day to 140 mg/day. The composition recited hereinabove is described in Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease (Chrusciel et al. 2014), the entire contents of which are incorporated by reference. [0403] The recommended dose and schedule for Sampatrilat is 50 mg to 100 mg daily. The composition recited hereinabove is described in Sustained Antihypertensive Actions of a Dual Angiotensin-Converting Enzyme Neutral Endopeptidase Inhibitor, Sampatrilat, in Black Hypertensive Subjects (Norton et al. 1999), the entire contents of which are incorporated by reference.
[0404] Gemopatrilat is described in Metabolism Of [14c] Gemopatrilat After Oral Administration To Rats, Dogs, And Humans (Wait et al. 2006), the entire contents of which are incorporated by reference.
[0405] The recommended dose and schedule for Fasidotril is 100 mg twice daily. The composition recited hereinabove is described in Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans (Laurent et al. 2000), the entire contents of which are incorporated by reference.
[0406] The recommended dose and schedule for Omapatrilat is 10 mg to 80 mg daily. The composition recited hereinabove is described in Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial (Kostis et al. 2004), the entire contents of which are incorporated by reference.
[0407] The recommended dose and schedule for Candoxatril is 200 mg twice a day to 400 mg twice a day. The composition recited hereinabove is described in Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure (Northridge et al. 1999), the entire contents of which are incorporated by reference.
[0408] The recommended dose and schedule for Digoxin is 8 to 12 mcg/kg through intravenous administration for the total loading dose and increased to 0.1 to 0.4 mg/day for the maintenance regiment. For oral administration, the dose and schedule is 10 to 15 mcg/kg for the total loading dose and increased to 3.4 to 5.1 mcg/kg/day. Another dosing option is 0.125 to 0.25 mg per day for oral or intravenous administration, with higher doses of 0.375 to 0.5 mg/day rarely needed. The composition recited hereinabove is described in Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction (Virgadamo et al. 2015), the entire contents of which are incorporated by reference.
[0409] The recommended dose and schedule for Ivabradine is 5 mg orally twice a day with meals. This dose is increased as tolerated, but is not to exceed 7.5 mg orally twice a day. The composition recited hereinabove is described in U.S. Patent Nos. 7,361,649; 7,361,650; 7,867,996; and 7,879,842, the entire contents of which are incorporated by reference.
[0410] The recommended dose and schedule for Hydralazine is 10 mg orally 4 times a day for the first 2 to 4 days, increased to 25 mg orally 4 times a day for the balance of the first week. This dose is increased to 50 mg orally 4 times a day for week 2 and subsequent weeks. The composition recited hereinabove is described in U.S. Patent Nos. 6,465,463 and 6,784,177, the entire contents of which are incorporated by reference.
[0411] The recommended dose and schedule for Seralaxin is three 48-hour intravenous infusions of 30 pg/kg/day. The composition recited hereinabove is described in RELAX-REPEAT: A Multicenter, Prospective, Randomized, Double-Blind Study Evaluating the Safety and Tolerability of Repeat Doses of Serelaxin in Patients with Chronic Heart Failure (Teerlink et al. 2016), the entire contents of which are incorporated by reference.
[0412] The recommended dose and schedule for Nesiritide is 2 mcg/kg IV bolus, followed by 0.01 mcg/kg/min via continuous IV infusion; not to be titrated more frequently than every 3 hours to a maximum of 0.03 mcg/kg/min. The composition recited hereinabove is described in U.S. Patent No. 5,114,923, the entire contents of which are incorporated by reference.
[0413] A subset of second agents that have a beneficial effect in a combination therapy with levosimendan include: K-ATP channel activators (e.g. pinacidil, diazoxide, bimakalim, levocromakalim, cromakalim, rimakalim, and nicorandil, etc.); nitrates (e.g. nitroglycerin-NTG, isosorbide dinitrate, etc.); nitrites (e.g. sodium nitrite, amyl nitrite, etc.); NO donors- (Sodium nitroprusside, Nitric Oxide, Molsidomine, linsidomine); PDE inhibitors (e.g. Milrinone, Pimobendan, Enoximone, etc.); natriuretic peptides, such as BNP (e.g. nesiritide), ANP (e.g. carparetide and ularitide), CDNP (e.g. cenderitide), and others (e.g. CNP, DNP, MANP, etc.); NEP inhibitors (e.g. sacubitril, sampatrilat/sympatril, fasidotril, omapatrilat/omapatril, candoxatril, etc.); and ARNIs (Entresto). Furthermore, a combination therapy with levosimendan may include any of the above second agents, a diuretic, or both.
[0414] Additionally, it is noted that combined pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc-PH-HFpEF) is a small and special phenotype of certain PH- HFpEF patients. These patients may benefit from agents that reduce pulmonary vascular resistance (Opitz 2016). The HELP Study identified that Levosimendan did not decrease pulmonary vascular resistance, particularly upon chronic administration. Therefore, Cpc-PH-HFpEF patients may benefit from a combination therapy comprising Levosimendan and an agent that reduces pulmonary vascular resistance. Accordingly, a combination therapy of Levosimendan with a pulmonary vasodilator, including but not limited to, phosphodiesterase-5 inhibitors (PDE-5 inhibitors, e.g. sildenafil, tadalafil, etc.); endothelin receptor antagonists (ERAs, e.g. bosentan, ambrisentan, etc.); and prostacyclins (e.g. epoprostenol, iloprost, Treprostinil, etc.) may provide therapeutic benefits to Cpc-PH-HFpEF patients. [0415] Each drug can be administered in the dose and regiment that has been disclosed in the drug’s aforementioned literature.
[0416] The embodiments referred to above refer to several drugs being substantially effective in the body at a same time. Several drugs can be administered substantially at the same time, or can be administered at different times but have effect on the body at the same time. For example, this includes administering levosimendan before or subsequently, while functioning of levosimendan in the body is substantially extant.
[0417] Therefore, the state of the art at the time of fding is that the effects of combination therapy of two drugs, in particular levosimendan and a second agent, cannot be predicted until the results of combination studies are available.
[0418] Each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments. Thus, all combinations of the various elements described herein are within the scope of the invention.
[0419] The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention.
EXAMPLES
[0420] Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only. (HELP Study - Hemodynamic Evaluation of Levosimendan in PH-HFpEF)
Example 1
Brief Summary
[0421] A multicenter, Phase II, double-blind, randomized, placebo-controlled study is conducted of levosimendan in pulmonary hypertension patients with heart failure and preserved left ventricular ejection fraction (PH-HFpEF) designed to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects.
Intervention
[0422] Drug: Levosimendan
[0423] Subjects are administered Levosimendan as follows: A sterile Levosimendan 2.5 mg/mL concentrated solution that is diluted in 250-500mL of 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/mL solution for infusion.
[0424] Subjects are administered Matching Placebo as follows: A sterile Placebo 2.5mg/mL concentrate solution that is diluted in 250-500mL of 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/mL solution for infusion.
Study Arms
[0425] Experimental: Levosimendan 2.5mg/mL Injectable Solution a. 0.075 - 0.1 pg/kg/min for 24 hours (weekly) b. Intervention: Drug: Levosimendan [0426] Experimental: Matching Placebo a. 0.075 - 0.1 pg/kg/min for 24 hours (weekly) b. Intervention: Drug: Levosimendan Estimated Enrollment
[0427] 36 subjects Inclusion Criteria
[0428] Men or women, at least 18 years of age.
[0429] Confirmed diagnosis of WHO Group 2 Pulmonary Hypertension (PH) with heart failure and preserved ejection fraction (HFpEF).
[0430] WHO Group 2 Pulmonary Hypertension subjects with heart failure and preserved ejection fraction as defined by: a. Mean pulmonary arterial pressure (mPAP) > 35mmHg at rest or with legs up (at baseline right heart catheter/Lead-In) b. Pulmonary capillary wedge pressure (PCWP) > 20 mmHg at rest or with legs up (at baseline right heart catheter/Lead-In) c. NYHA Class II or III d. LVEF > 40% by echocardiogram within three months of enrollment with no change in clinical status suggesting the potential for deterioration in systolic function.
[0431] Signed (by the subjects or their legally acceptable representatives) informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
[0432] Ability to walk at least 50 meters, but not more than 550 meters in a six-minute walk test.
[0433] Long term oxygen treatment (if applicable) must be stable for 30 days prior to enrollment.
[0434] Subjects on a chronic medication or therapy for any underlying cardiac condition must be on a stable dose for > 30 days prior to randomization, with the exception of diuretics and antihypertensive medication for blood pressure control which may be discontinued if deemed appropriate.
[0435] Subjects on chronic medications for any underlying respiratory condition must be on a stable dose for > 30 days prior to randomization.
Randomization Criteria
[0436] Response to Lead-In Levosimendan: Patients who demonstrate a > 4mmHg reduction in PCWP from baseline measured during bicycle exercise (25 watts) with no more than a 10% decrease from baseline cardiac index following the 24-hour infusion of levosimendan.
Exclusion Criteria
[0437] Previous PCI or cardiac surgery (CABG) unless documented to have a negative stress test within the last 12 months. [0438] Clinically symptomatic mitral or aortic valvular heart disease.
[0439] Cardiac index greater than 4.0 L/min/m2.
[0440] In the opinion of the Principal Investigator, the subject has a primary diagnosis of PH other than WHO Group 2 PH-HFpEF
[0441] Congenital heart disease other than surgically corrected pre and post tricuspid shunts for at least 10 years.
[0442] Symptomatic coronary artery disease based on a positive stress test.
[0443] Patients planning lung or heart transplant; or cardiac surgery in the next 4 months.
[0444] Patients diagnosed with pulmonary hypertension associated with clinically significant lung disease at the time of initial diagnosis, or patients with a congenital defect of the lung. a. Clinically significant obstructive lung disease is defined as FEV1/FVC < 60% of predicted, unless a high-resolution chest CT scan shows no more than mild areas of emphysematous changes. b. Clinically significant restrictive lung disease is defined as a FVC of < 60% of predicted, unless a high resolution chest CT scan shows no more than mild areas of interstitial lung disease or pulmonary fibrosis.
[0445] Dialysis at randomization (either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafiltration).
[0446] Estimated glomerular filtration rate (eGFR) < 30mL/min/1.73m2.
[0447] Liver dysfunction with Child Pugh Class B or C.
[0448] Evidence of systemic bacterial, systemic fungal, or viral infection in last 2 weeks.
[0449] Weight > 150 kg.
[0450] Symptomatic low systolic blood pressure (SBP) that cannot be managed to ensure SBP > 100 mmHg at initiation of study drug.
[0451] Heart rate > 100 bpm with study drug, symptomatic and persistent for at least 10 minutes at Lead- In.
[0452] Hemoglobin < 80 g/L.
[0453] Serum potassium < 3.0 mmol/L or > 5.5 mmol/L at baseline. [0454] Pregnant, suspected to be pregnant, or breast-feeding.
[0455] Known allergic reaction or sensitivity to levosimendan or excipients.
[0456] A history of Torsades de Pointes.
[0457] Received levosimendan within 30 days before the planned start of study drug.
[0458] Received an experimental drug or used an experimental medical device within 30 days before the planned start of the study drug.
[0459] Concomitant administration of pulmonary vasodilator therapy, or taken within 14 days of randomization.
[0460] Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
[0461] Inability to comply with planned study procedures.
Description of Study (HELP Study)
[0462] This is a multicenter, Phase II, double-blind, randomized, placebo-controlled study of levosimendan in pulmonary hypertension patients with heart failure and preserved left ventricular ejection fraction (PH-HFpEF) designed to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects.
[0463] Enrolled PH-HFpEF subjects receive a lead-in 24-hour levosimendan infusion to determine their hemodynamic response and eligibility for the double-blind phase of the study. A total of 36 “responders” are randomized in the double-blind, placebo-controlled phase. “Responders” are identified as those subjects with a > 4mmHg reduction in PCWP during bicycle exercise (25 watts) and no more than a 10% decrease in cardiac index between the baseline measurements and repeated measurements following the initial infusion.
[0464] Study drug is administered via i.v. infusion over 24 hours weekly through Week 5 via a PICC line. Infusions (Week 2-5) are done in the subject’s home by a study nurse. Patients return to the study site for a visit between the Week 3 and Week 4 infusions for assessment of subject safety/response and need for dose adjustment. Each subject is to return on Week 6 for assessment of efficacy and safety on study drug. A right heart catheter will be inserted to obtain hemodynamic measurements at rest and exercise at baseline, the following day after the lead-in 24-hour infusion, and during Week 6. [0465] During the Lead-in phase of the study, a sufficient number of subjects are enrolled and receive levosimendan to identify a total of 36 ‘responders.’ The levosimendan ‘responders’ are randomized 1: 1, levosimendan or placebo, for the double-blind phase of the study.
[0466] During the Lead-in phase, levosimendan, supplied as a concentrated solution (2.5 mg/mL), is mixed with diluent and administered intravenously at 0.10 pg/kg/min for 24 hours +/- 30 min.
[0467] During the Double-blind phase, study drug concentrated solution (2.5 mg/mL), levosimendan or placebo, is mixed with diluent and administered via a PICC line as weekly infusions at 0.075 pg/kg/min for 24 hours. Patients undergo a dose escalation at Week 4 and 5 (0.10 pg/kg/min for 24 hours) unless there has been a meaningful change in blood pressure or heart rate. Infusion rates may be reduced to 0.05 pg/kg/min if the higher dose is not we 11 -tolerated at any time during the initial 5 weeks.
[0468] The study is divided into a Screening phase, a Lead-In phase, and a Double-Blind treatment phase. The Screening, Lead-In, Interim Office (between Weeks 3 and 4) and Week 6 visits occurs at the investigator’s office. Infusions at Weeks 2, 3, 4 and 5 occur at the subject’s home under the care of a home healthcare nurse. Subjects are instructed to contact the investigator at any time during the 24 hour at home infusions to report adverse events, or at any time they would like to speak with the investigator regarding the study or to report adverse events during the entirety of the trial.
[0469] Visits during the Lead-In phase of the trial require a subject to be hospitalized for the entire infusion period, which at a minimum will last 24 hours. Once the infusion is complete, hemodynamic measurements are collected to ensure subject eligibility. Visits for Week 2 through Week 6 are calculated based on the date of the Lead-in infusion.
[0470] At least 72 hours prior to the first infusion (Lead-In Visit), all patients wear a small, lightweight cardiac monitoring sensor on their chest to measure heart rate and to detect any arrhythmias. This patch is water-resistant and can be worn in the shower by the patient. The patch is removed prior to the first infusion of study drug. Additionally, the following procedures are performed: Obtain signed main study ICF (must be obtained prior to performance of any study-specific tests or evaluations that are not considered standard of care), confirm inclusion/exclusion criteria, history of qualifying hemodynamics, conduct a medical history, body weight, record prior/concomitant medications including all prescription and non-prescription drugs, vitamins, and dietary or herbal supplements, record demographic information, perform complete physical examination, including height and body weight, urine pregnancy test (women of child-bearing potential only), hematology and clinical chemistry blood samples, measure vital signs (BP, PR, respiratory rate, temperature), Child-Pugh Class, NYHA Functional Class, Conduct 12-lead ECG, Echocardiogram (within 3 months of Day 0) that must be repeated prior to Baseline, and perform 6-minute walk test. [0471] During the Lead-in Infusion (Day 0) the following procedures are performed: Measure vital signs (BP, PR, respiratory rate, temperature), venous sheath placement for right heart catheterization (The sheath will remain following the baseline study, and the patient is hospitalized where they receive the 24-hour levosimendan infusion (preferably through the venous sheath). The sheath is then used for access for the right heart catheterization study following the 24-hour levosimendan infusion, and then removed), right heart catheterization measurements: baseline (prior to levosimendan infusion) and post 24-hour infusion to establish qualifying baseline hemodynamics at rest and exercise and to establish qualifying response to levosimendan during exercise, assess adverse events, assess concomitant medications and/or procedures, pharmacokinetic sampling (to be taken at the end of infusion: 24 +/- 2 hours), genotyping sampling (to be taken at the end of infusion: 24 +/- 2 hours). Subjects who do not respond to levosimendan based on hemodynamic measurements are withdrawn from screening. A PICC line is placed in patients that meet eligibility criteria and who are randomized into the Double-Blind phase of the study.
[0472] Once eligibility is confirmed via hemodynamic measurements, post-lead-in infusion, subjects are randomized 1 : 1 to either receive levosimendan or placebo. This occurs at the same visit as the lead-in dose day (Day 0).
[0473] Visits at Weeks 2, 3, 4, and 5 are performed within +/- 48 hours of the scheduled visit. Visits for Weeks 2-5 are calculated based on the date of the Lead-in infusion. These visits are performed at the subject’s home with the aid of the home health care nurse. The home health care nurse remains with the patient for the first 2-3 hours of the infusion to ensure patient safety. The home health care nurse visits the patient again at 24 hours to stop the infusion and assess the patient’s status. During this visit, the following procedures are performed: Record any changes in procedures, prescription and non-prescription drugs, vitamins, and dietary or herbal supplements; measure vital signs prior to starting the infusion, after the first 2 hours (+/- 30 min), and after 24 hours (+/- 30 min); assess adverse events and study drug administration. At Week 5, all patients are given a new cardiac monitoring sensor to wear on their chest to measure cardiac rhythm, as was done during Screening. The patch is applied prior to (< 1 hour) the 24-hour infusion, remain monitoring the patient for a minimum of 72 hours and returned to the investigational site at the Week 6 visit.
[0474] The Interim Office Visit is performed 48 hours prior to the Week 4 infusion visit. This visit is performed at the investigator’s office. Infusions do occur at the office during these visits. During this visit, the following procedures are performed: 6-minute walk test, quality of life (QOL) assessment, NYHA Functional Class determination, body weight, dispense cardiac monitoring patch, and all procedures listed in the Weekly infusion visits with the exception of infusion. [0475] Visits at Week 6 should be performed 3-6 days following completion of the Week 5 infusion. During this visit, the following procedures are performed: record any changes in procedures, prescription and non-prescription drugs, vitamins, and dietary or herbal supplements; measure vital signs (BP, PR, respiratory rate, temperature); hematology and clinical chemistry blood samples; conduct 12-lead ECG; echocardiogram within +/- 72 hours of the Week 6 visit; right heart catheterization at rest and with exercise; QOL assessment; Child-Pugh Class, NYHA Functional Class, assess adverse events, 6 minute walk test; and pharmacokinetic sampling (sample to be taken prior to enrollment in Open-Label phase.
[0476] The 6-minute walk test (6MWT) is performed at approximately the same time of day at each study visit after the Baseline Visit and ideally, one of the first assessments to be performed. The ECHO and subject questionnaire are performed after the 6MWT has been completed. The 6MWT is performed using the methods described in the American Thoracic Society (ATS) Statement: Guidelines for the Six-Minute Walk Test. The test is performed at approximately the same time of day when assessed and by the same evaluator whenever possible.
[0477] The 2-dimensional (2D) echocardiogram complete with contrast is performed by trained personnel. These assessments are standard transthoracic 2D echocardiograms (with contrast to optimize accuracy and precision of intracardiac measurements. These may include, but are not limited to: left ventricular systolic and diastolic function, size, mass, and geometry; right ventricular size and function; pulmonary artery size; left atrial dimensions, volumes, and pressures; valvular (aortic, mitral, tricuspid and pulmonary) stenosis and regurgitation (severity); and pulmonary artery systolic pressure (PASP) and inferior vena cava (IVC) caliber.
[0478] Vital signs and body weight include: body temperature, heart rate, respiratory rate, and blood pressure (systolic and diastolic blood pressure). Blood pressure is determined by cuff (using the same method, same arm, and in the same position throughout the study).
[0479] All blood laboratory test collections must be performed prior to study drug dosing (where other exclusions do not apply). Blood specimens and serum chemistry are collected, and results obtained by local laboratories, except for the pharmacokinetic and genotyping samples. These samples are sent to external labs for analysis of Levosimendan, OR-1855 and OR-1896 metabolites. All clinical laboratory assays will be performed according to the laboratory’s normal procedures. Reference ranges are supplied by the laboratory and used to assess the clinical laboratory data for clinical significance and out-of-range pathological changes. [0480] The Hematology and Coagulation Panel includes the following tests: hematocrit, hemoglobin, white blood cell (WBC) count with differential, platelet count, prothrombin time, and partial thromboplastin time.
[0481] The Serum Chemistry Panel includes the following test: sodium, potassium, bicarbonate, blood urea nitrogen (BUN), and creatinine.
Results
Primary and Secondary Outcome Measures from Open-Label lead-in phase of the HELP Study first 30 randomized patients ( ~83% of planned enrollment)
[0482] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan reduces pulmonary capillary wedge pressure during rest by an average of 5.8mmHg (23.4 to 17.6mmHg), and during 25 watts of exercise by an average of 7.53mmHg (33.2 to 25.7mmHg). These results are presented in Figure 1.
Figure imgf000056_0001
[0483] Treatment with weekly 24-hour infusions of 0.075 - 0.1 mg/kg/min of levosimendan reduces right atrial pressure during rest by an average of 4.83 mmHg (16.2 to 11.3 mmHg), and during 25 watts of exercise by an average of 4.97 mmHg (27.9 to 23.0 mmHg). These results are presented in Figure 2.
Figure imgf000057_0001
[0484] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan reduces mean pulmonary arterial pressure during rest by an average of 5.4 mmHg (42.4 to 37.0 mmHg), and during 25 watts of exercise by an average of 5.1 mmHg (58.3 to 53.3 mmHg). These results are presented in Figure 3.
Figure imgf000058_0001
[0485] Treatment with weekly 24-hour infusions of 0.075 - 0.1 mg/kg/min of levosimendan increases cardiac output during rest by an average of 0.33 1/min (5.1 to 5.5 1/min), and during 25 watts of exercise by an average of 0.60 1/min (6.7 to 7.4 1/min). These results are presented in Figure 4.
Figure imgf000059_0001
Exploratory Outcome Measures
[0486] Hemodynamic response (PCWP decrease) to treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF can be predicted by a patient’s change in stroke volume seen between rest and exercise.
[0487] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a greater decrease in pulmonary capillary wedge pressure compared to subjects afflicted with PH-HFpEF treated with a placebo.
[0488] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a significantly greater reduction in right atrial pressure compared to subjects afflicted with PH-HFpEF treated with a placebo. [0489] Treatment with weekly 24-hour infusions of 0.075 - 0.1 mg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a significantly greater reduction in mean pulmonary arterial pressure compared to subjects afflicted with PH-HFpEF treated with a placebo.
[0490] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a significantly greater increase in cardiac output compared to subjects afflicted with PH-HFpEF treated with a placebo.
[0491] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a significantly increased six-minute walk test distance compared to subjects afflicted with PH-HFpEF treated with a placebo.
[0492] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan to subjects afflicted with PH-HFpEF results in a significantly higher proportion of subjects with an improved sense of well-being compared to subjects afflicted with PH-HFpEF treated with a placebo.
Example 2
Brief Summary
[0493] An open-label rollover study is conducted to allow patients to continue levosimendan treatment if the patient has tolerated treatment in the HELP clinical study seen in Example 1.
Inclusion Criteria
[0494] Completed double-blind therapy in a PH-HFpEF clinical study sponsored by Tenax Therapeutics, Inc.
[0495] May, in the opinion of the Investigator, benefit from continued levosimendan treatment.
[0496] Female patients of childbearing potential must agree to use a highly effective method of contraception.
[0497] Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
Exclusion Criteria
[0498] Discontinued treatment in the parent study for any reason other than study completion or Sponsor termination of the study.
[0499] Pregnant or breastfeeding women.
[0500] Local access to commercially available levosimendan. [0501] Inability to comply with planned study procedures.
[0502] Patients with scheduled lung or heart transplant or cardiac surgery.
[0503] Dialysis developed since enrollment in parent study (either hemodialysis, peritoneal dialysis, continuous veno venous hemofdtration, or ultrafdtration).
[0504] Estimated glomerular fdtration rate (eGFR) < 30 mL/min/1.732.
[0505] Livery dysfunction with Child Pugh Class B or C.
[0506] Evidence of systemic bacterial, systemic fungal, or viral infection refractory to treatment.
[0507] Weight > 150 kg.
[0508] Systolic blood pressure (SBP) cannot be managed to ensure SBP > 100 mmHg at initiation of study drug.
[0509] Heart rate > 100 bpm with study drug, persistent for at least 10 minutes at screening.
[0510] Hemoglobin < 80 g/L.
[0511] Serum potassium < 3.0 mmol/L or > 5.5 mmol/L at baseline that is unresponsive to management. Description of Study
[0512] This is an open-label rollover study to allow patients to continue levosimendan treatment if the patient has tolerated treatment in the HELP clinical study seen in Example 1.
[0513] Subjects are visited by the home healthcare nurse until they can satisfactorily demonstrate their ability to self-administer the study drug with a target for self-administration at Weeks 4-6, but not lasting past 8 weeks. After 8 weeks, home healthcare support ceases. Home healthcare visits can be scheduled later in the study if the investigator identifies a clinically urgent need. The subject is instructed on the preparation, administration, and disposal/retum of levosimendan (including ancillary supplies) by the home healthcare nurse. The process for distribution of study drug to the subject’s home is the same throughout the study
[0514] Study drug concentrated solution (2.5 mg/mL), levosimendan, is mixed with diluent and administered as weekly infusions at 0.075 pg/kg/min for 24 hrs. Patients may have a dose escalation at Weeks 3 at a rate of 0.10 pg/kg/min for 24 hours, unless there has been a meaningful change in blood pressure or heart rate or other prohibitive rationale.
[0515] If a subject was down-titrated to 0.05 pg/kg/min in the HELP study for either the Lead-In or during the double-blind portion of the study, the subject starts at this dose, with the first opportunity to up- titrate at Week 3 of this Open-Label Extension Study. [0516] If at the Week 3 visit the open-label levosimendan has been well-tolerated by the patient, the investigator reviews with the subject the opportunity to convert the PICC line to a port-a-cath in the coming weeks. Some patients may choose to continue use of the PICC line or have a port-a-cath inserted later in the study. Following the placement of a port-a-cath, the home health care nurse visits the subject to assist with the infusions to ensure the patient is self-sufficient in use of the port-a-cath. A subject that chooses to continue with a PICC line after Week 3 is transitioned to a port-a-cath once the PICC line fails or will be discontinued from the study.
[0517] At the final visit in the parent study, the Investigator (or an appropriate delegate at the study site) obtains written informed consent from each patient, after which confirmation of eligibility criteria is performed. During the screening visit, the following procedures are performed: Obtain signed main study ICF (must be obtained prior to performance of any study-specific tests or evaluations that are not considered standard of care); confirm inclusion/exclusion criteria, concomitant medications including all prescription and non-prescription drugs, vitamins, and dietary or herbal supplements; perform complete physical examination, including height and body weight; and information documented in the parent study for the following procedures is transferred to the eCRF of the current study.
[0518] Weekly visits, occurring approximately every 7 days, are performed within 48 hours of the scheduled visit. The first infusion for this extension study is typically scheduled a week after the last dose (Week 5) of the HELP study. As some patients will be receiving active study drug (levosimendan) for the first time (i.e., they were receiving placebo in the HELP study), subjects are visited by the home healthcare nurse to assure safety and tolerability through 8 weeks from the initiating the Open-Label Extension Study.
[0519] Subjects are visited by the home healthcare nurse until they can satisfactorily demonstrate their ability to self-administer the study drug, with a target for self-administration 4-6 weeks after beginning the study. After 8 weeks, home healthcare support ceases. Home health care visits can be scheduled later in the study if the investigator identifies a clinically urgent need. Once a subject adequately demonstrates their ability to self-administer the study drug, the procedures listed below will become not-applicable, other than reporting any adverse events to the investigational site. These visits may be performed at the subject’s home. Subjects are instructed to inform the investigator of any infusion related events or AEs that occur during this visit. During these visits, the following procedures are performed (as applicable): Record any changes in procedures, prescription and non-prescription drugs, vitamins, and dietary or herbal supplements; measure vital signs; assess adverse events; and study drug administration and accountability.
[0520] At the Week 3 office visit, patients are assessed for potential up-titration to 1.0 pg/kg/min for 24 hours. The decision to increase the dose is based on the absence of disease or drug related adverse events and the investigator’s discretion. [0521] Visits at Weeks 3, 6, 12, 24, 48 and Follow-Up Visit (at termination) are performed within 72 hours of the scheduled weekly visit. These visits are performed at the investigator’s office. The Follow-Up Visit (at termination) is calculated as the earlier of two years from the subject’s date of entry into this extension study or as soon as possible after study discontinuation, but within 1 week. During this visit, the following procedures are performed: Vital signs; body weight (Week 3 only); 6MWT; Quality of Fife assessment; NYHA Functional Class; Physician Assessment; assess adverse events, and concomitant medications and/or procedures.
Results
[0522] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan increases exercise capacity as measured by six-minute walk distance by an average of 30 meters (292 to 322 meters). These results are presented in Figure 5.
[0523] Treatment with weekly 24-hour infusions of 0.075 - 0.1 pg/kg/min of levosimendan increases overall sense of well-being as measured by a five-point Uikert Scale in 7 out of 8 patients, with an improvement of 1-2 points on the five-point Uikert scale. These results are presented in Figure 6.
[0524] The HEUP Study results indicate that Wwekly 24-hour dosing of Uevosimendan improves PCWP (left Heart Failure) in PH-HFpEF.
[0525] The HELP Study results indicate that weekly 24-hour dosing of Levosimendan improves 6- Minute Walk Distance (exercise capacity) in PH-HFpEF.
[0526] The HELP Study results indicate that weekly 24-hour dosing of Levosimendan improves right atrial pressure (right heart function) in PH-HFpEF.
[0527] The HELP Study results indicate that weekly 24-hour dosing of Levosimendan reduces Pulmonary Artery Pressure in PH-HFpEF.
[0528] The HELP Study results indicate that weekly 24-hour dosing of Levosimendan is safe and well tolerated.
[0529] HELP Study enrolled PH-HFpEF patients with biventricular failure (right and left failure) and therefore the positive results from the trial, support a claim for use in PH-HFpEF patients, including those with biventricular failure.
Example 3
[0530] A study is conducted analogous to Example 1. However, certain parameters are modified to allow for a different form of administration. [0531] A subcutaneous levosimendan formulation administered via subcutaneous administration. The subcutaneous formulation will be substantially similar to the intravenous formulation in Example 1.
[0532] Results are substantially similar to the result of Example 1, with a decrease in injection site and/or central line infections when compared to intravenous infusion administration. Additionally, an increase in quality of life assessment and/or convenience of administration occurs due to the easier route of delivery.
Example 4
[0533] A study is conducted analogous to Example 1. However, certain parameters are modified to allow for the combined administration of levosimendan with additional cardiovascular drugs.
[0534] A levosimendan formulation is administered substantially as in Example 1, but administered in combination with Entresto.
[0535] Results are substantially similar to Example 1, with an improvement in cardiovascular hemodynamics, exercise performance, and quality of life.
Example 5
[0536] A study is conducted analogous to Example 1. However, certain parameters are modified to allow for the combined administration of levosimendan with additional cardiovascular drugs
[0537] A levosimendan formulation is administered substantially as in Example 1, but administered in combination with Sacubitril and/or other neprilsyn inhibitors.
[0538] Results are substantially similar to Example 1, with an improvement in cardiovascular hemodynamics, exercise performance, and quality of life.
Example 6
[0539] A study is conducted analogous to Example 1. However, certain parameters are modified to allow for the combined administration of levosimendan with additional cardiovascular drugs.
[0540] A levosimendan formulation is administered substantially as in Example 1, but administered in combination with Ranolazine.
[0541] Results are substantially similar to Example 1, with an improvement in cardiovascular hemodynamics, exercise performance, and quality of life.
Example 7
Brief Summary [0542] A pharmacokinetic study was conducted in male Sprague Dawley rats to compare subcutaneous administration of a composition of the present invention with IV administration of a formulation of levosimendan. The study evaluated levosimendan blood levels and pain at the injection site.
Methodology
[0543] This study involved comparing the results of administering two subcutaneous compositions according to embodiments of the present invention to a previous pharmacokinetic study in which male rats were dosed by tail vein levosimendan as an IV bolus injection at 0.5 mg/kg using a 0.25 mg/ml solution. Thus, this study comprised three study arms: a. IV administration of a composition comprising levosimendan (0.25 mg/ml) and phosphate buffer (10 mmolar), prepared in sterile water for injection and adjusted to a pH of 7.0 to 7.9 using 1 N NaOH or 10 N NaOH; this composition was administered at a dose of 0.5 mg/kg. b. Subcutaneous administration of a composition comprising levosimendan (1.0 mg/ml), Captisol® (100 mg/ml), and phosphate buffer (10 mmolar), prepared in sterile water for injection and adjusted to a pH of 7.0 to 7.9 using 1 N NaOH or 10 N NaOH; this composition was administered at a dose of 0.5 mg/kg. c. Subcutaneous administration of a composition comprising levosimendan (1.0 mg/ml), Captisol® (300 mg/ml), and phosphate buffer (10 mmolar), prepared in sterile water for injection and adjusted to a pH of 7.0 to 7.9 using 1 N NaOH or 10 N NaOH; this composition was administered at a dose of 0.5 mg/kg.
[0544] Each of the compositions was sterile fdtered using a sterile 0.22 micron Millex-GV PVDF filter syringe filter prior to administration.
[0545] For the study, naive male Sprague Dawley rats were used that were between 10 to 12 months old. Blood samples were collected from the rats pre-dose and at the following time points after the dose: 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr, and 18 hr. Five 0.5-ml to 1.0-ml blood samples were collected from each rat. Four of these samples were collected from the tail vein and the fifth sample was collected by cardiac puncture following deep anesthesia with isoflurane inhalation and exsanguination. In each study arm, rats were divided into two groups, group A and group B, that contained three rats each. Sample collection points were alternated between three rats in group A and three rats in group B. Thus, samples were collected from group A rats at pre-dose, 15 min, 1 hr, 4 hr and 12 hr. Samples were collected from group B rats at 5 min, 30 min, 2 hr, 8 hr and 18 hr. A thoracotomy was preformed to insure death. Each arm of the study used six rats for a total of 18 rats. [0546] During the study following the subcutaneous and IV injections, the rats were observed for any clinical signs of adverse reactions. Behavior including licking, biting or scratching of the injection area, any loss of mobility, restlessness, unresponsiveness, and abnormal postures was monitored. No abnormal observations occurred, as the rats continued to act normally throughout the study.
[0547] Immediately after the rats were euthanized, the subcutaneous injection site along the back between the shoulders was examined for any signs of swelling or irritation. Three rats that received the 100 mg/ml Captisol® formulation for 12 hours and three rats that received the 300mg/ml Captisol® formulation for 18 hours were compared to three naive rats with no injection as a control. The epidermis of the rats was carefully removed, exposing the tissue directly surrounding the subcutaneous injection site. No swelling or signs of irritation were observed in the tissue.
[0548] Blood samples were stored in tubes containing EDTA as an anticoagulant and kept in an ice bath until centrifuged to separate the plasma. The plasma samples were stored at -20°C until assayed. Plasma obtained from each of the samples was used for liquid chromatographic/mass spectroscopic analysis of the compound.
[0549] Plasma samples were analyzed for levosimendan and OR- 1896 (the primary metabolite) by HPLC/MS/MS. A protein precipitation method was employed for sample preparation by the addition of an acetonitrile spiking solution or acetonitrile, and internal standard to a plasma sample or blank plasma. The internal standard for levosimendan was 13C6-labeled levosimendan, and for OR-1896 was 13C6-labeled ORM-25632 (racemic form of OR-1896). After addition of reagents, the mixture was vortexed and centrifuged. Approximately 75-80 mΐ was transferred to an autosampler vial with a plastic insert.
[0550] The HPLC/MS/MS method consisted of a Restek Raptor Biphenyl column, 2.7 pm, 100 x 3 mm. Mobile phase A consisted of 5 mM Ammonium Formate/0.1% Formic acid and mobile phase B was methanol. The flow rate was set to 0.6 ml/min and injection volume was 10 pi. Detection was performed with a Sciex 3200 Qtrap mass spectrometer in MRM mode.
Results
[0551] Levosimendan plasma concentrations after IV and subcutaneous dosing. The higher initial plasma levels for the IV formulation are typical for an IV injection. The more rapid initial decrease in the blood levels (a phase) is the distribution of the drug throughout the tissues in the body. After the initial distribution of the drug, the loss of drug from the blood is mainly due to metabolism (b phase). In levosimendan, the b phase starts at about 2 hours. Notably, Table 7 and Figure 2 show that the metabolism of levosimendan is very similar for the IV and the subcutaneous compositions. This is also supported by the nearly identical results for the plasma levels of the primary active metabolite, OR-1896.
Figure imgf000067_0001
[0552] OR-1896 plasma concentrations after IV and subcutaneous dosing. OR-1896, the major active metabolite of levosimendan, demonstrated very similar plasma concentrations regardless of route of administration or formulation.
Figure imgf000067_0002
[0553] Pharmacokinetic parameters for levosimendan after administration of the IV formulation and the subcutaneous compositions. A significantly lower Cmax was observed for both subcutaneous compositions versus the IV formulation, but the half-life for elimination was comparable for all formulations.
Figure imgf000068_0001
[0554] Pharmacokinetic parameters for OR- 1896 after administration of the IV formulation and the subcutaneous compositions. The Cmax, Tmax, and AUC for both subcutaneous compositions are very similar to the IV route of administration. The bioavailability of OR-1896 is 95-113% from the subcutaneous formulations.
Figure imgf000068_0002
[0555] These results show that OR- 1896 plasma concentrations following administration of the subcutaneous compositions of the invention were comparable to those observed following IV levosimendan administration. This was an unexpected finding given the substantially lower Cmax and AUC of levosimendan observed following the subcutaneous administration of the compositions of the invention as compared to IV administration.
[0556] In addition, there was no evidence of pain or visible signs of irritation at the injection site, nor were there any clinical-related adverse events or other signs of pain or distress observed for the rats. The Captisol®-containing subcutaneous compositions did not cause any apparent irritation of adverse reactions when administered subcutaneously.
Example 8 [0557] A study is conducted analogous to Example 7. However, certain parameters are modified to allow for the subcutaneous administration of levosimendan.
[0558] Results are substantially similar to Example 7, with a decrease in injection site and/or central line infections when compared to intravenous infusion administration. Additionally, an increase in quality of life assessment and/or convenience of administration occurs due to the easier route of delivery.
DISCUSSION
[0559] Clinical trials of levosimendan have focused exclusively on HFrEF patients. Patients afflicted with heart failure with preserved ejection fraction (HFpEF), who have an ejection fraction > 40% have been excluded from these levosimendan clinical trials. One reason that levosimendan has not been studied in HFpEF patients may be the historical concern that inotropes, and particularly calcium sensitizing inotropes such as levosimendan, have been thought to impair ventricular relacation which would be detrimental in HFpEF patients. One example of this safety concern is referenced by Hajjar et al. in Cardiovascular Drugs and Therapy that states: “This leads us to the conclusion that inotropic agents that increase the sensitivity of the myofilaments to CA2+ further impair relaxation in myopathic hearts, resulting in a reduced contractile reserve and diminished force production.”
[0560] Examples of major HFrEF clinical trials that have excluded HFpEF patients include: LIDO, REVIVE, SURVIVE, RUSSLAN, and LEVO-CTS. All of these trials have excluded patients with an ejection fraction > 36%. In addition, all clinical trials that have evaluated chronic intermittent dosing of levosimendan have excluded HFpEF patients. Examples of clinical trials that have evaluated chronic intermittent dosing of levosimendan that have excluded HFpEF patients include: LIONHEART, LEVOREP, LAICA, and numerous other single-center trials. Kleber et al. conducted a trial on intermittent dosing with levosimendan in patients afflicted with pulmonary hypertension, but this trial also did not recruit HFpEF patients and failed to show efficacy following chronic dosing over an 8-week period. Lastly, Jiang et al. conducted a trial of levosimendan in patients with various types of pulmonary arterial hypertension and acute heart failure; however, none of the patients were PH-HFpEF patients.
[0561] Levosimendan dosing in previous acute heart failure trials employed single 24-hour infusions of 0.5 to 0.2 mcg/kg/min to treat acutely decompensated heart failure patients in a hospital setting. Other trials have evaluated repeated or intermittent dosing of levosimendan in chronic heart failure patients, and these studies have employed a range of dosing alternatives that utilize IV infusions of less than 24 hours and administered with a repeated dosing frequency of every 2 to 4 weeks in a hospital setting. No studies to date have employed weekly 24-hour infusions administered outside of a hospital setting.
[0562] The data from the HELP study that evaluates the hemodynamic effects of levosimendan in PH- HFpEF patients is the first and only study to evaluate levosimendan in PH-HFpEF patients. Since no drugs have been shown to be effective and safe in PH-HFpEF patients, including numerous drugs that are effective in other forms of pulmonary hypertension, no one could have predicted the results of the HELP Study. In particular, in view of the numerous failed attempts, it was unreasonable to expect that in the HELP study levosimendan would lower PCWP, lower PA pressure, or increase cardiac output, increase 6-minute walk distance, or improve quality of life for PH-HFpEF patients. [0563] As reported herein, levosimendan is surprisingly found to provide effective treatment for a human subject afflicted with pulmonary hypertension and heart failure with preserved ejection fraction (PH- HFpEF). Levosimendan can improve cardiovascular hemodynamics, exercise capacity, and quality of life. The study showed evidence that the levosimendan infusion was able to reduce pulmonary capillary wedge pressure, right atrial pressure, and mean pulmonary arterial pressure. Additionally, levosimendan infusion was able to increase cardiac output, quality of life and 6-minute walk distance. The statistically significant improvement in 6-minute walk distance in levosimendan treated patients (Figure 15) is particularly noteworthy as this is the first multicenter placebo controlled trial in HFpEF or PH-HFpEF patients to ever show that a pharmacologic agent can improve in 6 minute walk distance. Since the trial was not sized or designed to show a difference in 6 minute walk distance this was a very surprising finding.
[0564] Furthermore, levosimendan is also surprisingly found to be safe when administered in a non hospital or non-clinical setting and when self-administered. Levosimendan treatment was provided in an outpatient setting, as well as in the human subject’s home. Based on the results from the study, there is confirmation for the first time that home administration of levosimendan can be done safely in PH-HFpEF patients.
[0565] Additionally, levosimendan is also surprisingly found to be safe when given to PH-HFpEF patients in weekly 24-hour infusions. While other studies have evaluated intermittent dosing of levosimendan to treat HFrEF patients, none of these studies have evaluated weekly 24-hour infusions of levosimendan. Most of these other studies evaluated infusions every 2, 3, 4 weeks with infusion durations of only 6-12 hours.
[0566] Results presented herein also show that we have discovered a means of identifying PH-HFpEF patients who have a high likelihood of responding to levosimendan, i.e. a means of identifying PH-HFpEF responders to levosimendan. The relative increase in patient’s stroke volume observed at 25 watts of exercise, compared to at rest, is a strong predictor of a patient’s response. Without being bound to any mechanistic theory, this indicator may identify whether a patient has adequate cardiac reserve needed to respond to levosimendan therapy.
[0567] These aforementioned surprising results are the first of their kind seen in PH-HFpEF patients and are even more surprising when viewed in light of the extremely high failure rate of previous trials. REFERENCES
[0568] Banfor, P. N., et al. (2008). Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and 02 consumption in dogs. American Journal of Physiology-Heart and Circulatory Physiology, 294(1), H238-H248.
[0569] Bittner, B., et al. (2018). Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs, 32(5), 425-440.
[0570] Borlaug et al. Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In PH-HFpEF: Primary Results from the Help-PH-HFpEF Multicenter Randomized Controlled Trial Heart Society of America - Late Breaking Clinical Trials Session, October 3, 20204:30 PM - 5:30 PM.
[0571] Burkhoff et al. "24-hour Levosimendan Infusion Decreases Biventricular Filling Pressures and Increases Cardiac Output at Rest and Exercise in PH-HFpEF." Circulation 142.Suppl_3 (2020): A15294- A15294.
[0572] Chrusciel, P., et al. (2014) Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs , 74(9), 971-980.
[0573] De Luca, L., et al. (2006). Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. Journal of the American Society of Echocardiography 19(2), 172-177.
[0574] Dixon, D. D., et al. (2015). Combined post-and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart failure reviews, 21(3), 285-297.
[0575] Du Toit, E. F., et al. (2008). A role for the RISK pathway and KATP channels in pre-and post conditioning induced by levosimendan in the isolated guinea pig heart British journal of pharmacology', 154(1), 41-50.
[0576] ElGuindy, A., et al. (2012). Heart failure with preserved ejection fraction. Global Cardiology Science and Practice, 2012(1), 10.
[0577] Erdei, N., et al. (2006). The levosimendan metabolite OR- 1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles. British journal of pharmacology, 148(5), 696-702.
[0578] Galie, N., et al. (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European heart journal , 50(20), 2493-2537. [0579] Gorter, T. M., et al. (2018). Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European journal of heart failure, 20(1), 16-37.
[0580] Grossini, E., et al. (2005). Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. Journal of cardiovascular pharmacology, 46(3), 333-342.
[0581] Haikala, H., et al. (1995). Mechanisms of action of calcium -sensitizing drugs. Journal of cardiovascular pharmacology, 26, S 10-9.
[0582] Hajjar, R. J., et al. (1991). Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view. Cardiovascular drugs and therapy, 5(6), 961-965.
[0583] Hasenfuss, G., et al. (1998). influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 98(20), 2141-2147.
[0584] Hawthorne, K. M., et al. (2012). Quality assessment dobutamine stress echocardiography: what are the clinical predictors associated with a non-diagnostic test?. Cardiology research, 5(2), 73.
[0585] Hoeper, M. M., et al. (2016). A global view of pulmonary hypertension. The Lancet Respiratory Medicine, 4(4), 306-322
[0586] Jiang, R., et al. (2018). Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension. The clinical respiratory journal, 12(4), 1518-1525.
[0587] Kheinen, P., et al. (2001). Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. Journal of cardiovascular pharmacology, 57(4), 367- 374.
[0588] Kelly, J. P., et al. (2015) Patient selection in heart failure with preserved ejection fraction clinical trials. Journal of the American College of Cardiology, 65(16), 1668-1682.
[0589] Kivikko, M., et al. (2002). Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. The Journal of Clinical Pharmacology, 42(1), 43-51.
[0590] Kivikko, M., et al. (2003). Sustained hemodynamic effects of intravenous levosimendan. Circulation, 107(1), 81-86.
[0591] Klapholz, M., et al. (2004). Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. Journal of the American College of Cardiology, 45(8), 1432-1438. [0592] Kleber, F. X., et al. (2009). Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. The Journal of Clinical Pharmacology , 49(1), 109-115.
[0593] Kostis, J. B., et al. (2004). Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial . American journal of hypertension , 17(2), 103-111.
[0594] Lai, Y. C., et al. (2019). Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction. The Journal of physiology, 597(4), 1143-1156.
[0595] Laurent, S., et al. (2000). Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension, 55(5), 1148-1153.
[0596] Levine, A. R., et al. (2019). Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction. Trends in cardiovascular medicine, 29(4), 207-217.
[0597] Louhelainen, M., et al. (2009). Effects of calcium sensitizer OR-1986 on cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats. Acta physiologica Polonica, 12(3), 41.
[0598] Louhelainen, M., et al. (2010). Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats. British journal of pharmacology, 160(\), 142-152.
[0599] Maytin, M., et al. (2005). Cardioprotection: a new paradigm in the management of acute heart failure syndromes. The American journal of cardiology, 96(6), 26-31.
[0600] McLaughlin, V. V., et al. (2009). ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. Journal of the American College of Cardiology, 53(17), 1573-1619.
[0601] Michaels, A. D., et al. (2005). Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation, 111(12), 1504-1509.
[0602] Northridge, D. B., et al. (1999). Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. American heart journal, 138(6), 1149-1157. [0603] Norton, G. R., et al. (1999). Sustained Antihypertensive Actions of a Dual Angiotensin- Converting Enzyme Neutral Endopeptidase Inhibitor, Sampatrilat, in Black Hypertensive Subjects. American journal of hypertension, 12(6), 563-571.
[0604] Oktay, A. A., et al. (2013). The emerging epidemic of heart failure with preserved ejection fraction. Current heart failure reports, 70(4), 401-410.
[0605] Oldroyd, S. H., et al. (2019). Pulmonary Hypertension.
[0606] Oudiz, R. I, et al. (2007). Pulmonary hypertension associated with left-sided heart disease. Clinics in chest medicine, 28(\), 233-241.
[0607] Opitz, Christian F., et al. (2016). Pre -capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. Journal of the American College of Cardiology 68.4 : 368- 378.
[0608] Pataricza, I, et al. (2000). Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. Journal of pharmacy and pharmacology, 52(2), 213-217.
[0609] Peacock, A. J., et al. (2004). Pulmonary Circulation: Diseases and Their Treatment. CRC Press.
[0610] Pollesello, P., et al. (1994). Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. Journal of Biological Chemistry, 269(46), 28584-28590.
[0611] Pollesello, P., et al. (2007). The cardioprotective effects of levosimendan: preclinical and clinical evidence. Journal of cardiovascular pharmacology, 50(3), 257-263.
[0612] Segreti, J. A., et al. (2008). Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR- 1896 [(R)-N-(4-(4-methyl~6-oxo-i, 4, 5, 6-tetrahydropyridazin~3-yl) phenyl) acetamide], OR-! 855 [(R)-6-(4-aminophenyl)-5 -methyl -4, 5-dihydropyridazm-3 (2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. Journal of Pharmacology and Experimental Therapeutics, 52.5(1), 331-340.
[0613] Shaw, S. J., et al. (2016). Phenotype -specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation, 734(1), 73-90.
[0614] Simonneau, G., et al. (2009). Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 54(1 Supplement), S43-S54. [0615] Sorsa, T., et al. (2004). The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Molecular and cellular biochemistry, 266(1-2), 87-107.
[0616] Szilagyi, S., et al. (2004). The effects of levosimendan and OR-1896 on isolated hearts, myocyte sized preparations and phosphodiesterase enzymes of the guinea pig. European journal of pharmacology, 486(1), 67-74.
[0617] Teerlink, J. R., et al. (2016). RELAX-REPEAT: a multicenter, prospective, randomized, double blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure. Journal of Cardiac Failure, 22(8), S14-S15.
[0618] Torres, R, et al. (2019). Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. European Respiratory Journal, 54(4).
[0619] Vandoni, M., et al. (2018). Six minute walk distance and reference values in healthy Italian children: A cross-sectional study. PloS one, 72(10).
[0620] Virgadamo, S., et al. (2015). Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World journal of cardiology, 7(11), 808.
[0621] Wait, J. C., et al. (2006). Metabolism of [ 14C] gemopatrilat after oral administration to rats, dogs, and humans. Drug metabolism and disposition, 34(6), 961-970.
[0622] Yancy, C. W., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), el47-e239.
[0623] Yancy, C. W., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 128(16), 1810-1852.
[0624] Yokoshiki, H., et al. (1997). Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide- sensitive K+ channel in rat arterial myocytes. European journal of pharmacology, 333(2-3), 249-259.

Claims

1. A method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH- HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, that is effective to treat the PH-HFpEF in the human subject.
2. The method of claim 1, wherein the treating comprises a) a reduction in the human subject’s pulmonary capillary wedge pressure at rest, preferably by 1 to 30 mmHg; b) a stabilization of the human subject’s pulmonary capillary wedge pressure at rest at 5 to 35 mmHg or 10 to 35 mmHg; c) a reduction in the human subject’s pulmonary capillary wedge pressure during exercise by the human subject, preferably by subject by 1 to 40 mmHg; d) stabilization of the human subject’s pulmonary capillary wedge pressure during exercise by the human subject, preferably at 10 to 50 mmHg; e) the treating does not comprise a significant change in pulmonary capillary wedge pressure during exercise by the human subject; f) a reduction in the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated, preferably the reduction is 1 to 30 mmHg; g) stabilization of the human subject’s pulmonary capillary wedge pressure when the human subject’s legs are elevated, preferably the stabilization is at 10 to 50 mmHg; h) a reduction in the human subject’s right atrial pressure at rest, preferably by 1 to 30 mmHg; i) stabilization of the human subject’s right atrial pressure at rest at 1 to 30 mmHg or at 5 to 30 mmHg; j) a reduction in the human subject’s right atrial pressure during exercise by the human subject, preferably by 1 to 30 mmHg; k) stabilization of the human subject’s right atrial pressure during exercise by the human subject at 5 to 40 mmHg; l) a reduction in the human subject’s right atrial pressure when the human subject’s legs are elevated; m) a reduction in the human subject’s mean pulmonary artery pressure at rest, preferably by 1 to 30 mmHg; n) stabilization of the human subject’s mean pulmonary artery pressure at rest at 15 to 65 mmHg; o) a reduction in the human subject’s mean pulmonary artery pressure during exercise by the human subject, preferably by 1 to 30 mmHg; p) stabilization of the human subject’s mean pulmonary artery pressure during exercise by the human subject at 25 to 85 mmHg or 25 to 80 mmHg; q) a reduction in the human subject’s mean pulmonary artery pressure when the human subject’s legs are elevated; r) an increase in the human subject’s cardiac output at rest, preferably by 0.01 to 3 liters/min; s) stabilization of the human subject’s cardiac output at rest at 2 to 10 liters/min; t) an increase in the human subject’s cardiac output during exercise by the human subject; u) an increase in the human subject’s cardiac output during exercise by the human subject by 0.01 to 5 liters/min or by 0.01 to 4 liters/min or by at 3.0 to 15.0 liters/min; v) does not comprise a significant increase in the human subject’s heart rate or does not comprise an increase in the human subject’s heart rate of more than 10 beats/min; w) an improvement in the human subject’s quality of life; x) an improvement in the human subject’s six (6) minute walk distance, preferably of 5 to 150 meters; y) an improvement in the physician’s assessment of the human subject’s functional class; z) a reduction in the incidence of hospitalization for heart failure; aa) a reduction in all-cause mortality; or bb) an improvement in right heart failure and/or right ventricular dysfunction, preferably as evidenced by a reduction in right atrial pressure at rest and during 25 watts of exercise.
3. The method of claim 2, wherein in (w) the improvement in the human subject’s quality of life is measured by a patient reported outcome assessment tool.
4. The method of claim 3, wherein the treating comprises an improvement in the human subject’s quality of life according to a change in the human subject’s patient reported outcome assessment tool score of at least 1, more preferably at least 2.
5. The method of any one of claims 1-4, wherein the human subject is a responder to levosimendan therapy.
6. The method of claim 5, wherein a) a responder to levosimendan therapy is a human subject whose pulmonary capillary wedge pressure decreases by at least 4mmHG during bicycle exercise at 25 watts following the initial infusion; b) a responder to levosimendan therapy is a human subject whose cardiac index decreases by no more than 10% between the baseline measurements and repeated measurements following the initial infusion; c) the human subject is a responder to levosimendan therapy if the human subject has cardiac reserve; d) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject; e) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when determined with a catheter in the human subject’s heart measuring the blood moving out of the left ventricle with every beat; f) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when estimated with an electrocardiogram and/or echocardiogram; g) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject when determined with a dobutamine stress test; h) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by at least 0.005 liters; i) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when determined with a catheter in the human subject’s heart measuring the blood moving out of the left ventricle with every beat; j) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when estimated with an echocardiogram, right heart catheterization, or other means; or k) the human subject is a responder to levosimendan therapy if the human subject’s stroke volume increases during exercise by the human subject by 1 to 50 mL when determined with a dobutamine stress test.
7. The method of any one of claims 1-6, wherein the human subject afflicted with PH-HFpEF a) has a left ventricular ejection fraction of at least 40%; b) has a baseline pulmonary arterial pressure of at least 35; c) has a baseline pulmonary capillary wedge pressure of at least 20; d) is classified as classification lib or classification III by the physician’s assessment of New York Heart Association Classification; e) has the ability to walk at least 50 meters in a six-minute walk test, does not have the ability to walk more than 550 meters in a six-minute walk test, or has the ability to walk at least 50 meters, but not more than 550 meters, in a six-minute walk test; f) is not afflicted with heart failure with reduced ejection fraction; g) is not afflicted with heart failure with preserved ejection fraction without pulmonary hypertension; h) has a primary diagnosis of Group 2 PH-HFpEF; i) is not afflicted with coronary artery disease; j) has not had previous percutaneous coronary intervention; k) has not had previous percutaneous coronary intervention, unless the human subject has had a negative stress test within the last year; l) has not had previous cardiac surgery; m) has not had previous cardiac surgery, unless the human subject has had a negative stress test within the last year; n) is not afflicted with congenital heart disease; o) is not afflicted with a clinically significant lung disease; p) does not have a planned heart or lung surgery; q) does not have a cardiac index greater than 4.0 L/min/m2; r) does not concomitantly receive pulmonary vasodilator therapy; s) has not received pulmonary vasodilator therapy within the last 14 days; t) does not receive dialysis treatment; u) does not have a Glomerular Filtration Rate less than 30 mL/min/1 73m2; v) does not have liver dysfunction with Child Pugh Class B or C; w) does not have evidence of systemic infection; x) does not weigh more than 150 kg; y) can manage their symptomatic systolic blood pressure to ensure it is greater than 100 mmHg; z) does not have a heart rate greater than or equal to 100 beats per minute with the drug; aa) does not have a heart rate greater than or equal to 100 beats per minute with the drug that is symptomatic and persistent for at least 10 minutes; bb) does not have hemoglobin less than 80 g/L; cc) does not have serum potassium less than 3.0 mmol/L at baseline; dd) does not have serum potassium greater than 5.5 mmol/L at baseline; ee) does not have serum potassium less than 3.0 mmol or greater than 5.5 mmol/L at baseline; ff) does not have severely compromised immune function; gg) is not pregnant, is not suspected to be pregnant, or is not breast-feeding; or hh) is a patient with Biventricular Failure.
8. The method of any one of claims 1-7, wherein the administering is via IV administration.
9. The method of any one of claims 1-8, wherein the administering takes place intermittently, weekly, or chronically.
10. The method of any one of claims 1-9, wherein the administering is given via a 24-hour infusion.
11. The method of any one of claims 1-9, wherein the administering is chronic administration given via a less than 24-hour infusion.
12. The method of any one of claims 1-11, wherein the administering is an administration of a dose of a) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol; b) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume; c) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose; d) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 0.9 Normal Saline; e) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 5 mL of total volume that is added to one 250 mL infusion bag of 5% Dextrose or 0.9 Normal Saline where the human subject weights less than 85 kg; f) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume; g) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose; h) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 0.9 Normal Saline; i) levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol and is supplied in 10 mL of total volume that is added to one 500 mL infusion bag of 5% Dextrose or 0.9 Normal Saline where the human subject weights at least 85 kg.
13. The method of any one of claims 1-12, wherein an administration infusion rate is reduced to 0.05 mg/kg/min when a dose is not well-tolerated by the human subject.
14. The method of any one of claims 1-7, wherein the administration is via oral dosing.
15. The method of claim 14, wherein the oral dosing comprises an immediate release formulation or an extended-release formulation.
16. The method of any one of claims 1-8, wherein the administration is subcutaneous administration of a subcutaneous formulation.
17. The method of claim 16, wherein the subcutaneous formulation is an intravenous formulation with additives.
18. The method of claim 16, wherein the subcutaneous formulation comprises a) 12.5 mg of levosimendan in a non-aqueous formulation that is added to 150 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.0833 mg/mL in the subcutaneous formulation; b) 12.5 mg of levosimendan in a non-aqueous formulation that is added to 250 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.05 mg/mL in the subcutaneous formulation; c) 12.5 mg of levosimendan in a non-aqueous formulation that is added to 500 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.025 mg/mL in the subcutaneous formulation; d) 12.5 mg of levosimendan in a non-aqueous formulation that is added to 1000 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.0125 mg/mL in the subcutaneous formulation; or e) 12.5 mg of levosimendan in a non-aqueous formulation that is added to 1500 mL of 5% Dextrose, 0.9 Normal Saline, or other pharmaceutically acceptable diluent or carrier to create a levosimendan concentration of 0.008333 mg/mL in the subcutaneous formulation.
19. The method of any one of claims 16-18, wherein the subcutaneous administration of the subcutaneous formulation comprises water in an amount effective to reduce pain caused by the subcutaneous administration.
20. The method of any one of claims 16-19, wherein the subcutaneous administration of the subcutaneous formulation comprises buffers to raise the pH higher than 3.5.
21. The method of any one of claims 16-20, wherein the subcutaneous administration of the subcutaneous formulation a) has reduced side effects relative to intravenous administration of levosimendan in the human subject; or b) reduces peak plasma concentrations of levosimendan relative to intravenous administration in the human subject, preferably by at least 1% to 25%.
22. The method of any of claims 1-21 wherein the amount of levosimendan its metabolites OR-1896 or OR- 1855, or a combination thereof, is administered in combination with a cardiovascular drug.
23. The method of claim 22, wherein the amount of levosimendan its metabolites OR-1896 or OR- 1855, or a combination thereof, and the amount of the cardiovascular drug when taken together is effective to reduce the symptoms of PH-HFpEF.
24. The method of any one of claims 22-23, wherein the cardiovascular drug is a drug used to treat pulmonary arterial hypertension (PAH), World Health Organization (WHO) Groups 1-5 pulmonary hypertension patients, coronary artery disease (CAD), or heart failure with reduced ejection fraction (HFrEF).
25. The method of any one of claims 22-23, wherein the cardiovascular drug is a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta-blocker (BB), an angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), a natriuretic peptide, a K-ATP channel activator, a NEP inhibitor, or a prostacyclin.
26. The method of any one of claims 22-23, wherein the cardiovascular drug is a pulmonary vasodilator drug.
27. The method of claim 26, wherein the pulmonary vasodilator is a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), or a prostacyclin.
28. The method of any one of claims 26-27, wherein the amount of levosimendan, its metabolites OR- 1896 or OR-1855, or a combination thereof, administered in combination with the pulmonary vasodilator drug is administered to a human subject afflicted with pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc-PH-HFpEF).
29. The method of any of claims 1-28 wherein no arrythmias, atrial or ventricular, are observed when comparing baseline electrocardiographic monitoring with 72-hour monitoring after 5 weeks of treatment.
30. The method of any one of claims 1-29 wherein treating presents no more statistically significant adverse events than the matching placebo.
31. The method of any one of claims 1-30, wherein a weekly 24-hour dosing of levosimendan results in steady state blood levels of OR1896 in the range of 0.20 ng/mL to 25.00 ng/mL.
32. An article of manufacture comprising: a) a 5mL vial dose of levosimendan 2.5 mg/mL infusion concentrate that includes levosimendan, povidone, citric acid, and ethanol; b) 250 mL of 5% Dextrose or 0.9 Normal Saline; and c) a buffer for increasing pH.
33. Use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH- HFpEF) in a human subject.
34. Use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for preparing medicament for administering to a human subject afflicted with Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF to effectively treat PH- HFpEF in the human subject.
35. A medicament comprising an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for use in effectively treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
36. Use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, in combination with a cardiovascular drug to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
37. Use of an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for preparing a medicament in combination with a cardiovascular drug for administering to a human subject afflicted with Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH- HFpEF) to effectively treat PH-HFpEF in the human subject.
38. A medicament comprising an amount of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, for use in combination with a cardiovascular drug to effectively treat Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a human subject.
39. A subcutaneous formulation of levosimendan for use in treating PH-HFpEF in a human subject afflicted with PH-HFpEF, wherein the subcutaneous formulation is obtained from a dried powder, wherein the dried powder is obtained from a pharmaceutical composition comprising: (a) levosimendan; (b) sulfo-butyl-ether beta-cyclodextrin; (c) sodium hydroxide or acetic acid; and water for injection.
40. The composition of claim 39, wherein the amount of levosimendan is 2.5mg / ml water for injection.
41. The composition of any one of claims 39-40, wherein the amount of sulfo-butyl-ether beta- cyclodextrin is 0.175mg / ml water for injection.
42. The composition of any one of claims 39-41, wherein the sodium hydroxide or acetic acid is in a suitable amount to adjust the pH to a range of 7.2 to 7.8.
43. The composition of any one of claims 39-42, wherein the pharmaceutical composition is lyophilized.
44. The composition of any one of claims 39-43, wherein subcutaneous formulation of levosimendan is obtained from the dried powder by reconstitution of the dried powder in an amount of aqueous solution suitable for subcutaneous administration.
45. The composition of claim 44, wherein the reconstituted subcutaneous formulation is pH adjusted to 7.2 to 7.8 with sodium hydroxide or acetic acid.
46. A method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH- HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of a cardiovascular drug that is effective to treat the PH-HFpEF in the human subject, wherein the cardiovascular drug is selected from the group consisting of a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta-blocker (BB), an angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), a natriuretic peptide, a K-ATP channel activator, a NEP inhibitor, and a prostacyclin.
47. A method for treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH- HFpEF) in a human subject afflicted with PH-HFpEF comprising administering to the human subject an amount of a pulmonary vasodilator drug that is effective to treat the PH-HFpEF in the human subject, wherein the pulmonary vasodilator drug is selected from the group consisting of a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), and a prostacyclin.
48. The method of claim 47, wherein the amount of the pulmonary vasodilator drug is administered to a human subject afflicted with pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc-PH-HFpEF).
49. A cardiovascular drug for use in treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a subject, wherein the cardiovascular drug is selected from the group consisting of a PDE inhibitor, a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), a prostanoid, a soluble guanylate cyclase stimulator, a nitrate, a nitrite, an NO donor, a calcium channel blocker (CCB), a fatty acid oxidation inhibitor, a beta-blocker (BB), an angiotensin-converting enzyme (ACE) inhibitor, a neprilysin inhibitor, a neprilysin and angiotensin receptor blocker (ANRI), an angiotensin II receptor blocker (ARB), a diuretic, an aldosterone antagonist, digoxin, ivabradine, hydralazine, seralaxin, a natriuretic peptide, an atrial natriueretic peptide (ANP), a natriuretic peptide, a K-ATP channel activator, a NEP inhibitor, and a prostacyclin.
50. A pulmonary vasodilator drug for use in treating Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) in a subject, wherein the pulmonary vasodilator drug is selected from the group consisting of a phosphodiesterase-5 (PDE5) inhibitor, an endothelin receptor antagonist (ERA), and a prostacyclin.
51. The method of claim 50, wherein the Pulmonary Hypertension Heart Failure with preserved ejection fraction (PH-HFpEF) is pre and post capillary pulmonary hypertension and heart failure with preserved ejection fraction (Cpc-PH-HFpEF).
52. The method of claim 1, wherein the subject is orally administered a capsule comprising up to 0. lmg, 0.25mg, 0.5mg, 0.75mg, lmg, 2mg, 3mg, or 4mg, more preferably l-3mg, of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof.
53. The method of claim 52, wherein the subject is administered a capsule once a day for a time period of 1-60 days, preferably 14 days.
54. The method of any one of claims 52-53, wherein the subject increases the number of capsules taken per day after every time period if the treatment is tolerated by the subject.
55. The method of any one of claims 52-54, wherein the subject is orally administered between 0.1- lOmg of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof, per day, preferably between l-4mg of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof per day.
56. The method of any one of claims 52-55, wherein the subject received a final intravenous injection of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof at least one day, more preferably at least one week, before beginning oral administration of levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof.
PCT/US2020/065166 2019-12-16 2020-12-15 LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF) WO2021126884A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2020408323A AU2020408323A1 (en) 2019-12-16 2020-12-15 Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)
JP2022537748A JP2023507626A (en) 2019-12-16 2020-12-15 Levosimendan for the treatment of pulmonary hypertension with preserved ejection fraction heart failure (PH-HF-pEF)
CA3161960A CA3161960A1 (en) 2019-12-16 2020-12-15 Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
EP20900848.1A EP4076398A4 (en) 2019-12-16 2020-12-15 Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hf-pef)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962948735P 2019-12-16 2019-12-16
US62/948,735 2019-12-16
US202062967920P 2020-01-30 2020-01-30
US62/967,920 2020-01-30
US202062988720P 2020-03-12 2020-03-12
US62/988,720 2020-03-12
US202063033773P 2020-06-02 2020-06-02
US63/033,773 2020-06-02
US202063064671P 2020-08-12 2020-08-12
US63/064,671 2020-08-12

Publications (1)

Publication Number Publication Date
WO2021126884A1 true WO2021126884A1 (en) 2021-06-24

Family

ID=76316595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/065166 WO2021126884A1 (en) 2019-12-16 2020-12-15 LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)

Country Status (6)

Country Link
US (4) US11969424B2 (en)
EP (1) EP4076398A4 (en)
JP (1) JP2023507626A (en)
AU (1) AU2020408323A1 (en)
CA (1) CA3161960A1 (en)
WO (1) WO2021126884A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
WO2023130028A1 (en) * 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
WO2023210634A1 (en) * 2022-04-28 2023-11-02 国立大学法人東海国立大学機構 Pharmaceutical composition for treatment of heart failure with diastolic dysfunction

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11213524B2 (en) * 2018-08-21 2022-01-04 Tenax Therapeutics, Inc. Pharmaceutical compositions for subcutaneous administration of levosimendan
JP2023507626A (en) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド Levosimendan for the treatment of pulmonary hypertension with preserved ejection fraction heart failure (PH-HF-pEF)

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6743798B1 (en) 1998-07-29 2004-06-01 Bayer Aktiengesellschaft Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
US7173037B2 (en) 2002-05-08 2007-02-06 Bayer Healthcare Ag Carbamate-substituted pyrazolopyridines
US7205302B2 (en) 2001-04-26 2007-04-17 Nippon Shinyaku Co., Ltd. Heterocyclic compound derivatives and medicines
US7361649B2 (en) 2005-02-28 2008-04-22 Les Laboratoires Servier β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
US7361650B2 (en) 2005-02-28 2008-04-22 Les Laboratoires Servier γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US7959945B2 (en) 2005-05-17 2011-06-14 Actelion Pharmaceuticals Ltd. Dispersible bosentan tablet
US7999007B2 (en) 2007-09-07 2011-08-16 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US8377933B2 (en) 2006-12-12 2013-02-19 Gilead Colorado, Inc. Method for treating a pulmonary hypertension condition
US8791122B2 (en) 2009-06-26 2014-07-29 Nippon Shinyaku Co., Ltd. Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
US8877938B2 (en) 2005-11-09 2014-11-04 Novartis Pharmaceuticals Corporation Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
US9173881B2 (en) 2008-08-13 2015-11-03 Actelion Pharmaceuticals Ltd. Therapeutic compositions containing macitentan
US9199908B2 (en) 2003-05-22 2015-12-01 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
US20150374689A1 (en) * 2014-06-30 2015-12-31 Tenax Therapeutics, Inc. Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
US9549926B2 (en) 2010-10-15 2017-01-24 Gilead Sciences, Inc. Compositions and methods of treating pulmonary hypertension
US9593066B2 (en) 2007-12-17 2017-03-14 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin®
US20170182127A1 (en) * 2014-05-23 2017-06-29 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Method and composition for treating heart failure with preserved ejection fraction
US9713599B2 (en) 2003-12-16 2017-07-25 United Therapeutics Corporation Parenteral formulations of treprostinil
US20180318210A1 (en) * 2015-11-06 2018-11-08 Carinopharm Gmbh Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
US20190091194A1 (en) * 2013-08-23 2019-03-28 Reata Pharmaceuticals, Inc. Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
WO2020041180A1 (en) 2018-08-21 2020-02-27 Tenax Therapeutics, Inc. Pharmaceutical compositions for subcutaneous administration of levosimendan

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A (en) 1997-09-26 1999-03-27 Orion Yhtymae Oy Oral compositions of levosimendan
FI974578A (en) 1997-12-19 1999-06-20 Orion Yhtymae Oyj Method of administering levosimendan
FI980902A (en) 1998-04-23 1999-10-24 Orion Yhtymae Oyj Stable compositions of levosimendan
FI105389B (en) 1998-04-23 2000-08-15 Orion Yhtymae Oyj Procedure for monitoring the tolerance of levosimendan administration
FI980901A (en) 1998-04-23 1999-10-24 Orion Yhtymae Oyj Oral compositions that controlled release the levosimendan
FI104718B (en) 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4- (2-Azido-3-methyl-5-oxotetrahydrofuran-2-yl) phenyl] hydrazono] propanedonitrile for use as reference substance in the analysis of batches of levosimendan
FI981473A (en) 1998-06-25 1999-12-26 Orion Yhtymae Oyj A method of treating pulmonary hypertension
GB9915179D0 (en) 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm
FI109659B (en) 1999-09-10 2002-09-30 Orion Yhtymae Oyj Pharmaceutical solutions of levosimendan
EP1248620B1 (en) 1999-10-22 2004-11-17 Orion Corporation A new use of levosimendan
FI20001542A (en) 2000-06-29 2001-12-30 Orion Yhtymae Oyj A method of treating septic shock
FI20002525A (en) 2000-11-17 2002-05-18 Orion Yhtymae Oyj Anti-inflammatory substances
FI20002526A (en) 2000-11-17 2002-05-18 Orion Yhtymae Oyj New use of pyridazinone derivatives
FI20002755A0 (en) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Method of therapy for erectile dysfunction
FI20010233A0 (en) 2001-02-08 2001-02-08 Orion Corp A method for treating heart failure
FI20011465A0 (en) 2001-07-04 2001-07-04 Orion Corp New use of pyridazinone derivative
FI20011464A0 (en) 2001-07-04 2001-07-04 Orion Corp Combination therapy for the treatment of heart failure
FI20020197A0 (en) 2002-02-01 2002-02-01 Orion Corp A combination treatment method for acute myocardial infarction
FI20030015A0 (en) 2003-01-03 2003-01-03 Orion Corp A method of treating renal failure
WO2005102347A1 (en) 2004-04-23 2005-11-03 Orion Corporation Calcium sensitisers for treating symptoms of venomous bites and stings
FI20040674A0 (en) 2004-05-12 2004-05-12 Orion Corp A method of inhibiting thromboembolic diseases
FI20040675A0 (en) 2004-05-12 2004-05-12 Orion Corp A method of treating and preventing cardiac hypertrophy
JP2008530186A (en) 2005-02-18 2008-08-07 オリオン コーポレーション Heart failure treatment
WO2006097570A1 (en) 2005-03-14 2006-09-21 Orion Corporation A combination treatment for enhancing diuresis
JP2010514778A (en) 2006-12-28 2010-05-06 オリオン コーポレーション Levosimendan formulation for parenteral administration
CA2675176A1 (en) 2007-01-17 2008-07-24 Orion Corporation Levosimendan for use in treating chronic valvular disease
AR068814A1 (en) 2007-08-29 2009-12-09 Orion Corp PHARMACEUTICAL COMPOSITION INCLUDING LEVOSIMENDAN AND AN INHIBITOR OF THE CONVERSINE ENZYME OF ANGIOTENSIN (ACE), AND USE
WO2010097501A2 (en) 2009-02-26 2010-09-02 Orion Corporation A combination treatment
WO2011027021A1 (en) 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
AU2015332367B2 (en) 2014-10-15 2020-05-14 Orion Corporation Levosimendan for use in the treatment of motor neuron diseases (e.g. ALS)
CA3145456A1 (en) 2019-07-01 2021-01-07 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
JP2023507626A (en) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド Levosimendan for the treatment of pulmonary hypertension with preserved ejection fraction heart failure (PH-HF-pEF)

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US6743798B1 (en) 1998-07-29 2004-06-01 Bayer Aktiengesellschaft Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
US6852724B2 (en) 1998-09-10 2005-02-08 Cv Therapeutics, Inc. Sustained release ranolazine formulations
US6525057B2 (en) 1998-09-10 2003-02-25 Cv Therapeutics, Inc. Sustained release ranolazine formulations
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6503911B2 (en) 1998-09-10 2003-01-07 Cv Therapeutics, Inc. Sustained release ranolazine formulations
US6620814B2 (en) 1998-09-10 2003-09-16 Cv Therapeutics, Inc. Sustained release ranolazine formulations
US6562826B1 (en) 1998-09-10 2003-05-13 Cv Therapeutics, Inc. Sustained release ranolazine formulations
US6617328B2 (en) 1998-09-10 2003-09-09 Cv Therapeutics, Inc Sustained release ranolazine formulations
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6369062B1 (en) 1998-09-10 2002-04-09 Cv Therapeutics, Inc. Sustained release ranolazine formulations
US6864258B2 (en) 1998-09-10 2005-03-08 Andrew A. Wolff Sustained release ranolazine formulations
US6784177B2 (en) 1999-09-08 2004-08-31 Nitro Med, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US6465463B1 (en) 1999-09-08 2002-10-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7205302B2 (en) 2001-04-26 2007-04-17 Nippon Shinyaku Co., Ltd. Heterocyclic compound derivatives and medicines
US8796331B2 (en) 2002-01-17 2014-08-05 Novartis Ag Methods of treatment and pharmaceutical composition
US8404744B2 (en) 2002-01-17 2013-03-26 Novartis Ag Methods of treatment and pharmaceutical composition
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US8101659B2 (en) 2002-01-17 2012-01-24 Novartis Ag Methods of treatment and pharmaceutical composition
US7173037B2 (en) 2002-05-08 2007-02-06 Bayer Healthcare Ag Carbamate-substituted pyrazolopyridines
US9199908B2 (en) 2003-05-22 2015-12-01 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
US10076505B2 (en) 2003-12-16 2018-09-18 United Therapeutics Corporation Inhalation formulations of Treprostinil
US9713599B2 (en) 2003-12-16 2017-07-25 United Therapeutics Corporation Parenteral formulations of treprostinil
US7879842B2 (en) 2005-02-28 2011-02-01 Les Laboratoires Servier Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
US7867996B2 (en) 2005-02-28 2011-01-11 Les Laboratories Servier γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
US7361650B2 (en) 2005-02-28 2008-04-22 Les Laboratoires Servier γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
US7361649B2 (en) 2005-02-28 2008-04-22 Les Laboratoires Servier β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
US8309126B2 (en) 2005-05-17 2012-11-13 Actelion Pharmaceuticals, Ltd. Dispersible bosentan tablet
US7959945B2 (en) 2005-05-17 2011-06-14 Actelion Pharmaceuticals Ltd. Dispersible bosentan tablet
US9388134B2 (en) 2005-11-09 2016-07-12 Novartis, Ag Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
US8877938B2 (en) 2005-11-09 2014-11-04 Novartis Pharmaceuticals Corporation Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
US8377933B2 (en) 2006-12-12 2013-02-19 Gilead Colorado, Inc. Method for treating a pulmonary hypertension condition
US9474752B2 (en) 2006-12-12 2016-10-25 Gilead Sciences, Inc. Method for treating a pulmonary hypertension condition
US7999007B2 (en) 2007-09-07 2011-08-16 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US8658694B2 (en) 2007-09-07 2014-02-25 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US8653137B2 (en) 2007-09-07 2014-02-18 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
US9593066B2 (en) 2007-12-17 2017-03-14 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin®
US9604901B2 (en) 2007-12-17 2017-03-28 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in Remodulin®
US9173881B2 (en) 2008-08-13 2015-11-03 Actelion Pharmaceuticals Ltd. Therapeutic compositions containing macitentan
US8791122B2 (en) 2009-06-26 2014-07-29 Nippon Shinyaku Co., Ltd. Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
US8791122C1 (en) 2009-06-26 2014-07-29
US9284280B2 (en) 2009-06-26 2016-03-15 Nippon Shinyaku Co., Ltd. Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
US9549926B2 (en) 2010-10-15 2017-01-24 Gilead Sciences, Inc. Compositions and methods of treating pulmonary hypertension
US20190091194A1 (en) * 2013-08-23 2019-03-28 Reata Pharmaceuticals, Inc. Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
US20170182127A1 (en) * 2014-05-23 2017-06-29 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Method and composition for treating heart failure with preserved ejection fraction
US20150374689A1 (en) * 2014-06-30 2015-12-31 Tenax Therapeutics, Inc. Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
US20180318210A1 (en) * 2015-11-06 2018-11-08 Carinopharm Gmbh Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
US10507179B2 (en) 2015-11-06 2019-12-17 Carinopharm Gmbh Formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
WO2020041180A1 (en) 2018-08-21 2020-02-27 Tenax Therapeutics, Inc. Pharmaceutical compositions for subcutaneous administration of levosimendan

Non-Patent Citations (60)

* Cited by examiner, † Cited by third party
Title
BANFOR, P. N. ET AL.: "Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and 02 consumption in dogs", AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, vol. 294, no. 1, 2008, pages H238 - H248
BITTNER, B. ET AL.: "Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities", BIODRUGS, vol. 32, no. 5, 2018, pages 425 - 440, XP055884493, DOI: 10.1007/s40259-018-0295-0
BORLAUG ET AL.: "Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In PH-HFpEF: Primary Results from the Help-PH-HFpEF Multicenter Randomized Controlled Trial Heart Society of America", LATE BREAKING CLINICAL TRIALS SESSION, 3 October 2020 (2020-10-03)
BURKHOFF ET AL.: "24-hour Levosimendan Infusion Decreases Biventricular Filling Pressures and Increases Cardiac Output at Rest and Exercise in PH-HFpEF", CIRCULATION, vol. 142, 2020, pages A15294 - A15294
CHRUSCIEL, P. ET AL.: "Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease", DRUGS, vol. 74, no. 9, 2014, pages 971 - 980
DE LUCA, L. ET AL.: "Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study", JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, vol. 19, no. 2, 2006, pages 172 - 177, XP005266901, DOI: 10.1016/j.echo.2005.08.016
DIXON, D. D. ET AL.: "Combined post-and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction", HEART FAILURE REVIEWS, vol. 21, no. 3, 2015, pages 285 - 297, XP035910070, DOI: 10.1007/s10741-015-9523-6
DU TOIT, E. F. ET AL.: "A role for the RISK pathway and KATP channels in pre-and post-conditioning induced by levosimendan in the isolated guinea pig heart", BRITISH JOURNAL OF PHARMACOLOGY, vol. 154, no. 1, 2008, pages 41 - 50
ELGUINDY, A. ET AL.: "Heart failure with preserved ejection fraction", GLOBAL CARDIOLOGY SCIENCE AND PRACTICE, vol. 2012, no. 1, 2012, pages 10
ERDEI, N. ET AL.: "The levosimendan metabolite OR-1896 elicits vasodilation by activating the KATP and BKCa channels in rat isolated arterioles", BRITISH JOURNAL OF PHARMACOLOGY, vol. 148, no. 5, 2006, pages 696 - 702, XP071146427, DOI: 10.1038/sj.bjp.0706781
GALIE, N. ET AL.: "European heart journal", vol. 30, 2009, THE EUROPEAN RESPIRATORY SOCIETY (ERS, article "Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC", pages: 2493 - 2537
GORTER, T. M. ET AL.: "Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology", EUROPEAN JOURNAL OF HEART FAILURE, vol. 20, no. 1, 2018, pages 16 - 37
GROSSINI, E. ET AL.: "Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig", JOURNAL OF CARDIOVASCULARPHARMACOLOGY, vol. 46, no. 3, 2005, pages 333 - 342
HAIKALA, H. ET AL.: "Mechanisms of action of calcium-sensitizing drugs", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 26, 1995, pages 10 - 9
HAJJAR, R. J. ET AL.: "Calcium-sensitizing inotropic agents in the treatment of heart failure: a critical view", CARDIOVASCULAR DRUGS AND THERAPY, vol. 5, no. 6, 1991, pages 961 - 965
HASENFUSS, G. ET AL.: "Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium", CIRCULATION, vol. 98, no. 20, 1998, pages 2141 - 2147
HAWTHORNE, K. M. ET AL.: "Quality assessment in dobutamine stress echocardiography: what are the clinical predictors associated with a non-diagnostic test?", CARDIOLOGY RESEARCH, vol. 3, no. 2, 2012, pages 73
HOEPER, M. M. ET AL.: "A global view of pulmonary hypertension", THE LANCET RESPIRATORY MEDICINE, vol. 4, no. 4, 2016, pages 306 - 322
JIANG, R. ET AL.: "Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension", THE CLINICAL RESPIRATORY JOURNAL, vol. 12, no. 4, 2018, pages 1518 - 1525
KELLY, J. P ET AL.: "Patient selection in heart failure with preserved ejection fraction clinical trials", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 65, no. 16, 2015, pages 1668 - 1682
KHEINEN, P. ET AL.: "Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels", JOURNAL OF CARDIOVASCULARPHARMACOLOGY, vol. 37, no. 4, 2001, pages 367 - 374
KIVIKKO, M. ET AL.: "Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 42, no. 1, 2002, pages 43 - 51, XP009141969
KIVIKKO, M. ET AL.: "Sustained hemodynamic effects of intravenous levosimendan", CIRCULATION, vol. 107, no. 1, 2003, pages 81 - 86, XP002390697, DOI: 10.1161/01.CIR.0000043245.00859.11
KLAPHOLZ, M. ET AL.: "Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 43, no. 8, 2004, pages 1432 - 1438
KLEBER, F. X. ET AL.: "Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 49, no. 1, 2009, pages 109 - 115
KOSTIS, J. B. ET AL.: "Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial", AMERICAN JOURNAL OF HYPERTENSION, vol. 17, no. 2, 2004, pages 103 - 111
LAI, Y. C. ET AL.: "Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction", THE JOURNAL OF PHYSIOLOGY, vol. 597, no. 4, 2019, pages 1143 - 1156
LAURENT, S. ET AL.: "Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans", HYPERTENSION, vol. 35, no. 5, 2000, pages 1148 - 1153
LEVINE, A. R. ET AL.: "Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction", TRENDS IN CARDIOVASCULAR MEDICINE, vol. 29, no. 4, 2019, pages 207 - 217, XP085648627, DOI: 10.1016/j.tcm.2018.08.005
LOUHELAINEN, M. ET AL.: "Effects of calcium sensitizer OR-1986 on cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats", ACTA PHYSIOLOGICA POLONICA, vol. 12, no. 3, 2009, pages 41
LOUHELAINEN, M. ET AL.: "Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats", BRITISH JOURNAL OF PHARMACOLOGY, vol. 160, no. 1, 2010, pages 142 - 152
MAYTIN, M. ET AL.: "Cardioprotection: a new paradigm in the management of acute heart failure syndromes", THE AMERICAN JOURNAL OF CARDIOLOGY, vol. 96, no. 6, 2005, pages 26 - 31, XP005148448, DOI: 10.1016/j.amjcard.2005.07.018
MCLAUGHLIN, V. V. ET AL.: "Journal of the American College of Cardiology", vol. 53, 2009, AMERICAN THORACIC SOCIETY, INC., article "ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians", pages: 1573 - 1619
MICHAELS, A. D. ET AL.: "Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake", CIRCULATION, vol. 111, no. 12, 2005, pages 1504 - 1509
NORTHRIDGE, D. B. ET AL.: "Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure", AMERICAN HEART JOURNAL, vol. 138, no. 6, 1999, pages 1149 - 1157, XP005690153, DOI: 10.1016/S0002-8703(99)70082-7
NORTON, G. R. ET AL.: "Sustained Antihypertensive Actions of a Dual Angiotensin-Converting Enzyme Neutral Endopeptidase Inhibitor, Sampatrilat, in Black Hypertensive Subjects", AMERICAN JOURNAL OF HYPERTENSION, vol. 12, no. 6, 1999, pages 563 - 571, XP055682537, DOI: 10.1016/S0895-7061(99)00009-6
OKTAY, A. A. ET AL.: "The emerging epidemic of heart failure with preserved ejection fraction", CURRENT HEART FAILURE REPORTS, vol. 10, no. 4, 2013, pages 401 - 410
OLDROYD, S. H. ET AL., PULMONARY HYPERTENSION, 2019
OPITZ, CHRISTIAN F. ET AL.: "Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 68, no. 4, 2016, pages 368 - 378, XP029645576, DOI: 10.1016/j.jacc.2016.05.047
OUDIZ, R. J. ET AL.: "Pulmonary hypertension associated with left-sided heart disease", CLINICS IN CHEST MEDICINE, vol. 28, no. 1, 2007, pages 233 - 241
PATARICZA, J. ET AL.: "Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 52, no. 2, 2000, pages 213 - 217
POLLESELLO, P. ET AL.: "Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 46, 1994, pages 28584 - 28590
POLLESELLO, P. ET AL.: "The cardioprotective effects of levosimendan: preclinical and clinical evidence", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 50, no. 3, 2007, pages 257 - 263
See also references of EP4076398A4
SEGRETI, J. A. ET AL.: "Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-l, 4, 5, 6-tetrahydropyridazin-3-yl) phenyl) acetamide", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 325, no. 1, 2008, pages 331 - 340
SENNI M., PAULUS W. J., GAVAZZI A., FRASER A. G., DIEZ J., SOLOMON S. D., SMISETH O. A., GUAZZI M., LAM C. S. P., MAGGIONI A. P., : "New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes", EUROPEAN HEART JOURNAL, vol. 35, no. 40, 2 October 2014 (2014-10-02), GB, pages 2797 - 2815, XP055838349, ISSN: 0195-668X, DOI: 10.1093/eurheartj/ehu204 *
SHAW, S. J. ET AL.: "Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap", CIRCULATION, vol. 134, no. 1, 2016, pages 73 - 90
SHIBATA ET AL.: "Congestive heart failure with preserved ejection fraction isassociated with severely impaired dynamic Starling mechanism", J. APPL. PHYSIOL., vol. 110, no. 4, 10 February 2011 (2011-02-10), pages 964 - 971, XP055838344 *
SIMONNEAU, G. ET AL.: "Updated clinical classification of pulmonary hypertension", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 54, 2009, pages S43 - S54, XP026218348, DOI: 10.1016/j.jacc.2009.04.012
SORSA, T. ET AL.: "The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 266, no. 1-2, 2004, pages 87 - 107
SZILAGYI, S. ET AL.: "The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 486, no. 1, 2004, pages 67 - 74
TEERLINK, J. R. ET AL.: "RELAX-REPEAT: a multicenter, prospective, randomized, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure", JOURNAL OF CARDIAC FAILURE, vol. 22, no. 8, 2016, pages S14 - S15
TORRES, F. ET AL.: "Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial", EUROPEAN RESPIRATORY JOURNAL, vol. 54, no. 4, 2019
VALJAKKA-KOSKELA ET AL.: "Transdermal delivery of levosimendan", EUR. J. PHARM. SCI., vol. 11, 11 July 2000 (2000-07-11), pages 343 - 350, XP055687630 *
VANDONI, M. ET AL.: "Six minute walk distance and reference values in healthy Italian children: A cross-sectional study", PLOS ONE, vol. 13, no. 10, 2018
VIRGADAMO, S. ET AL.: "Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction", WORLD JOURNAL OF CARDIOLOGY, vol. 7, no. 11, 2015, pages 808
WAIT, J. C. ET AL.: "Metabolism of [14C] gemopatrilat after oral administration to rats, dogs, and humans", DRUG METABOLISM AND DISPOSITION, vol. 34, no. 6, 2006, pages 961 - 970
YANCY, C. W. ET AL.: "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 62, no. 16, 2013, pages e147 - e239
YANCY, C. W. ET AL.: "2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines", CIRCULATION, vol. 128, no. 16, 2013, pages 1810 - 1852
YOKOSHIKI, H. ET AL.: "Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 333, no. 2-3, 1997, pages 249 - 259

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
WO2023130028A1 (en) * 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
WO2023210634A1 (en) * 2022-04-28 2023-11-02 国立大学法人東海国立大学機構 Pharmaceutical composition for treatment of heart failure with diastolic dysfunction

Also Published As

Publication number Publication date
US11969424B2 (en) 2024-04-30
US20240269134A1 (en) 2024-08-15
US20210177840A1 (en) 2021-06-17
JP2023507626A (en) 2023-02-24
EP4076398A4 (en) 2024-01-03
US20210393625A1 (en) 2021-12-23
EP4076398A1 (en) 2022-10-26
CA3161960A1 (en) 2021-06-24
US11607412B2 (en) 2023-03-21
US20230107461A1 (en) 2023-04-06
US11701355B2 (en) 2023-07-18
AU2020408323A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US11701355B2 (en) Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
Agarwal et al. Current therapeutics and practical management strategies for pulmonary arterial hypertension
AU2024205251A1 (en) Dosing regimens for the treatment of fabry disease
US20170056404A1 (en) Combination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in pten/tp53
AU2024204913A1 (en) Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
US20200352914A1 (en) Methods of treating hypertension with activators of tie-2
EP4440568A1 (en) Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CA3240614A1 (en) Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
JP2008530186A (en) Heart failure treatment
WO2022036111A1 (en) Methods and compositions for treating sickle cell disease
CN114728002A (en) Method for treating pulmonary hypertension
US12121517B2 (en) Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
US20230364077A1 (en) Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
WO2023230491A1 (en) Methods of using neuregulin-4 compounds
Miller Phase I study of INCB039110 in combination with dabrafenib and trametinib in patients with BRAF-mutant melanoma and other solid tumors. Coordinating Center: Massachusetts General Hospital Cancer Center Protocol Office Massachusetts General Hospital
NZ615726B2 (en) Dosing regimens for the treatment of fabry disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20900848

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3161960

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022537748

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020900848

Country of ref document: EP

Effective date: 20220718

ENP Entry into the national phase

Ref document number: 2020408323

Country of ref document: AU

Date of ref document: 20201215

Kind code of ref document: A